

Curriculum Vitae

Matthew Linley Anderson, MD, PhD, FACOG

Department of Obstetrics & Gynecology

University of South Florida

ADDRESSES:

7/1/2025

Department of Obstetrics & Gynecology
12901 Bruce B. Downs Blvd, MDC4146D
Tampa, FL 33612
Phone: (813) 974-1806
Email: mlander5@usf.edu

Tampa General Hospital Cancer Center
2 Tampa General Circle
Tampa, FL
Phone: 813-259-8527

DATE OF BIRTH:

August 21, 1965

CITIZENSHIP:

United States of America

EDUCATION:

Doctor of Philosophy (PhD) 1995

Yale University, New Haven, CT
Dissertation Title: "Cholecystokinin induces a novel form of
activated PKC-alpha in pancreatic beta cells"
Mentor: Howard Rasmussen, MD, PhD

Doctor of Medicine (M.D) 1995

Yale University, New Haven, CT

Master of Philosophy/Master of Science (M.S., M.Ph.) 1992

Yale University, New Haven, CT
Degrees Awarded with Academic Distinction

Bachelor of Science (B.S., Cell Biology), Summa cum Laude 1986

University of Miami, Coral Gables, FL

ACADEMIC APPOINTMENTS

Current Faculty Position(s):

Primary Appointments

Professor (Tenured) Department of Obstetrics & Gynecology USF Morsani College of Medicine, Tampa, FL	2021 - current
--	----------------

Associate Director for Research Analytics & Shared Resources Tampa General Hospital Cancer Institute	2024 - current
---	----------------

Adjunct Appointments

Collaborative Member, Cancer Biology and Evolution Program H. Lee Moffitt Cancer Center and Research Institute	2019 - current
---	----------------

Previous Faculty Position(s):

Primary Appointments

Associate Director for Data Analytics & Shared Resources Tampa General Hospital Cancer Institute	2024 –
---	--------

Associate Director for Shared Resources Tampa General Hospital Cancer Institute	2021-2024
--	-----------

Associate Professor (Tenured) Department of Obstetrics & Gynecology USF Morsani College of Medicine, Tampa, FL	2018- 2021
--	------------

Associate Professor (Tenured) Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX	2016-2018
--	-----------

Assistant Professor (Tenure Track), Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX	2009-2016
--	-----------

Assistant Professor (Non-Tenure Track) Department of Obstetrics & Gynecology, Baylor College of Medicine, Houston, TX	2002-2009
---	-----------

Instructor, Department of Gynecologic Oncology The University of Texas M.D. Anderson Cancer Center	1999-2002
---	-----------

Secondary Appointments

Professor, Molecular Pharmacology & Physiology University of South Florida Morsani College of Medicine	2021 –
---	--------

Assistant Professor, Translational Biology & Molecular Medicine 2010-2018
Baylor College of Medicine, Houston, TX

Assistant Professor, Department of Pathology & Immunology, 2003-2018
Baylor College of Medicine, Houston, TX

Center Appointments

Founding Member, Aerospace Science Technology, Research and 2025
Applications (ASTRA), University of South Florida

Tampa General Hospital Cancer Institute 2019 -

Center for Reproductive Medicine (CRM) 2013-2018
Baylor College of Medicine

Institute for Clinical and Translational Research (ICTR) 2013-2018
Baylor College of Medicine

Full Member, Cancer Biology Program, Dan L. Duncan Cancer Center 2006-2018
Baylor College of Medicine

Adjunct Appointments

Adjunct Assistant Professor 2011-2013
Department of Biology and Biochemistry
University of Houston, Houston, TX

Adjunct Assistant Professor, Department of Gynecologic Oncology, 2002-2008
University of Texas M. D. Anderson Cancer Center, Houston, TX

POST GRADUATE TRAINING

Fellowship

Subspecialty: **Gynecologic Oncology** 1999-2002
Institution: The University of Texas M.D. Anderson Cancer Center,
1515 Holcombe Boulevard, Houston, TX 77030
Program Director: Diane Bodurka, MD

Residency

Specialty: **Obstetrics & Gynecology** 1995-1999
Institution: Yale-New Haven Hospital, 20 York Street, New Haven,
CT 06510
Program Director: Ray Bahado-Singh, MD, MBA

Other Advanced Training Experience

Davinci Robotic Surgery Certification, Intuitive, Inc. 2019

Board Certification

Obstetrics and Gynecology (MOC Current through 12/31/25)	01/2006-
Gynecologic Oncology (MOC Current through 12/31/25)	04/2012

Medical Licensure

Florida – ME137699, issued 8/23/2018. Valid through 1/31/2027
Texas – K9716, issued 5/19/2000. Valid through 2/28/2026

AWARDS, HONORS AND HONORARY SOCIETY MEMBERSHIP

Academic

Semi-Finalist, National Merit Scholarship	1983
Henry King Stanford Scholarship, University of Miami	1983-1985
Aid Association for Lutherans (Thrivent) Academic Scholarship	1983-1985
Dean's List, College of Arts and Sciences, University of Miami	1983-1985
Phi Beta Kappa Honor Society	1984
Phi Eta Sigma Honor Society	1985
Anatomy Prize, University of Miami School of Medicine	1985
Gammage Medical Scholarship, University of Miami School of Medicine	1985-1987
Special Honors in Physiology/Biophysics, University of Miami School of Medicine	1986
HHMI Predoctoral Fellowship (Ranked first of 40 recipients out of 2,209 candidates)	1989-1993
M.S. Awarded with Academic Distinction, Yale University	1992
American Association of Obstetrics and Gynecology Foundation (AAOGF) Presidential Travel Award	2013
Elected Member, American Gynecologic & Obstetrical Society (AGOS)	2020
Elected Faculty Member, Alpha Omega Alpha Medical Honor Society	2020

Research

American Heart Association Research Fellowship	1986
NIH Summer Research Fellowship	1986
HHMI-NIH Research Scholar, Howard Hughes Medical Institute	1987-1989
Medical Scientist Training Program Fellowship, Yale University	1993-1995
Wyeth-Ayerst Research Award	1999
Clinical Research Award, U.T. M.D. Anderson Cancer Center	1999
Research Fellowship, Building Interdisciplinary Careers in Women's Health Program (Funded by K award to Baylor College of Medicine, J. Simpson, PI)	2005-2007
AAOGF Fellowship (Awarded, But Declined)	2003
Eli Lilly Award in Ovarian Cancer Research, Women's Cancer Foundation	2004
Finalist, Clinical Scientist Development Award, Doris Duke Foundation	2005
Presidential Plenary Presentation, Society for Gynecologic Investigation	2007
Best Basic Science Presentation, Society of Gynecologic Oncologists	2010
Basic Science Poster Award, Society of Gynecologic Oncologists	2011
Honorable Mention, Hearst Prize for Excellence in Population Health (with M. Jibaja-Weiss on behalf of BCM)	2017

Clinical

Academic Chief Resident, Obstetrics & Gynecology, Yale-New Haven Hospital	1994-1995
First Physician of the Quarter, Ben Taub General Hospital	2005

Fellow, American College of Obstetrics and Gynecology	2006
Award for Excellence in Patient Care, Department of Obstetrics & Gynecology, Baylor College of Medicine	2011
Full Member, Society for Gynecologic Oncology	2013
External Advisory Board, UTMDACC Department of Sarcoma Medicine	2013-2018
Top Doctor, Houstonia Magazine	2017
Gynecology "Bragging Rights," Ben Taub General Hospital	2018
Texas Super Doctor, Texas Monthly Magazine	2018
Tampa Doctors of the Year, TampaStyle Magazine	2020, 2023
Best in Florida Physician	2023, 2024
Castle-Connelly Top Doctors	2023, 2024, 2025
Tampa Bay Metro Magazine	2025

Teaching & Education

Medical Student Education Award, Obstetrics & Gynecology, Baylor College of Medicine (BCM)	2004
Certificate of Teaching Appreciation, Obstetrics & Gynecology, BCM	2012
Inaugural Resident Research Mentor of the Year, Obstetrics & Gynecology, BCM	2014
Fulbright & Jaworski Faculty Award for Excellence in Teaching & Evaluation	2015
Academy of Distinguished Educators, Baylor College of Medicine	2016
Research Mentor of the Year, Obstetrics & Gynecology, Baylor College of Medicine	2017
Resident Research Mentor Award, Obstetrics & Gynecology, Baylor College of Medicine	2017

Other Non-Academic Leadership Positions

Medical Director, Office of Clinical Research Tampa General Hospital, Tampa, FL	2019-current
Board of Directors, Sarcoma Alliance, Marin, CA	2012-2014
President and Chief Executive Officer, Agenetx, LLC,	2011-2017
Board of Directors, Newton-Foster Home Health Agency	1996-2000

TEACHING

Didactic Teaching & Lectures

Courses Taught at University of South Florida Morsani College of Medicine within Primary Department

Molecular Basis of Cancer	2025 -
Gynecologic Oncology Fellowship Didactics (4 sessions/year)	2023 -
Resident/Fellow Research Boot Camp, (~20 learners session; 1 session/yr)	2019 - 2024
Management of Adnexal Masses (~ 15 learners session/1 session/yr)	2020 -

Courses Previously Taught at Baylor College of Medicine within Primary Department

Medical Student Core Clerkship Lecture. Two 1 hour lectures/rotation for 6 rotations/year, ~20 learners/session.	2002-2009
Didactic Lectures. Four 1 hour lectures with 2-4 hours prep/year; ~40 learners/session.	2002-2011
CREOG Lectures. Two 1 hour lectures with 3-5 hours prep/year; ~40 learners/session	2002-2006

Courses Previously Taught at Baylor College of Medicine outside Primary Department

Translational Cancer Biology Course, Graduate School of Biologic Sciences One 2-hour lecture/discussion, co-led with M.Y. Williams-Brown, MD, MPH	2013-2018
Women's Health Physician's Assistant Program, BCM School of Allied Health; One 1 hour lecture/year, ~30 learners/session	2012-2014
Resident Lecture Series, Department of Radiation Oncology; One 1 hour lecture/year; ~10 learners/session	2013-2018

Courses Taught at Other Institutions

Cancer Biology, Department of Biology, Rice University; One 1 hour lecture with 5 hours of prep/year, ~100 learners/session	2004-2006
Chemotherapeutics, College of Pharmacy, University of Houston; One 1 hour lecture with 6-8 hours of prep/year, ~125 learners/session	2004-2006

Curriculum Development

Coordinator, Oncology Learning Society, Department of OB/GYN, Baylor College of Medicine One 5 hour session/quarter; ~12 learners/session	2008-2010
Structured CME Learning Modules in Ovarian Cancer, Merck, Inc.	2011-2012
Cervical Cancer Education Program, American College of Physicians	2013

Non-Didactic Teaching

Medical Student and Resident Training at University of South Florida Morsani College of Medicine

Tampa General Hospital: ~15 hours/week	2018 - current
---	----------------

Operative Surgical Training of Residents, Fellows and Medical Students (including inpatient consultations, perioperative management and postoperative ward rounds)

Tampa General Hospital: ~15 hours/week 2018 - current

Medical Student and Resident Clinical Training at Baylor College of Medicine

Operative Surgical Training of Residents, Fellows and Medical Students including intraoperative skills, inpatient consultations, perioperative management and postoperative ward rounds, 3 residents per month /12 rotations/year). Hourly commitments to teach vary per institution and year

Ben Taub General Hospital: 40-50 hours/month 2002-2018
20-25 hours/month 2003-2011

Saint Luke's Episcopal Hospital: ~8 hours/month 2011-2018

Outpatient Clinical Management of Gynecologic Cancers (OBGYN Residents, BCM Medical Students, Visiting Elective Medical Students, Medical Oncology Fellows and/or University of Houston College of Pharmacy Graduate Students 5-10 learners/session, 3 sessions weekly throughout the year)

Ben Taub General Hospital/Smith Clinic: ~35 hours/month 2002-2011
~15 hours/month 2011-2018

Simulated Surgical Skills Lab (1 hour/week for 6 weeks/annually) 2002-2005

Clinical Resident Advisor, Department of Obstetrics & Gynecology

Gillian Hsieh, MD 2013-2015
Jennifer Stanley, MD 2015-2016

Prior Clinical Fellow Training at Other Institutions

Operative Surgical Training, Gynecologic Oncology Fellow (UTMB/Houston Methodist Hospital) 2 residents per monthly rotation, 2-4 hrs/rotation, 12 rotations/year 2008-2010

Operative Surgical Training, Pediatric Gynecology and Minimally Invasive Surgical Fellowships, Baylor College of Medicine (~5 hrs/ year, 1 learner/fellowship) 2010-2018

Other Laboratory/Research Mentorship

High School Students

Sarah Garcia, BCM Saturday Morning Science Summer Research Program. 2014

Amanda Knox, BCM Center for Reproductive Medicine Summer Student 2014

Andrew Park, DeBakey High School for Health Professions, One manuscript in preparation as co-author. 2015

Jake Rymer, Pinecrest Academy, Three abstracts, one manuscript in preparation. Preliminary Patent application submitted; Current: University of Chicago 2021 -

Undergraduate/Postbaccalaureate Students

<u>Cynthia Chin, MS</u> Undergraduate Student, Rice University; Two abstracts published. Graduate School: University of Wisconsin, Current: Research Scientist, Hologic, Inc.	2003-2005
<u>Diana Keselman, MD</u> Undergraduate Student, Rice University MFM Fellow, Department of Obstetrics & Gynecology, Baylor College of Medicine. Current: Assistant Professor, University of Texas Health Science Center at Houston.	2003
<u>Mahjabeen Khan, MD</u> Undergraduate Student, University of Houston; Previous: University of Texas School of Public Health and then. Medical Student: Ross University School of Medicine. Four abstracts and one manuscript published; Lalor Foundation Prize, Keystone Symposia. Current: Resident, Department of Family Medicine, LSU Health Sciences Center, Shreveport, LA.	2007-2009
<u>Amy Pham, MD</u> , Undergraduate Student, University of Houston Previous: UT Southwestern School of Medicine; Current: Resident, Department of Radiation Oncology, Baylor College of Medicine.	2008-2009
<u>Emuejevoke Olokpa, Ph.D.</u> , BCM SMART Program Trainee. Three abstracts and one manuscript published. Finalist, Cancer Biology, Dan L. Duncan Cancer Center Annual Symposium 2009; Graduate Student, Biochemistry and Cancer Biology, Meharry Medical College. Current: Postdoctoral Fellow: Baylor College of Medicine	2007-2009
<u>Olivia Dziadzek, MD</u> . Undergraduate Student, University of Houston Four abstracts and one manuscript published; Private Practice, Obstetrics & Gynecology, Houston, TX.	2007-2009
<u>Dominica Rohozinski, PhD</u> Undergraduate Student, University of Washington; Current: Doctoral Candidate, Program in Plant Biology, University of California, Berkeley.	2008-2009
<u>Roy Emanuel, MD, PhD</u> Undergraduate Student, University of Houston; Medical Scientist Training Program, Washington. Univ. St. Louis. Current: Resident, Barnes Hospital	2008-2009
<u>Pankti Gala, B.S.</u> , BCM SMART Student, Undergraduate at Illinois Institute of Technology. Current: Doctoral Candidate, Department of Biology & Biochemistry.	2009-2010
<u>Joy Akinfenwe, Ph.D.</u> , BCM SMART Program Trainee; Previous: Undergraduate, University of Houston; Two abstracts, one manuscript as SMART student; Graduate Student in TBMM at Baylor College of Medicine. Current: Science Writer, Houston Methodist Hospital	2009-2010
<u>Thomas Magliaro, M.S</u> , Tulane University; Two abstracts and one manuscript published. Current: Medical student, Texas A&M College of Medicine.	2013-2014

<u>Jonathan Newsome</u> , University of Saint Thomas. Shadowing experience on PAMS medical mission trip to Chinchu, Peru. Current: Medical Student, University of Texas Houston Health Science Center	2014
<u>Sarah Linesch</u> , Notre Dame University; One manuscript and two abstracts published.	2014-2015
<u>Benjamin Herr</u> , University of South Florida	Summer, 2019
<u>Hannah Guest</u> , University of South Florida, one abstract accepted	2022 - 2023
<u>Liliana Rodriguez</u> , Johns Hopkins University	Summer, 2022
<u>Kosha Upadhyaya</u> , University of South Florida; three abstracts accepted	2023 - present
<u>Santoshi Ghosh</u> , University of South Florida; three abstracts accepted	2023 - present
<u>Alex Saffa</u> , University of South Florida, two abstracts accepted	2023 - present
<u>Rodrigo Rosado</u> , University of South Florida, two manuscripts, three abstract accepted; Current: Graduate Program in Molecular Medicine, USF	2023 – 2025
<u>Jake Rymer</u> , University of Chicago – two manuscript published, one in prep three abstracts accepted	2024 - present

Medical Students

<u>Diana Herrera</u> , Medical Student, Baylor College of Medicine	2012-2014
<u>Roxana Fatimezhadeh</u> , Medical Student, Baylor College of Medicine	2013-2014
<u>Beth Zhou</u> , Medical Student, Baylor College of Medicine	2014-2015
<u>Yiwen Cui, MD.</u> , Medical Student, Baylor College of Medicine; Three abstracts, one manuscript published, three manuscripts in preparation working with me. Current: MFM Fellow, Department of OB/GYN, Medical College of Wisconsin	2014-2016
<u>Andrew M. MacDonald, B.S.</u> , Medical Student, University of Texas Health Science Center. Three abstracts, one manuscript published; one manuscript in revision.	2014-2016
<u>Margaret G. Taylor, B.S.</u> , Medical Student, Baylor College of Medicine, Two manuscripts in preparation working with me.	2014-2017
<u>Alison Yoder, M.D.</u> , Medical Student, Baylor College of Medicine, Three manuscripts published; three in preparation, > 5 abstracts published. Current: Resident, Department of Radiation Oncology, U.T.M.D. Anderson Cancer Center	2017-2019
<u>Lara Alexander</u> , Medical Student -2, USF Morsani College of Medicine	2020 –2021
<u>Ali Wells</u> , Medical Student-4, USF Morsani College of Medicine	2020 – 2021

Lauren Karnolt, Medical Student-2, USF Morsani College of Medicine, Two abstracts 2021- 2022

Jody Wellcome, Medical Student, USF Morsani College of Medicine, One manuscript submitted 2022- 2023

Residents

Hany Ahmed, M.D., OB-GYN Resident, BCM. Current: Private practice, Houston, TX 2003-2004

Liz Han, M.D., OB-GYN Resident, BCM. Mentored for research project on surgical management of ovarian cancer conducted in China as part of Fulbright Award (Acknowledged in published manuscript); Fellowship. The University of Texas M.D. Anderson Cancer Center; Previous: Assistant Professor, The University of Texas Southwestern School of Medicine. Current: Private Practice, Gynecologic Oncology, Kaiser-Permanente, San Francisco, CA. 2003-2004

Israel Zighelboim, M.D., OB-GYN Resident, BCM. One abstract published with me while at BCM; Fellowship: Washington Univ. St. Louis; Previous: Assistant Professor (GYN ONC), Washington University in St. Louis; >80 publications. Recipient of R21 grant from NIH. Current: Chair, Department of OB-GYN, St. Luke's Medical System, Allentown, PA. 2004-2005

Shannon Hawkins, M.D., Ph.D., OB-GYN Resident, BCM 2004-2005
Previous: Assistant Professor (OB-GYN), Baylor College of Medicine; Four manuscripts and multiple abstracts published (1st place: Resident Research Day, BCM; Pritchard Prize for Resident Research, Texas Association of Obstetricians and Gynecologists (TAOG), Recipient of Liz Tilberis Ovarian Cancer Research grant from Ovarian Cancer Research Fund. Current: Associate Professor, Indiana University School of Medicine.

Rebecca Woo, M.D., MPH. OB-GYN Resident, BCM. (2nd Place Prize, Resident Research Day). Current: Department of Psychiatry, Georgia Regents University. 2005-2006

Kathleen Herway, M.D., OB-GYN Resident, Previous: Postdoctoral Fellowship: Weill Cornell Medical College; Fellowship: Division of Maternal Fetal Medicine, University of Arizona; Current: Assistant Director, Maternal Fetal Medicine, Staten Island University Hospital. 2005-2007

Meaghan Tenney, M.D., OB-GYN Resident, BCM. One abstract. Fellowship: University of Oklahoma School of Medicine; formerly Assistant Professor (GYN ONC), University of Chicago School of Medicine >8 years. Current: Private Practice, Atlanta, GA 2006-2007

Celestine Tung, M.D., OB-GYN Resident, BCM. One publication Fellowship: The University of Texas M.D. Anderson Cancer Center; Current: Assistant Professor (GYN ONC) and Associate Residency Director, Baylor College of Medicine. 2005-2007

<u>Janos Tanyi, M.D.</u> , OB-GYN Resident, BCM. Two publications from projects with me as a resident. Fellowship: University of Pennsylvania School of Medicine. Current: Assistant Professor (GYN Onc) and Leader of Ovarian Cancer Immunotherapy Program, University of Pennsylvania School of Medicine. Active grant-funded researcher in immunotherapy.	2006-2008
<u>Jennifer Burzawa, M.D.</u> , OB-GYN Resident, BCM. One publication collaborating with my laboratory. Fellowship: The University of Texas M.D. Anderson Cancer Center. Current: Assistant Professor (GYN Onc), University of Washington Hutchison Cancer Center.	2006-2008
<u>Saketh Guntupalli, M.D.</u> , OB-GYN Resident, BCM. 2nd place prize at BCM Resident Research Day, 2008; Paper published from research project started in my lab has been cited >100 times Fellowship: Washington University St. Louis; Current: Associate Professor, Director of GYN Onc and Vice-Chair, University of Colorado Anschutz School of Medicine. Recipient of multiple industry sponsored research grants.	2006-2008
<u>Nonna Kolomeyevskaya, M.D.</u> , OB-GYN Resident, BCM. 2nd Place, Resident Research Day, BCM. Two publications Current: GYN Oncology Fellowship, Roswell Park Cancer Center. Current: Private Practice, RWJ/Barnabas Health System, Wall, NJ	2008-2011
<u>Behrouz Zand, M.D.</u> , OB-GYN Resident, BCM. One collaborative manuscript. Fellowship: The University of Texas M.D. Anderson Cancer Center. Current: Assistant Professor (GYN Onc), The University of Texas M.D. Anderson Cancer Center.	2011-2012
<u>Yanett Anaya, M.D.</u> , OB-GYN Resident, BCM. One manuscript in preparation in collaboration with S. Hawkins, MD; Fellow, Division of Reproductive Endocrinology, University of California, San Francisco. Current: Private Practice, Houston, TX.	2011-2013
<u>Marianne Peck, M.D.</u> , OB-GYN Resident, BCM. One manuscript submitted. Post-residency: Gynecologic Surgery Fellowship, G. Fromm, MD, Houston, TX; Current: Private Practice, Kingwood, TX.	2011-2013
<u>Gillian Hsieh, M.D.</u> , OB-GYN Resident, BCM. Two manuscripts and three abstracts published; one manuscript submitted. Featured Poster, 2014 Annual SGO Meeting; First Prize, BCM Resident Research Day. Fellow, Gynecologic Oncology, Stanford University/University of California, San Francisco. Current: Faculty, Palo Alto Foundation, CA.	2013-2015
<u>Anna Biernacka, M.D.</u> , Pathology Resident, BCM. One abstract published and one manuscript in preparation. Fellow, Department of Pathology, The University of Texas M.D. Anderson Cancer Center. Current: Assistant Professor, University of Chicago.	2014-2015
<u>Brittany Van Beek, D.O.</u> OB-GYN Resident, BCM. Collaboratively mentoring with R. Masand (Pathology)	2015-current

<u>Barrett Lawson, M.D.</u> , Pathology Resident, BCM. One abstract submitted. Collaboratively mentoring with R. Masand (Pathology). Current: Private Practice, Akron, OH.	2015-2016
<u>Heather Miller, M.D.</u> , OB-GYN Resident, BCM. Two manuscripts published. One manuscript in preparation. 1st Place Prize, Texas Gynecologic Surgery Symposium, 2017; 2nd Place, 2017 Resident Research Symposium (BCM); Current: Fellowship (Gynecologic Oncology), University of Southern California Keck School of Medicine	2016-current
<u>Joie Guner, MD</u> , OB-GYN Resident, BCM. One abstract presented. One Manuscript in preparation. 2016 SRI Pfizer President's Presenter (SRI); 1st Place, 2017 Resident Research Symposium (BCM); 2019 SRI Pfizer President's Presenter Award, Current: Fellow, REI, Baylor College of Medicine	2016-2018
<u>Michelle Kuznicki, MD</u> , OB-GYN Resident USF MCOM. Plenary Presentation, 2020 Annual Meeting Society for Gynecologic Oncology. Current: Gyn Oncology Fellow, Cleveland Clinic	2018-2019
<u>Angelika Gandhi, MD</u> , OB-GYN Resident, USF Morsani College of Medicine	2018-2019
<u>Clarissa Lam, MD</u> , OB-GYN Resident, USF Morsani College of Medicine. One Manuscript published. Current: Fellowship (Gynecologic Oncology), Memorial Sloan Kettering Cancer Center, NY, NY	2019 - 2022
<u>Brittany Roberts, MD</u> , OB-GYN Residents, USF Morsani College of Medicine; One Abstract; One manuscript submitted	2019 – 2022
<u>Sayed H. Erfani, MD</u> , OB-GYN Resident, Baylor College of Medicine	2020 – 2021
<u>Michelle Whittum, MD</u> , OB-GYN Residents, USF Morsani College of Medicine	2022 – present
<u>Jhaveri Vasanti, MD</u> , OB-GYN Resident, University of Florida Two abstracts published	2022-2023
<u>Jody Wellcome, MD</u> , OB-GYN Resident, University of South Florida; two abstracts, one manuscript submitted	2023 - present

Postdoctoral Fellows

<u>WeiWei Shan, Ph.D.</u> , Department of Obstetrics & Gynecology, BCM; One publication, three abstracts, including an oral presentation at SGI annual meeting. Current: Research Scientist, Castle Biosciences.	2010-2012
<u>Ying-Wooi Wan, Ph.D.</u> Department of Obstetrics & Gynecology, BCM; 8 publications (one highlighted in Nature) and 9 abstracts in 26 months; Co-investigator on 3 funded grants; Manuscript highlighted in Nature. Current: Assistant Professor, Department of Genetics, Baylor College of Medicine.	2012-2019
<u>Abayomi Ogunwale, M.D., M.P.H.</u> , Department of Obstetrics & Gynecology, BCM. Two manuscripts and four abstracts published; One manuscript in press,	2013-2015

two manuscripts in preparation. Current: Fellow, Department of Family Medicine, Duke University

Yiwen Cui, MD, Department of Obstetrics & Gynecology, BCM. Two manuscripts published; one manuscript submitted; three manuscripts in preparation. Current: MRM Fellow, Dept of OB/GYN, Medical College of Wisconsin 2015 - 2017

Ali Wells, MD, Department of Obstetrics & gynecology, USF. One manuscript submitted; 2 manuscripts in preparation. 5 projects ongoing 2020 - 2021

Clinical Fellows

Gary Fruhman, MD, Genetics Fellow, BCM; Current: MFM Fellow, Department of Obstetrics & Gynecology, St. Louis University. 2008-2009

Meaghan Delaney, MD, REI Fellow, BCM. Two abstracts published; three manuscripts in preparation. Featured/Outstanding Abstract, BCM Reproductive Health Symposium; Best Poster Award, Texas Forum for Reproductive Science, 2015. 2016 SRI Pfizer President's Award; Current: Private Practice, Pensacola, FL and Adjunct Faculty, Florida State College of Medicine. 2012-2015

Katy Antony, MD, MFM Fellow, BCM. Two abstracts published and one manuscript submitted. Current: Assistant Professor (MFM), Medical College of Wisconsin. 2013-2015

Joie Guner, MD, Reproductive Endocrinology Fellow, BCM Department of Obstetrics & Gynecology; Two Abstracts Accepted 2018 -2022

Adriane Mallen, MD. Gynecologic Oncology, USF/Moffitt Cancer Center. 10 manuscripts, 11 abstracts, 1 grant awarded, AAOGF Young Investigator Award Submitted (compares to K award). Current: Assistant Professor, University of Minnesota 2019-2020

Andrea Buras MD, Gynecologic Oncology, USF/Moffitt Cancer Center. Two manuscripts published 2019 - 2020

Susan Read, MD. Gynecologic Oncology Fellow, USF. Three abstracts published; one manuscript published, three in preparation. 2019 - 2020

Maya Yasukawa, MD Gynecologic Oncology Fellow, USF/Moffitt; one abstract accepted. One manuscript. 2023 - present

Begum Mathyk, MD Reproductive Endocrinology Fellow, USF Morsani College of Medicine; three manuscripts submitted; 5 abstracts accepted; 7 grants submitted 2024 - present

Graduate Research Training

Graduate Research Mentor

<u>Zhen Li, BS</u> , Doctoral Candidate, Beijing University/Baylor College of Medicine; Two publications. Current: Postdoctoral Fellow, Beijing, China.	2008-2010
<u>Zara Dehgani, BS</u> (Masters Candidate, Department of Biology & Biochemistry, University of Houston; One abstract; Current: Doctoral Candidate, Department of Biology & Biochemistry, Univ. Houston	2009-2011
<u>Jong Kim, BS</u> , (Master Candidate, Department of Biology, University of Houston – Clearlake); Two publications and 4 abstracts; Current: Graduate Student, Department of Biology & Biochemistry, University of Houston	2010-2012
<u>Holli Loomans, BS</u> . (MPH Candidate, University of Texas School of Public Health; PhD (Cell biology), Vanderbilt University. One publication and one abstract. Current: Postdoctoral Fellowship, NCI.	2011-2017
<u>Triparna Ghosh-Choudhury, B.S.</u> , (PhD Candidate, Program in Translational Biology and Molecular Medicine, Baylor College of Medicine. Two manuscripts published; two manuscripts in preparation, four abstracts published. 2014 Georgio Pardi Award for Outstanding Young Investigator, Society for Gynecologic Investigation. 3rd Place Prize, TBMM Retreat, 2015	2012-2015
<u>Laura Sheedy, B.A.</u> (MS Candidate), School of Allied Health, Baylor College of Medicine. One manuscript published. Current: Private Practice, Houston, TX	2010-2012
<u>Jennessa Rooker</u> , BSN (PhD Candidate), University of South Florida College of Nursing, Tampa, FL. Two abstracts published.	2021 -

Thesis Committees

<u>Kari Brewer-Savannah, B.S.</u> , Graduate School, The University of Texas Health Science Center, Houston and The University of Texas M.D. Anderson Cancer Center	2012-2015
<u>Joy Akinfenwe, B.S.</u> , Doctoral Candidate, Translational Biology and Molecular Medicine Program, Baylor College of Medicine	2013-2018
<u>Ninad Oak, B.S.</u> , Doctoral Candidate, Molecular and Human Genetics, Baylor College of Medicine (S. Plon, PhD, Advisor)	2015-2017
<u>Michaela Huynh, B.S.</u> , Doctoral Candidate, Combined MD/PhD Program, University of Texas Medical Branch (L. Sowers, PhD, Advisor).	2016-2018
<u>Julie Tomolonis, B.S.</u> , Doctoral Candidate, Translational Biology and Molecular Medicine Program, Baylor College of Medicine	2016-2018
<u>Jennessa Rooker</u> , BSN, Doctoral Candidate, College of Nursing, University of South Florida	2023 –
Afeyodion Akhator, Bs (PhD Candidate), University of South Florida, Tampa, FL	2025 -

Other Mentoring:

Gynecologic Oncology Rotation, University of Houston College of Pharmacy. Total of 19 Students completed rotation One manuscript published; two abstracts published, including one that was awarded Best Poster, 2012 Annual Meeting, Association of Hospital System Pharmacists. Average Evaluation of Rotation: 5/5 from 19 submitted evaluations	2010 - 2017
Undergraduate Medical Interest Group Rice University Seminar Leader, National Youth Leadership Forum, Organized and led seminar discussions and Q&A sessions on career paths towards health sciences biannually; ~40 high school students/seminar; Mean rating: 4.75 out of 5.0 (best)	2010-2013

Lectures by Invitation (international, national, regional, local)

National

<i>"Spectrophotometric characterization of troponin activation states."</i> Eastern Student Research Forum , Miami, Florida, March 7, 1987.	3/1987
<i>"Identification of Novel Protein Kinase C Activation States."</i> Annual Meeting, American Society for Biochemistry and Molecular Biology , San Diego, CA, June 14, 1993.	6/1993
<i>"The Role of Sustained Protein Kinase C Activation in Insulin Secretion."</i> Annual Fellows Retreat, Howard Hughes Medical Institute , Bethesda, MD, June, 1993.	6/1993
<i>"Challenges in Analyzing Complex Immunohistochemical Patterns."</i> Department of Statistics, Yale University , New Haven, CT, March, 1994.	3/1994
<i>"The role of protein kinase C-alpha in mediating insulin dependent responses in vascular endothelial cells."</i> Annual Meeting, Endocrine Society , Washington, D.C., June, 1995.	6/1995
<i>"A Unique Protein Kinase C Activation State in Pancreatic Beta Cells."</i> Student Research Symposium, Yale School of Medicine , New Haven, CT. June, 1996.	6/1996
<i>"Gene Therapy for Gynecologic Malignancies."</i> Grand Rounds, Department of Obstetrics and Gynecology, Yale University , New Haven, CT. May, 1999.	5/1999
<i>"Characterization of L-plastin expression in tissues relevant to the gene therapy of ovarian cancer."</i> National Gynecologic Oncology Fellows Symposium , San Diego, CA, March, 2000.	3/2000
<i>"Identification of cell cycle proteins involved in the induction of replicative senescence."</i> Annual Meeting, Felix Rutledge Society , Houston, TX, June 15, 2000.	6/2000
<i>"Outcomes of patients undergoing resection of recurrent uterine leiomyosarcoma."</i> Society of Gynecologic Oncologists , Miami, FL, March, 2002.	3/2002

- "Sarcomas and Senescence."* Arizona Cancer Center Grand Rounds, **The University of Arizona Health Science Center**, Tucson, AZ, April 17, 2002. 4/2002
- "Insights into Ovarian Cancer from an Invertebrate Model of Epithelial Invasiveness."* **Women's Health Interdisciplinary Research Symposium, National Institutes of Health**, Bethesda, MD. October 4, 2004. 10/2004
- "Using Drosophila to Understand Ovarian Cancer."* One of four presentations for a plenary mini-symposium on the use of model organisms to understand epithelial carcinogenesis in gynecologic malignancies organized by M.L. Anderson as part of the 52nd Annual Meeting, **Society for Gynecologic Investigation**, Los Angeles, CA, March 26, 2005. 3/2005
- "Dissecting Ovarian Cancer Metastasis."* Department of Obstetrics and Gynecology, **Oregon Health and Science University**, Portland, OR, September 30, 2005. 9/2005
- "Understanding Ovarian Cancer Metastasis."* Department of Obstetrics and Gynecology, **Yale University School of Medicine**, New Haven, CT, December 13, 2005. 12/2005
- "Steroid Hormone Signaling in Ovarian Cancer."* Grand Rounds, Department of Obstetrics and Gynecology. **Emory University School of Medicine**, Atlanta, GA. July 11, 2006. 7/2006
- "Deciphering Steroid Hormones in Ovarian Cancer Metastasis."* Invited Lecture, Women's Health Research Program. **Wayne State University School of Medicine**, Detroit, Michigan, June 5, 2006. 6/2006
- "Activation of Retrogene UTP146 in Ovarian Cancer"* Invited Plenary Presentation, 38th Annual Meeting, **Society of Gynecologic Oncologists**. San Diego, CA May 7, 2007. 5/2007
- "Activation of Spermatogenesis-Related Retrogenes in Ovarian Cancer"*. **Society for Gynecologic Investigation**. Presidential Plenary Address, March 15, 2007. 3/2007
- "Activation of Spermatogenesis-Related Retrogenes in Ovarian Cancers"* Invited Lecture, Women's Health Research Program and Annual Symposium. **Oregon Health Sciences University**. Portland, Oregon, May 17, 2007. 5/2007
- "Novel Genetic Models for Understanding Ovarian Cancer"* Grand Rounds, Department of Obstetrics & Gynecology, **University of Kansas Medical Center**, Kansas City, KS, June 15, 2008. 6/2008
- "Use of Next Generation Sequencing to Identify microRNAs Involved in Ovarian Cancer"* **American Association for Advancement of Science Southwestern Area Regional Meeting**, Houston, Texas, April 9, 2010. 4/2010
- "MicroRNAs and Ovarian Cancer"* One of four presentations for a plenary minisymposium organized by M.L. Anderson as part of the 57th Annual Meeting. **Society for Gynecologic Investigation**, Miami Beach, FL. March 25, 2010. 3/2010

- "MicroRNAs and Novel Paradigms for the Origin of Uterine Cancer,"* 5/2011
Invited Lecture, **International Gynecology Society**, Houston, Texas, May 20, 2011.
- "HPV Genotyping and Cervical Cancer Screening."* Grand Rounds, 5/2011
Department of Obstetrics and Gynecology, **St David's Medical Center**, Austin, Texas, May 10, 2011.
- "The Emerging Role of HPV Genotyping in Clinical Practice",* Grand 5/2011
Rounds, Department of Obstetrics & Gynecology, **Peninsula Regional Medical Center**, Salisbury, Maryland, May 17, 2011.
- "Molecular Diagnostics for Cancer Screening"* Grand Rounds, Department of 9/2011
Obstetrics and Gynecology, **Michigan State University**, Kalamazoo, MI. September 9, 2011.
- "Novel Roles for Non-coding RNAs and RNA Processing in Gynecologic Cancers."* 9/2011
Grand Rounds, Department of Obstetrics & Gynecology and Mott Center for Reproductive Biology, **Wayne State University School of Medicine**, Detroit, MI, September 18, 2011.
- "Integrating HPV Genotyping with Cervical Cancer Screening"* Grand Rounds, 10/2011
Department of Obstetrics & Gynecology, **Michigan State University**, Kalamazoo, MI, October 2, 2011.
- "Novel Roles for MicroRNAs in Ovarian Cancer"* Invited Lecture, Cancer Biology 2/2012
Seminar Series, **Roswell Park Cancer Center**, Buffalo, New York, February 28, 2012
- "Novel Strategies for Molecular Targeting of Ovarian Cancer."* Grand Rounds, 10/2012
Department of Obstetrics and Gynecology, **Medical College of Wisconsin**, Milwaukee, WI, October 4, 2012.
- "Novel Bioinformatic Strategies for Parsing Role of Lin28 Gene Products in Ovarian Cancer."* 2nd Annual Meeting, **Cancer Genome Atlas Consortium**, Arlington, VA, 10/2012
October 24, 2012.
- "Parsing Key Drivers for Ovarian Cancer."* Invited Research Seminar, Georgia 3/2013
Cancer Center, **Georgia Regents University**, Augusta, GA, March 5, 2013.
- "Update on Uterine Smooth Muscle Tumors"* Inaugural Speaker, Cancer Biology 9/2013
Lecture Series, **University of Connecticut Neag Comprehensive Cancer Center**, Farmington, CT. September 20, 2013.
- "MicroRNAs in Uterine Plasticity and Sarcomagenesis"* Invited Research Seminar, 12/2013
University of Maryland Comprehensive Cancer Center, December 9, 2013.
- "MicroRNAs and Novel Pathways Driving Ovarian Cancer Growth and Metastasis"* 4/2015
Invited Research Seminar, **Simon Cancer Center, Indiana University School of Medicine**, April 14, 2015.

<i>“Emerging Strategies for Gynecologic Cancer Prevention”</i> American College of Obstetricians and Gynecologists , Annual Clinical and Scientific Meeting, San Francisco, CA, May 2, 2015.	5/2015
<i>“Personalized Therapy for Ovarian Cancer: Promise and Pitfalls”</i> The Ella T. Grasso Memorial Conference (Jointly sponsored by Yale University and The University of Connecticut), Hartford, CT, November 11, 2015.	11/2015
<i>“Novel Strategies for the Prevention of Gynecologic Cancers”</i> Department of Women’s Health, The University of Texas Dell School of Medicine , Austin, TX, September 1, 2016.	9/2016
<i>“Novel Roles of microRNAs in Ovarian Cancer”</i> Department of Obstetrics & Gynecology, Albert Einstein College of Medicine, Bronx, NY, July 10, 2016.	7/2016
<i>“System-based Approaches to Cervical Cancer Prevention”</i> Montefiore/ Albert Einstein College of Medicine Cancer Center , Bronx, NY, September 6, 2016.	9/2016
<i>“Impact of CPRIT funding on Medically Underserved Texans”</i> Texas State Legislature . Austin, TX, March 30, 2017.	3/2017
<i>“Personalized Therapy for Ovarian Cancer: Powered by PARP.”</i> OVARCOME National Conference , Houston, Texas, September 29, 2017.	9/2017
<i>“Progress towards Genetically Targeted Therapies for Ovarian Cancer- Powered by PARP.”</i> The Ella T. Grasso Memorial Conference (Jointly sponsored by Yale University and The University of Connecticut), Hartford, CT, November 15, 2017.	11/2017
<i>“The Emerging Role of PARP Inhibitors in Ovarian Cancer”</i> University of California Davis School of Medicine , Sacramento, CA, January 8, 2018.	1/2018
<i>“System-based approaches for Improving Rates of Cervical Cancer Screening.”</i> Florida Leadership Summit to Eliminate HPV-related Cancers , Moffitt Cancer Hospital and Research Institute, Tampa, FL, March 4, 2020.	3/2020
<i>“Use of PARP inhibitors for treatment of ovarian cancer”</i> Targeted Oncology Virtual Case-Based Roundtable . Tampa, FL June 25, 2020.	6/2020
<i>“Ovarian Cancer”</i> Targeted Oncology Virtual Case-Based Roundtable . Tampa, FL April 28, 2022.	4/2022
<i>“Ovarian Cancer”</i> Targeted Oncology Virtual Case-Based Roundtable , Florida-wide Event, April 20, 2023	4/2023
<i>“Personalizing Ovarian Cancer Therapy”</i> State of the Science Symposium – Gynecologic Cancers , Moderator and Speaker, Tampa, FL, October 26, 2023	10/2023
<i>“Addressing Disparities in Women’s Health”</i> Center for the Study of Women, Gender, and Sexuality , Rice University, November 16, 2023	11/2023

- "Parsing the Role of Heated Intraperitoneal Chemotherapy in Management of Ovarian Cancer"* **Michigan Ovarian Cancer Symposium**, Wayne State University, Detroit, Michigan, November 3, 2023 11/2023
- "The Need for Novel Strategies to Address Health disparities"* Innovation Challenge Kick-Off, **Synapse Florida Symposium**, Nova University, Fort Lauderdale, FL December 6, 2023 12/2023
- "Update on Endometrial Cancer Biology"* **Florida Society for Gynecologic Oncology (FSGO)**, Longboat Key, FL; June 7, 2024 6/2024

International

- "Conditioning-specific Changes in the Distribution of Protein Kinase C in the Rabbit Hippocampus."* **European Neuroscience Association/European Brain and Behavior Society**, Zurich, Switzerland, September 4, 1988. 9/1988
- "Long-term Learning Specific Changes in the Distribution of Protein Kinase C in Rabbit Hippocampus."* **Society for Neuroscience**, Toronto, Canada, November 13, 1988. 11/1988
- "Small Molecule Inhibitors for Polo-Like Kinase-1 (PLK-1) Sensitize Uterine Leiomyosarcoma to Rapamycin."* 17th Annual Meeting, **Connective Tissue Oncology Society**, Prague, Czech Republic, November 16, 2012. 11/2012
- "Update on Cervical Cancer"* **Peruvian American Medical Society**, Chinchu, Peru, February 5, 2013. 2/2013
- "Emerging Techniques for Cervical Cancer Screening"* **Peruvian Medical Association**, Joint Annual Meeting, Iquitos, Peru, August 15, 2014. 8/2014
- "Clinical Management of Recurrent Ovarian Cancer: Successes and Challenges"* **Glaxo Smith Kline Clinical Immersion in Ovarian Cancer Retreat**, London, England, December 10, 2020 (invited lecture; >500 participants worldwide) 12/2020
- "Case-Based Roundtable"* **Glaxo Smith Kline Clinical Immersion in Ovarian Cancer Retreat**, London, England, December 10, 2020 (invited lecture, >500 participants worldwide) 12/2020
- "Use of PARP inhibitors as first line maintenance therapy for ovarian cancer"* **European Society for Medical Oncology**, Virtual Review Course; October 24 2021 10/2021

Regional/Local

- "Management of Gynecologic Malignancies in Pregnancy."* Invited Lecture, Department of Gynecologic Oncology, **The University of Texas M.D. Anderson Cancer Center**, April, 2000. 4/2000
- "Characterization of L-plastin expression in tissues relevant to gene therapy of ovarian cancer."* Research Symposium, **The University of Texas M.D. Anderson Cancer Center**, Houston, TX, April, 2000. 4/2000

- “Ku-80 expression correlates inversely with the onset of replicative senescence.”* 4/2001
Trainee and Fellow Research Symposium, **The University of Texas M.D. Anderson Cancer Center**, Houston, TX, April 27, 2001.
- “Pelvic Sarcomas.”* Invited Research Lecture, Department of Gynecologic Oncology, **The University of Texas M.D. Anderson Cancer Center**, Houston, TX, August 8, 2001. 8/2001
- “Outcomes of Patients Undergoing Resection of Recurrent Uterine Leiomyosarcoma.”* Invited Lecture, **Felix Rutledge Society**, Houston, TX, June 8, 2002. 6/2002
- “Sarcomas and Senescence.”* Obstetrics and Gynecology Research Conference, **Baylor College of Medicine**, Houston, TX, October 24, 2002. 10/2002
- “A Molecular Approach to Female Reproductive Malignancies.”* **Rice University**, Houston, TX, February 18, 2003. 2/2003
- “Molecular Pathogenesis of Cervix Cancer.”* Department of Gynecologic Oncology, **University of Texas M.D. Anderson Cancer Center**, Houston, TX, April 25, 2003. 4/2003
- “A Genetic Model for Understanding Epithelial Invasiveness.”* Plenary Address, Resident Research Day, **Baylor College of Medicine**, Houston, TX, May 9, 2003. 5/2003
- “Novel Approaches to Dissecting Epithelial Invasiveness.”* BIRCWH Seminar Series, **Baylor College of Medicine**, Houston, TX, May 20, 2003. 5/2003
- “Dissecting the Role of AIB-1 in Epithelial Ovarian Cancer.”* Grand Rounds, Department of Obstetrics and Gynecology, **Baylor College of Medicine**, October 29, 2003. 10/2003
- “Genetic Approaches to Understanding Ovarian Cancer.”* **The Partnership for Baylor College of Medicine**, St. Regis, Houston, TX, November 18, 2003. 11/2003
- “A Translational Model for Understanding Ovarian Cancer.”* Director’s Research Initiative, **Baylor Cancer Center**, Houston, TX, November 26, 2003. 11/2003
- “Role of AIB1 in Ovarian Cancer.”* Research Workshop Series, Department of Molecular and Cellular Biology, **Baylor College of Medicine**, Houston, TX, April 8, 2004. 4/2004
- “Nitrogen Mustards and Chemoprotectants.”* School of Pharmacy, **University of Houston**, Houston, TX, August 9, 2004. 8/2004
- “Cancers of the Female Reproductive Tract.”* **Rice University**, Houston, TX, February 23, 2005. 2/2005

- “Cervical Dysplasia, HPV, and New Vaccines.”* Community Outreach Program, **Houston Northwest Medical Center**, Houston, TX, December 6, 2005. 12/2005
- “Steroid Hormone Signaling in Ovarian Cancer.”* Interdisciplinary Women’s Health Seminar Series, **Baylor College of Medicine**, Houston, TX, March 3, 2006. 3/2006
- “HPV and Cervical Cancer”* Grand Rounds, Department of Obstetrics and Gynecology, **Baylor College of Medicine**. Houston, TX September 5, 2006. 9/2006
- “HPV, Cervix Cancer and New Immunizations: From Bench to Clinic”* Grand Rounds, Department of Medicine, **Saint Luke’s Episcopal Health System**, Houston, TX. October 23, 2006. 10/2006
- “The Impact of Ethnicity on Access to Hospice”* End-of-Life Care Symposium. **Harris County Hospital District**, Houston, TX January 12, 2007. 1/2007
- “Small RNAs and Uterine Smooth Muscle Tumors.”* Grand Rounds, Department of Obstetrics and Gynecology, **Baylor College of Medicine**, October 29, 2008. 10/2008
- “Update on Cervical Cancer.”* **Harris County Hospital District Clinical Retreat**, January 23, 2009. 1/2009
- “Non-Coding RNAs and Novel Growth-Regulating Pathways in Uterine Smooth Muscle”* Research Seminar Series, Department of Molecular and Cellular Biology, **Baylor College of Medicine**, March 9, 2009. 3/2009
- “Non-coding RNAs and Uterine Smooth Muscle Tumors”* Seminar Series, Department of Sarcoma Biology, **The University of Texas M.D. Anderson Cancer Center**, September 17, 2009 9/2009
- “Update on Ovarian Cancer.”* Grand Rounds, Department of Internal Medicine, **St. Luke’s Episcopal Hospital**, Houston, Texas, September 28, 2009 9/2009
- “Genetic Susceptibility to Ovarian Cancer”* Invited Lecture, **Temple Beth Israel**, Houston, Texas June, 2009 6/2009
- “What do I need to know about ovarian cancer?”* Undergraduate Cancer Alliance, **University of Houston**, April 11, 2010. 4/2010
- “Revolutionizing Care for Ovarian Cancer”* Invited Lecture for >250 community members, **Partnership for Baylor College of Medicine**, Houston, Texas, September 20, 2010. 9/2010
- “Update on HPV and Cervical Cancer”* Grand Rounds, Department of Family Practice, **Baylor College of Medicine**, Houston, Texas, October 20, 2010 10/2010
- “The Genetic Evolution of Cervical Cancer Screening”* Grand Rounds, Department of Obstetrics and Gynecology, **The University of Texas Health Science Center**, Houston, Texas, November 23, 2010. 11/2010

" <i>Novel Diagnostic and Therapeutic Roles for Small Non-coding RNAs in Ovarian and other Gynecologic Cancers</i> " Grand Rounds, Texas Woman's Hospital , Houston, Texas, January 7, 2011.	1/2011
" <i>MicroRNAs and Ovarian Cancer</i> ," Invited Lecture for ~50 community members, Cancer Fighters of Texas , Houston, Texas, March 21, 2011	3/2011
" <i>Novel Roles for microRNAs in Gynecologic Cancers</i> ," Grand Rounds Department of Cancer Biology & Metastasis Research Center Seminar Series, The University of Texas M. D. Anderson Cancer Center , Houston, Texas, April 19, 2011.	4/2011
" <i>Managing Ovarian Cancer Risk</i> ." First Annual Hereditary Breast and Ovarian Cancer Conference, Baylor College of Medicine , Houston, TX, October 28, 2011.	10/2011
" <i>Update on Cervical Cancer Prevention Efforts</i> " Cancer Committee Executive Meeting, Harris County Hospital District , Houston, Texas, May 14, 2012.	5/2012
" <i>Cervical Cancer and Prostate Cancer Prevention: Contrasting Efficacies</i> " Invited Lecture, Physician Oncology Education Program, Texas Medical Association Houston, TX October 30, 2012.	10/2012
" <i>Recent Insights into Ovarian Cancer</i> ". Invited Lecture, First Annual Cancer Summit, Saint Luke's Episcopal Health System , Houston, TX, March 28, 2013.	3/2013
" <i>Management of Uterine Leiomyosarcoma: Emerging Strategies</i> " Grand Rounds, Texas Women's Hospital , Houston, TX, April 5, 2013.	4/2013
" <i>Uterine Smooth Muscle Tumors</i> " Grand Rounds, Department of Obstetrics and Gynecology, Texas Children's Hospital Pavilion for Women , May 1, 2013.	5/2013
" <i>System-Based Approaches to Improving Rates of Cervical Cancer Screening</i> " Grand Rounds, Department of Obstetrics & Gynecology, Texas Children's Hospital Pavilion for Women . September 23, 2014.	9/2014
" <i>Novel Insights into Smooth Muscle Tumorigenesis</i> " Featured Speaker, BCM Reproductive Health Science Day , February 25, 2015.	2/2015
" <i>Precision Approaches to Ovarian Cancer</i> " Dan L. Duncan Cancer Center Symposium , Houston, TX, November 6, 2015.	11/2015
" <i>Update on CPRIT-funded Cervical Cancer Prevention Activities</i> " Grand Rounds, Department of Obstetrics & Gynecology, Texas Children's Hospital Pavilion for Women , Houston, Texas, September 7, 2016.	9/2016
" <i>Systems-level Interventions to Improve Cervical Cancer Screening</i> " 2023 Tampa Bay HPV Leadership Roundtable , American Cancer Society, Tampa, FL October 5, 2023	10/2023
"The Challenge of Rural Cancer Care in Florida" Cancer Control Continuum in Rural Communities Symposium, Florida Department of Health , Brooksville, FL March 5, 2025.	3/2025

- “Cervical Cancer Prevention and Screening Through Rural Outreach” Cancer Control Continuum in Rural Communities Symposium, **Florida Department of Health**, Brooksville, FL March 5, 2025. 3/2025
- “Role of the Microenvironment in Determining Response of Endometrial Cancers to Immune Checkpoint Inhibitors” **Tampa General Hospital Cancer Institute**, Tampa, FL, May , 2025 4/2025
- “Role of Somatic Tumor Profiling in Gynecologic Malignancies” **Florida Society for Gynecologic Oncology**, Longboat Key, FL, June 12, 2025 6/2025

SCHOLARLY ACTIVITY

Grants

Pending (Submitted, or Awarded but not yet active)

Agency: **Florida Department of Health**

9/1/2025 -

Title: An AI-enhanced Platform to Overcome Barriers to Cancer Prevention In Rural Communities

Role: PI

Total Direct Costs: \$1,991,178

Project Goals: 1) Develop an AI-enhanced navigation platform to support the implementation of “point of destination” HPV self-testing and 2) Leverage CareComm to overcome barriers to the evaluation and treatment of abnormal cervical cancer screening results in communities with limited access to specialized gynecologic care

Status: Awarded, pending activation

Agency: **National Institute of Health** (CFD Research)

Pending

Title: An Organ-On-A-Chip Approach to Evaluating Human Reproduction

Role: Site PI

Total Direct Costs: \$231,998 (USF only)

Project Goals: Develop a complete 3-D model of human uterus suitable for evaluating the impact of microgravity of human reproduction and dysfunction

Status: In Review

Agency: **Regeneron Pharmaceuticals, Inc.**

4/2025 -

Title: A Multi-Arm Phase 2 Study of Ubamatamab Bispecific antibody with or without additional agents in platinum-resistant ovarian cancer. (R4018-ONC-2445)

Role: Site PI

Total Direct Costs: \$229,480

Project Goals: Assess the ORR of ubamatamab alone or in combination with bevacizumab, cemiplimab plus fianlimab, or liposomal doxorubicin

Status: Awarded, Awaiting Site Activation

Agency: National Aeronautics and Space Agency (**NASA**).

4/2025 -

Title: **Florida Space Grant Consortium**

Role: Co-PI

Total Direct Costs: \$25,000

Project Goals: Assess the impact of microgravity on human endometrium and its implications for reproductive health

Status: Under review

Active (20 total)

Agency: **Elephas Biosciences, Inc.**

5/1/2025 -

Title: Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (BSK22-562)

Role: Site PI

Anticipated Total Direct Costs: \$22,961

Project Goals: Determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1

Agency: **University of South Florida**

Title: Aerospace Science, Technology, Research, and Applications Center (ASTRA)

Role: co-I

Total Direct Costs: \$150,000

Projects Goals: Foster collaboration across disciplines, including engineering, medicine, business, arts, and sciences and establish USF a leading presence in space travel and research.

Agency: **University of South Florida IDEA Award**

9/1/2024 –

Title: Precision Medicine Initiative

8/31/2027

Role: Co-I

Total Direct Costs: \$1.5M

Project Goals: Expand and establish dedicated infrastructure for single cell and spatial transcriptomics at the University of South Florida

Agency: **University of South Florida CREATE Award**

9/1/2024 –

Title: Precision Medicine Initiative

8/31/2027

Role: Co-I

Total Direct Costs: \$500,000

Project Goals: Utilize spatial transcriptomics to decipher the role of spatially restricted patterns of CD73 expression on determining the immune microenvironment of uterine leiomyomas

Source: **U.S. Department of Defense Ovarian Cancer CDMRP**

10/1/2024 –

Title: Multi-omic Evaluation of Ovarian Cancer Responses to Heated Intraperitoneal Chemotherapy

9/30/2027

Role: Initiating PI

Total Direct Costs: \$1,200,000

Project Goals: (1) identify unique patterns of preexisting genomic alterations and gene expression associated with prolonged progression-free survival (PFS) following HIPEC, (2) interrogate the EOC proteome and phosphoproteome to identify signaling pathways associated with prolonged PFS following HIPEC, and (3) determine whether HIPEC downregulates BRCA2 and other gene products involved in HR in EOC *in vivo*.

Agency: **National Institutes of Health (Theradex, Inc)**

3/19/2024 -

Title: **Cancer** Moonshot Biorepository

Role: Site PI

Total Direct Costs: Pending

Project Goals: Leverage the TGH/USF Health Precision Medicine Biorepository to support the scientific objectives of the Cancer Moonshot-funded NCI Drug Resistance and Sensitivity Network

Agency: **Cybrexa 2, Inc.**

6/1/2025 -

Title: CBX-12-201: A Randomized Phase 2 Study of CBX-12 in Subjects with Platinum Resistant or Refractory Ovarian Cancer

Role: Site PI

Total Direct Costs: Pending

Project Goals: Evaluate the preliminary anti-tumor activity of CBX-12 in platinum resistant or refractory ovarian cancer based on objective response rate (ORR) per RECIST criteria

Agency: **Gilead Sciences, Inc.**

9/16/2024 –

Title: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants with Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

9/15/2027

Role: Site PI

Total Direct Costs: Pending

Project Goals: Assess the impact of sacituzumab govitecan on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS)

Agency: **Genelux, Inc**

8/01/2021-

Title: A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer (OnPrime/GOG-3076 Study)

7/31/2025

Role: Site PI

Total Direct Costs: pending

Project Goals:

Agency: **Patient Center Outcomes Research Network (PCORnet)**

4/15/2020 -

Title: OneFlorida PCORnet (Phase 3)

9/30/2026

Project Number: RI-FLORIDA-01-MC/SUB00003061

Role: Site PI/Program Wide Co-Investigator (10% Effort), Lead for Program Engagement

Total Direct Costs: \$574,200 (USF site only)

Project Goals: 1) Expand and enhance participation of USF and TGH in OneFlorida Data Trust; 2) Serve as network-wide investigator with role of developing and promoting pragmatic clinical trial platforms.

Agency: **National Cancer Institute (NCI)**

4/16/2019-

Title: University of South Florida as a Tissue Source Site for the Clinical Proteomics Tumor Analysis Consortium (CPTAC).

6/30/2026

Project Number: 75N91020F00030

Role: P.I.

Total Direct Costs: \$250,000 (est)

Project Goals: 1) Generate and provide high quality specimens of five specific cancer types along with matched clinical demographics and clinical images that conform to pre-determined criteria; 2) Contribute to relevant CPTAC disease working groups as scientific and medical content expert.

Agency: **National Institute of Health Disparities (NIH)**

12/11/2023 –
12/10/2025

Title: Prospective Evaluation of Self-Sample HPV Testing as Additive Strategy to Improve Primary Cervical Cancer Screening.

Project Number: RO1 MD013715

Role: Co-I (Relinquished role of co-PI in multi PI trial to join USF)

Total Direct Costs: \$1,224,663

Project Goals: 1) Prospectively determine whether mailed self-sample HPV testing with one-on-one patient education/navigation improves participation in primary cervical cancer screening among women who fail to participate in standard of care strategies. 2) Evaluate the cost-effectiveness of cervical cancer screening strategies for integrated health systems that include self-sample HPV testing for non-attendees

Source: **Sutro BioPharma, Inc**

6/6/2023 –
6/5/2028

Title: A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab (002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)

Project Number: STRO-002-GM3/GOG-3086:

Role: Site PI

Total Direct Costs: \$154,899

Project Goals: 1) To evaluate the efficacy of luveltamab tazevibulin in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1. 2) To evaluate the safety and tolerability of luveltamab tazevibulin in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1.

Source: **Glaxo Smith Kline, LLC**

1/3/2022 –
1/2/2027

Title: OPALCohort C/ Tesaro: An Open-Label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Carboplatin-Taxane Doublet Chemotherapy as Neoadjuvant Treatment In Participants With Homologous-Recombination Deficient Stage III/I

Role: Site PI

Total Direct Costs: \$88,975

Project Goals: 1) To evaluate the efficacy of the study drug or study drug combination as determined in each cohort-specific supplement. 2) To evaluate the safety and tolerability of the study drug or study drug combination as defined in each cohort-specific supplement

Source: **Sutro BioPharma, Inc**

1/24/2022 –
1/23/2027

Title: A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolR α) Antibody Drug Conjugate with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Endometrial Cancer)

Project Number: STRO-002-GM2

Role: Site PI

Total Direct Costs: \$116,182

Project Goals: 1) To evaluate the safety and tolerability of STRO-002 as a monotherapy. 2) To characterize the PK of STRO-002 when administered as a monotherapy

Source: **K-Group Beta, Inc.**

2/1/2021 -

Title: A Phase 2 Open-Label, Multicenter Study To Evaluate The Efficiency and Safety of ZN-C3 In Adult Women With Recurrent Or Persistent Uterine Carcinoma With Solid Tumors

Project Number: ZN-C3-004/ GOG-3065

Role: Site PI

Total Direct Costs: \$2,232,889

Project Goals: 1) To investigate the antitumor activity of ZN-c3 based on objective response rate (ORR). 2) To further investigate antitumor activity based on duration of response (DOR) and progression-free survival

Agency: **Caris, Inc.**

1/3/2021 –

Title: Caris Tissue Biorepository

10/31/2026

Role: Site PI

Total Direct Costs: (\$500/specimen)

Project Goals: 1) Procedure specimens of whole blood from recently diagnosed with advanced stage ovarian and uterine cancers (target enrollment >250 women/year); 2) Abstract and submit matched clinical demographics linked to submitted specimens.

Source: **K-Group Beta, Inc.**

9/26/2022 –

Title: A Phase 1 study of ZN-C3 as A Single Agent In Subjects With Solid Tumors

6/30/2025

Project Number: ZN-C3-001:

Role: Site PI

Total Direct Costs: \$67,628

Project Goals: 1) To investigate the association between molecular characteristics of tumor tissue and clinical effects of ZN-C3. 2) Determination of parameters including, but not limited to HER2 status, microsatellite instability/mismatch repair (MSI/MMR) status, and Cyclin E expression in tumor tissue

Agency: **Caris Life Sciences, Inc.**

2/8/2023 –

Title: ROADMAP: Caris Retrospective Real-world Outcomes-Associated Database, Multi-site Precision Oncology Alliance™ Protocol (ROADMAP)

9/11/2023

Project Number: COE-002-1116

Role: Site PI

Total Direct Costs: \$222,222

Project Goals: 1) Effecting change in disease treatment processes by advancing precision medicine and improving care for cancer through acquiring and sharing valuable molecular tumor profiling information and clinical outcomes in a collaborative, secure environment. 2) Performing retrospective research including clinical presentation, treatment and outcomes. This eligible cohort includes select subjects who have already undergone Caris profiling evaluation for diagnosis and/or treatment management.

Agency: **MT Group, Inc.**

Title: Translational Medicine: Discovery and Evaluation of

Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients

Project Number: MT-3505A

Role: Site PI

Total Direct Costs: \$107,407

Project Goals: 1) Optimize translational research, diseased and normal tissue and peripheral blood are required during the discovery, selection, and validation phases of pharmacogenomic/proteomic research to optimize the effectiveness of existing and new drugs along with the development of novel assays. 2) These biologic material samples have gone a long way in advancing basic and translational research and the commercialization of drugs and assays that have improved patient outcome

Completed (54 total)

Agency: **U.S. Department of Defense Ovarian Cancer CMRP**

6/1/2020-

Title: Subset of Pre-Existing, Poly-Resistant Cancer Stem Cells in High-Grade Serous Ovarian Cancer

8/21/2023

Role: Co-Investigator

Total Direct Costs: \$60,954 at USF

Project Goals: 1) Identifying Pre-existing, Poly-Resistant Clones Across Cohort of HGSOc cases. 2) Establish the Epigenetic Basis of Polyresistance within Each Case. 3) Mechanisms Underlying and Therapeutic Targeting of Poly-Resistance.

Agency: **Tesaro, Inc**

5/1/2018 –

Title: NIVIX: A phase I/II study of niraparib with radiotherapy for treatment of metastatic invasive carcinoma of the cervix.”

8/31/2023

Role: Co-PI

Total Direct Costs: \$453,000

Project Goals: 1) establish the maximum tolerated dose (MTD) of niraparib when administered concurrently with whole pelvic radiotherapy and b) determine the local (pelvic) control rates for patients with metastatic cervical cancer treated with definitive radiotherapy.

Agency: **Mersana, Inc.**

9/15/2022 –

Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy For Participants With Recurrent, Platinum-Sensitive Ovarian Cancer (UP-NEXT)

9/15/2023

Project Number: MERXMT 153603/ GOG-3049

Role: Site Co-PI

Total Direct Costs: \$96,688

Project Goals: 1) Demonstrate superiority in Progression-free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) of upifitamab rilsodotin versus placebo as maintenance therapy. 2) Evaluate safety and tolerability in participants treated with upifitamab rilsodotin versus placebo as maintenance therapy

Agency: **National Institute of Allergy and Infectious Disease (NIAID)**

5/1/2020 –

Title: Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)

4/28/2023

Role: Site PI

Total Direct Costs: \$315,849

Project Goals: Assess the relationship between COVID19 viral burden and molecularly defined immune signatures to delineate biomarkers of acute disease severity, mortality, the development of durable immunity, and long-term outcomes in survivors.

Agency: **Astra Zeneca**

9/15/2022-

Title: FLAME: First Line Olaparib Maintenance Beyond BRCA: An Observational Cohort Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy Beyond BRCA Mutant Status in Newly Diagnosed Advanced Ovarian Cancer,

1/20/2024

Role: Site PI

Costs: \$88,975

Project Goals:

Source: **Sutro BioPharma, Inc**

6/20/2020 -

Title: A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolR α) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Primary Peritoneal Cancers) and Endometrial Cancers

8/15/2023

Project Number:

Role: Site PI

Total Direct Costs: Pending

Project Goals: Evaluate the safety, and tolerability of STRO-002 in adult subjects with relapsed and/or progressive EOC (including fallopian tube and primary peritoneal cancer) and epithelial endometrial cancer.

Agency: **InterVenn Biosciences**

6/15/2022 -

Title: VOCAL: Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy

1/18/2024

Role: Site PI

Costs: \$36,150

Project Goals: The primary objective of this study is to determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the Venn Ovarian Cancer Liquid Biopsy among women with ovarian adnexal mass for which a surgery is planned. Tumor primary site and malignancy will be confirmed by histopathologic examination

Agency: **Cancer Prevention and Research Institute of Texas (CPRIT)**

12/1/2016-

Title: RP170387: Development and Validation of a Network-guided, Multi-objective Optimization Model for Cancer Data Analysis

11/30/2019

Role: Co-PI (Multi-PI Project Format)

Total Direct Costs: \$889,679

Project Goals: 1) Analyze the performance of the proposed Multi-outcome Prediction Algorithm (MPA) on cancer genomics profiles in simulated and pan-cancer datasets. 2) Develop Methods for Network Guided Multi-outcome prediction from heterogeneous genomic and epigenomic data. 3) Validate the ability of MPA to identify functional gene modules determining survival and the response of ovarian cancer to platinum-based chemotherapy.

Agency: **National Cancer Institute (NCI)**

3/1/2016-

Title: Baylor College of Medicine as a CPTAC Tissue Source Site

12/31/2018

Role: Principal Investigator

Total Direct Costs: \$189,000

Project Goals: Collect and submit high quality specimens of 6 cancer types along with matched, coded clinical demographics to CPTAC consortium.

Agency: **Cancer Prevention and Research Institute of Texas (CPRIT)** 12/1/2015-
Title: PP160049: Expansion of a Comprehensive Cervical Cancer Screening Program 12/31/2018
for Medically Underserved Women in Harris County

Role: PI

Total Direct Costs: \$1,500,000

Project Goals: Increase the numbers of high risk under- and uninsured women in Harris County screened for cervical cancer and pilot a medical home model for cervical cancer prevention.

Agency: **National Cancer Institute (NCI)** 4/1/2018-
Title: Phase I/2 trial of ABT-888, an inhibitor of poly (ADP-Ribose) Poly-merase 10/20/2018
(PARP) & topotecan (TPT) in patients with solid tumors (Phase 1) and relapse ovarian cancer or primary peritoneal cancer (Phase 2) after prior platinum containing first-line chemotherapy

Role: Site PI

Project Goals: Assess the safety and efficacy of ABT-888, a novel PARPi, in combination with topotecan for patients with ovarian cancer.

Agency: **U.S. Department of Defense Ovarian Cancer CMRP** 1/1/2015-
Title: OC140269: Utilizing Synthetic Lethality to Sensitize Ovarian Cancers to 12/31/2018
Chemotherapy

Role: co-P.I.

Total Direct Costs: \$225,000

Project Goals: 1) Dissect the role of miR-520h in sensitizing ovarian cancer to chemotherapy; 2) Determine relationship between mesenchymal transition, ovarian cancer self-assembly and patterns of mir-520h regulated gene expression.

Agency: **Tesaro, Inc.** 5/20/2017-
Title: A phase I dose escalation and cohort expansion of TSR-042, an anti-PD-1 10/20/2018
monoclonal antibody in patients with advanced solid tumors

Role: Site PI

Total Direct Cost: \$22,952/pt

Project Goals: Assess the safety and preliminary efficacy of TSR-042.

Agency: **KK125 Foundation** 3/1/2016-
Title: Viral Microbiome and High Risk BRCA Mutations 12/31/2018

Role: Principal Investigator

Total Direct Costs: \$50,000

Project Goals: 1) Determine whether high risk BRCA1/2 mutations impact the microbiome of the distal human fallopian tube.

Agency: **U.S. Department of Defense Ovarian Cancer CMRP** 1/1/2015-
Title: OC140330: Viral MicroRNAs in Ovarian Cancer Growth and Metastasis 12/31/2017

Role: P.I.

Total Direct Costs: \$225,000

Project Goals: 1) Evaluate the clinical significance of additional EBV, HCMV and KSV viral microRNAs; 2) Assess the impact of dysregulated EBV, HCMV, KSV microRNA expression in ovarian cancers.

Agency: **Cancer Prevention and Research Institute of Texas (CPRIT)** 12/1/2014-
Title: Empowering the Medically Underserved Through a Community Network for 11/30/2017
Cancer Prevention

Role: Co-Investigator

Total Direct Cost: \$1,499,234

Project Goals: 1) Develop educational outreach to improve rates of cervical and colorectal cancer screening 2) Expand patient navigation systems to improve rates of follow up for abnormal cervical cytology.

Agency: **National Science Foundation/National Institute of General Medical Sciences** 10/1/2013-
9/30/2017

Title: 1-DMS-1263932: Statistical Methods for Integrated Analyses of High-Throughput Biomedical Data

Role: Co-Investigator

Total Direct Costs: \$438,436

Project Goals: Develop statistical tools needed to analyze and mine data for biomarker discovery, delineation of disrupted disease networks.

Agency: **Golfers Against Cancer Foundation** 4/1/2016-
3/31/2017

Title: Microbiome of the Distal Human Fallopian Tube

Role: P.I.

Total Direct Costs: \$47,000

Project Goals: 1) Define microbiome of distal fallopian tube; 2) Assess impact of ovarian cancer risk factors on fallopian tube microbiome

Agency: **Burroughs Wellcome Foundation** 7/1/2013-
6/30/2017

Title: BWF1012536: Progesterone Receptor Function in Gravid Myometrium

Role: Co-P.I.

Total Direct Costs: \$600,000

Project Goals: 1) Dissect progesterone regulated pathways in human myometrium 2) Ascertain the role of PR-regulating signaling in premature labor.

Agency: **Cancer Prevention and Research Institute of Texas (CPRIT)** 9/1/2014-
8/31/2016

Title: RP140225: Viral MicroRNAs in Ovarian Cancer Growth and Metastasis

Role: P.I.

Total Direct Costs: \$199,985

Project Goals: 1) Assess the clinical relevance of viral microRNA expression in epithelial ovarian cancer. 2) Dissect the mechanisms by which ebv-miR-BART3 and hcmv-miR-UL112 impact ovarian cancer growth and metastasis in vitro and in vivo.

Agency: **Computational and Integrative Biomedical Research Center (CIBR)** 1/1/2015-
12/31/2015

Title: Network Guided Multi-outcome Models for Cancer Genomics

Role: Co-P.I.

Total Direct Costs: \$15,000

Project Goals: 1) Analyze the performance of NetMomo algorithm on cancer genomics profile in simulated and pan-cancer datasets; 2) Establish that the overexpression of Alk sensitizes ovarian cancers to standard of care platinum chemotherapy in vitro and in vivo.

<u>Agency:</u> Ovarian Cancer Research Foundation (OCRF)	1/1/2012-
<u>Title:</u> Diagnostic Strategies for Detection of Ovarian Cancer.	12/31/2015
<u>Role:</u> Co-Program Leader (5% Effort)	
<u>Total Direct Costs:</u> \$846,880	
<u>Project Goals:</u> 1) Use mouse model for ovarian cancer to identify secreted gene products useful for early detection of ovarian cancer. 2) Dissect patterns of alternative RNA splicing in ovarian cancer.	
<u>Agency:</u> National Cancer Institute (NCI) (P30 Supplement)	9/1/2014-
<u>Title:</u> The Houston HPV Initiative	10/31/2015
<u>Role:</u> Co-Investigator	
<u>Total Direct Costs:</u> \$100,000	
<u>Project Goals:</u> 1) Perform a community survey to assess needs for improving rates of HPV vaccination in pediatric populations.	
<u>Agency:</u> National Institute of Genome Research (NIHGR)	9/1/2012-
<u>Title:</u> HHSN261200800001E: TCGA Clinical Repository	8/31/2015
<u>Role:</u> P.I.	
<u>Total Direct Costs:</u> \$108,000	
<u>Project Goals:</u> 1) Collect high quality specimens of gynecologic cancers suitable for TCGA goals 2) Abstract de-identified demographics for submitted specimens.	
<u>Agency:</u> Cancer Prevention and Research Institute of Texas (CPRIT)	3/1/2012-
<u>Title:</u> PP120091: Developing a Comprehensive Cervical Cancer Screening Program for High Risk Under- and Uninsured Women in Harris County	8/31/2015
<u>Role:</u> PI	
<u>Direct Costs:</u> \$1,616,212	
<u>Project Goals:</u> 1) Increase the numbers of high risk under- and uninsured women in Harris County screened for cervical cancer. 2) Pilot a medical home model for cervical cancer prevention.	
<u>Agency:</u> Cancer Fighters of Texas Foundation	7/1/2012-
<u>Title:</u> Targeting MicroRNAs in Ovarian Cancer	6/20/2015
<u>Role:</u> P.I.	
<u>Total Direct Costs:</u> \$75,000	
<u>Project Goals:</u> 1) Determine whether miR-520h can be used to reverse clinically acquired platinum resistance. 2) Develop novel near infrared labeled microRNA mimics for localizing in vivo microRNA delivery.	
<u>Agency:</u> Alkek Foundation	7/1/2012-
<u>Title:</u> Novel Strategies for Sensitizing Ovarian Cancer to Chemotherapy	6/30/2015
<u>Role:</u> P.I.	
<u>Total Direct Costs:</u> \$200,000	
<u>Project Goals:</u> 1) Determine whether miR0529g/h reverse clinically acquired platinum resistance. 2) Assess safety profile tolerability and preliminary efficacy of miR-520g/h loaded nanoparticles.	
<u>Agency:</u> March of Dimes	6/1/2013-
<u>Title:</u> 21#FY13-156: Dissecting the Role of Progesterone Receptor in Preterm Labor	5/30/2015
<u>Role:</u> Co-Investigator	
<u>Total Direct Cost:</u> \$375,000	

Project Goals: 1) Dissect genomic binding sites for the progesterone receptor in human myometrium. 2) Examine the role of PR in regulating myometrial growth and development using novel transgenic knockout mouse model.

Agency: **Saks Key to a Cure Foundation**

Title: MicroRNAs and Uterine Sarcomas

Role: P.I.

Total Direct Costs: \$80,000

Project Goals: 1) Comprehensively profile microRNA transcriptome of normal myometrium, benign uterine leiomyomas and uterine leiomyosarcomas. 2) Identify key microRNA: mRNA interactions relevant to tumor growth and proliferation.

7/1/2008-
6/30/2013

Agency: **Whitaker Foundation**

Title: Ovarian Cancer Stem Cells

Role: P.I.

Total Direct Costs: \$100,000

Project Goals: 1) Isolate ovarian cancer stem cells. 2) Define molecular signatures that specify differentiation and chemotherapy sensitivity.

9/1/2008-
8/31/2012

Agency: **Young Texans Against Cancer Foundation**

Title: The Role of Non-Coding RNAs in Ovarian Cancer

Role: P.I.

Total Direct Costs: \$100,000

Project Goals: 1) Characterize the role of specific non-coding RNAs in ovarian and other gynecologic cancers. 2) Confirm direct biologic interactions between putative microRNA: mRNA pairs.

12/1/2008-
11/30/2012

Agency: **Cancer Prevention and Research Institute of Texas (CPRIT)**

Title: Novel siRNA/MiRNA-Conjugated Gold Nanoparticles for Sensitizing Cancer Cells to Chemotherapy."

Role: Co-PI (8% Effort) Multi-PI Program Grant

Total Direct Costs: \$191,000

Project Goals: 1) Assess the impact of altered expression 19q13.41-OvCa-miR expression on ovarian cancer. 2) Develop non-cytotoxic Interior Functionalized Dendron-conjugated Nanoparticles (NIFD-AuNPs) for intracellular delivery of therapeutic siRNAs, miRNAs, small molecule inhibitors and drugs designed to sensitize tumors to cancer drugs.

1/1/2011-
12/31/2012

Agency: **Merck Pharmaceuticals, Inc.**

Title: Randomized Phase II Evaluation of Carboplatin/Paclitaxel with and without Trastuzumab (HERCEPTIN®) in Her2/Neu+ Patients with Advanced/Recurrent Uterine Serous Papillary Carcinoma

Role: Site PI

Direct Cost: \$4500/patient

Project Goals: 1) Estimate whether the addition of trastuzumab to paclitaxel and carboplatin chemotherapy improves progression free survival (PFS) when compared to paclitaxel and carboplatin alone in USPC patients overexpressing HER2/neu at 3+ level by IHC or positive by FISH.

11/9/2011-
10/31/2013

Agency: **Joann Rosenberg Fund for Ovarian Cancer Research**

Title: Identification of Novel Mediators of Epithelial Invasiveness

11/1/2003-
10/31/2005

Role: P.I.

Total Direct Costs: \$50,000

Project Goals: Dissect the role of AIB1 in ovarian cancer using a reverse genetic screen.

Agency: **Gynecologic Cancer Foundation**

7/1/2004-

Title: Dissecting the Role of AIB-1 in Ovarian Epithelial Invasiveness

6/30/2005

Role: P.I.

Total Direct Costs: \$25,000

Project Goals: 1) Dissect the role of AIB1 in ovarian cancer. 2) Identify gene products mediating its functional impact.

Agency: **Dan L. Duncan Cancer Center Seed Funding Competition**

10/1/2003-

Title: A Novel Genetic Model for Ovarian Cancer

9/30/2004

Role: P.I.

Total Direct Costs: \$25,000

Project Goals: Identify novel mechanisms mediating the role of AIB1 in ovarian cancer using a novel forward genetic screen.

Agency: **National Institutes of Health/NICHD**

7/24/2002-

Title: Characterization of E6- and E7-Responsive Elements in Cervical Epithelia

7/24/2005

Type: K-12 Training Grant (BIRCWH) (Simpson, J, PI)

Role: Scholar Subaward Direct Costs: \$121,000/yr

Project Goals: Dissect the role of E6- and E7-regulated patterns of gene expression in cervical cancer pathogenesis.

Agency: **Expression Genetics, Inc.**

5/1/2006-

Title: A Phase 1, Open Label, Dose Escalation Study of the Safety, Tolerability and Preliminary Efficacy of Intraperitoneal EGEN-001 in Patients with Recurrent Epithelial Ovarian Cancer.

9/1/2006

Role: Site P.I.

Direct Cost: \$19,500/patient

Project Goals: 1) To establish the safety, tolerability, and efficacy profiles of EGEN-001 alone and in combination with cancer chemotherapeutic drugs in patients with recurrent epithelial ovarian cancer. 2) These studies will examine the biological effects of EGEN-001 on circulating and local cytokine levels by measuring IFN- γ , TNF- α , and IL-12.

Agency: **Saks Fifth Avenue Key to a Cure Foundation**

8/1/2006-

Title: Spermatogenesis-Related Patterns of Gene Expression in Epithelial Ovarian Cancers

7/31/2007

Role: P.I.

Total Direct Costs: \$50,000

Project Goals: 1) Identify patterns of retrogene expression in ovarian cancers 2) Compare patterns of retrogene expression to the expression of their X-linked progenitors.

Agency: **National Cancer Institute (NCI)**

7/1/2007-

Title: RO1CA087751: Molecular Analysis of Metastasis

7/1/2008

Role: Co-Investigator (7% Effort) (Goode, PI)

Total Direct Cost: \$1,050,000

Project Goals: 1) Order the pathway by which the basolateral junction signals through Wts and Mats (Lats and Mob1a) to activate DAIB1 (AIB1) expression in the nucleus, 2) Establish the molecular mechanisms by which the basolateral junction signals to AIB1/DAIB1, and 3) Establish the importance of the basolateral junction signaling pathway for suppressing human tumor cell invasion.

Agency: **Expression Genetics, Inc.**

9/1/2007-
12/15/2008

Title: A Phase I, Open-Label, Dose Escalation Study of the Safety and Preliminary Efficacy of EGEN-001 in Combination with Carboplatin and Docetaxel in Women with Recurrent, Platinum-Sensitive, Epithelial Ovarian Cancer

Role: Site P.I.

Direct Costs: \$26,350/patient

Project Goals: 1) Assess the safety and tolerability of EGEN-001 In combination with standard of care chemotherapy for ovarian cancer.

Agency: **Nventa Pharmaceuticals, Inc.**

12/1/2007-
5/15/2008

Title: A Multicenter, Nonrandomized, Open-label Phase I Safety Study of HSP E7 and Poly-ICLC Administered Concomitantly in Cervical Intraepithelial Neoplasia (CIN) Subjects

Role: P.I.

Direct Costs: \$26,750/patient

Project Goals: Assess the safety and tolerability of HspE7 and Poly-ICLC administered concomitantly.

Agency: **Marshall-Edwards, Pty.**

3/7/2008-
6/30/2009

Title: A Multi-Center, Randomized, Double-blind, Phase III Efficacy Study Comparing Phenoxodiol in combination with Carboplatin versus Carboplatin with Placebo in Patients with Platinum-resistant or Platinum-Refractory Late-stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at least Second Line Platinum Therapy

Role: Site P.I.

Direct Costs: \$23,000/patient

Project Goals: Confirm the efficacy and safety of phenoxodiol in combination with carboplatin for the treatment of platinum-resistant or platinum-refractory late-stage epithelial ovarian, fallopian or primary peritoneal cancer.

Agency: **Ariad Pharmaceuticals, Inc.**

8/6/2008-
7/1/2009

Title: A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients with Metastatic Soft- tissue or Bone Sarcomas

Role: Site P.I.

Total Direct Costs: \$13,767/patient

Project Goals: Assess the preliminary efficacy and safety of a novel therapeutic strategy in soft tissue sarcomas.

Agency: **Third Wave Technologies, Inc.**

9/1/2006-
6/1/2011

Title: A Multi-Center Prospective Clinical Study to Evaluate the Performance and Clinical Predictive Value of the Invader HPV HR Molecular Assay and Invader HPV 16 / 18 Molecular Assay for the Detection of Human Papillomavirus in Cervical Cytology Samples.

Role: Site P.I.

Direct Cost: \$136,000/1st year, \$21,300 years 2, 3.

Project Goals: 1) Determine the sensitivity, specificity, positive predictive value and negative predictive values of the Invader HR© assay for detecting high risk HPV genotypes 2). Assess the specificity, positive predictive value and negative predictive values of the Invader HR© assay for detecting high grade cervical dysplasia.

Agency: **Genentech, Inc.**

11/19/2008-

Title: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of GDC-0449 as maintenance therapy in patients with ovarian cancer in a second or third complete remission

3/15/2011

Role: P.I.

Total Direct Costs: \$14,326/patient

Project Goals: 1) Assess the safety and tolerability of GDC-0449 in Women in 2nd clinical recurrences of epithelial ovarian cancer. 2) Identify molecular markers predictive of clinical responses to GDC-0449.

Agency: **Ovarian Cancer Research Fund**

1/1/2008-

Title: MicroRNAs as Diagnostic and Therapeutic Targets in Ovarian Cancer

12/31/2010

Role: Project Leader (15%)

Total Direct Costs: \$900,000

Project Goals: 1) Use state-of-the-art sequencing technology to comprehensively profile microRNA expression in human epithelial ovarian cancers, normal ovaries and primary cultures of normal ovarian surface epithelial. 2) Understand the mechanistic consequences of altered microRNA expression in normal ovarian surface epithelia and established ovarian cancer cell lines. 3) Create in vivo models for studying the pathophysiologic consequences of microRNA deletions and testing the validity of microRNAs as biological targets for treating ovarian cancer.

Agency: **Sarcoma Foundation of America**

4/15/2009-

Title: Targeting Centrosomes in Uterine Leiomyosarcoma

3/31/2010

Role: P.I.

Total Direct Costs: \$25,000

Project Goals: 1) Assess clinical significance of Aurora kinase misexpression in uterine leiomyosarcoma. 2). Determine impact of targeting Aurora kinases using a novel animal model of the disease.

Agency: **Sarcoma Foundation of America**

7/1/2010-

Title: MicroRNAs in Uterine Leiomyosarcoma

6/30/2011

Role: P.I.

Total Direct Costs: \$25,000

Project Goals: 1) Assess the role of 2) Determine whether novel gold-based nanoparticles can be used to effectively deliver microRNAs to impair ULMS growth and metastasis.

Agency: **Mary Kay Ash Foundation**

7/1/2010-

Title: Developing MiR-31 Based Therapies for Ovarian Cancer

6/30/2012

Role: Co-Investigator

Total Direct Costs: \$100,000

Project Goals: 1) Dissect the role of miR-31 in ovarian cancer and 2) Validate novel miR-31 conjugated gold nanoparticles for killing ovarian cancer cells in vitro and in vivo.

Agency: **Southwestern Oncology Group**

1/5/2011-

Title: GOG-0240: A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, with and Without NCI-Supplied Bevacizumab in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix.

6/1/2012

Role: Site PI

Direct Costs: \$2,300/patient

Project Goals: 1) Determine whether the addition of bevacizumab to chemotherapy improves overall survival. 2) To determine and compare the frequency and severity of adverse events for administered regimens.

Agency: **Baylor College of Medicine Endowment (IDEA AWARD)**

9/1/2010-

Title: The Role of COUP-TFII in Ovarian Cancer Angiogenesis & Metastasis

8/31/2012

Role: Co-PI

Total Direct Costs: \$75,000

Project Goals: 1) Decipher the role of COUP-TFII expression on ovarian cancer metastasis and angiogenesis in ovarian cancer in vitro and in vivo. 2) Identify downstream transcriptional targets for COUP-TFII in epithelial ovarian cancers.

Agency: **Howard Hughes Medical Institute/National Institute of Health**

7/1/1987-

Title: Molecular Mechanisms of Memory and Learning

6/30/1989

Role: Fellow

Project Goals: Dissect the role of neurotransmitters mediating interactions between the visual vestibular networks in an invertebrate model of associative conditioning

Agency: **The University of Texas M.D. Anderson Cancer Center Foundation**

9/1/1999-

Title: Mechanisms of Cellular Senescence

8/3/2000

Role: P.I.

Total Direct Costs: \$5,000.

Project Goal: Dissect the role of Ku-80 in the senescence of mesenchyme

Published Bibliography

Published in Peer Review Journals

1. **Anderson ML**, Schoenberg M. Possible cooperativity in cross bridge detachment in muscle fibers having magnesium pyrophosphate at the active site. *Biophysical J.* 1987; 49: 1077-1082. PMID: 2827801.
2. Olds JL, **Anderson ML**, McPhie DL, Staten LD, Alkon DL. Imaging of memory-specific changes in the distribution of protein kinase C in the hippocampus. *Science* 1989; 245: 866-869. PMID: 2772638.
3. Alkon D, **Anderson ML**, Kuzirian AJ, Rogers DF, Fas, DM, Collin C, Nelson TJ, Kapetanovic IM, Matzel LD. GABA-mediated synaptic interaction between the visual and vestibular pathways of Hermissenda. *J Neurochem.* 1993; 61: 556-566. PMID: 8336142.

4. Rasmussen H, Throckmorton DC, Isales CM, **Anderson M**, McCarthy D. Diacylglycerol production, Ca²⁺ influx and protein kinase C activation in sustained cellular responses. *Endocrine Reviews*. 1995; 16(5): 649-81. PMID: 8529575.
5. Beuers U, Throckmorton DC, **Anderson ML**, Isales CM, Thasle W, Kullak-Ublick GA, Sauter G, Koebe HG, Baumgartner G, Boyer JL. Tauroursodeoxycholic acid activates PKC in isolated rat hepatocytes. *Gastroenterol*. 1996; 110(5): 1553-63. PMID: 8613063.
6. Ijdo JW, Zhang Y, **Anderson ML**, Goldberg D, Fikrig E. Heat shock protein 70 of human granulocytic Ehrlichiosis binds to *Borrelia burgdorferi* antibodies. *Clin Diag Lab Immunol*. 1998; 5(1): 118-120. PMID: 9455892.
7. Coleman NM, Smith-Zagone MJ, Tanyi J, **Anderson ML**, Coleman RL, Dyson SW, Reid JA. Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype. *Am J Surg Pathol*. 2006; 30(3): 405-410. PMID: 16538063.
8. Robertson H, Velasco V, Gutierrez MC, **Anderson ML**. Adnexal mass, Elevated CA125 and Ascites: Report of an Entero-ovarian Fistula. *Obstet Gynecol*. 2006; 108: 764-6. PMID: 17018495.
9. Tung C, Zigelboim I, Scott B, **Anderson ML**. Human acellular dermal matrix for closure of a contaminated gynecologic wound. *Gynecol Oncol*. 2006; 103(1): 354-6. PMID: 17048346.
10. Janat-Amsbury MM, Yockman JW, **Anderson, ML**, Kieback DK, Kim SW. Combination of Local, Non-Viral IL12 Gene Therapy and Systemic Paclitaxel Chemotherapy in a Syngeneic ID8 Mouse Model for Human Ovarian Cancer. *Anticancer Res*. 2006; 160(5A): 3223-8. PMID: 17094433.
11. Janat-Amsbury MM, Yockman JW, **Anderson ML**, Kieback DK, Kim SW. Comparison of ID8 MOSE and VEGF-modified ID8 Cell Lines in an Immunocompetent Animal Model for Human Ovarian Cancer. *Anticancer Res*. 2006; 160(8): 793-800. PMID: 16886597.
12. **Anderson ML**, Bodurka DC. Thoracotomy for Management of Recurrent Vaginal Leiomyosarcoma. *Int J Gynecol Cancer*. 2008 Jan-Feb; 18(1): 188-190. PMID: 17506839.
13. Guntupalli S, **Anderson, ML**, Bodurka, DC. Alveolar Soft Part Sarcoma of the Cervix: case report and literature review. *Arch Gynecol Obstet*. 2009; 279(2):263-5. PMID: 18548261.
14. Kolomeyevskaya NV, Tanyi JL, Coleman NM, Beasley AD, Miller HJ, **Anderson, ML**. Balloon tamponade of hemorrhage after uterine curettage for gestational trophoblastic disease. *Obstet Gynecol*. 2009; 113(2):557-60. PMID: 19155956.

15. Sivasankaran S, Itam P, Ayensu-Coker L, Sanchez J, Egler RA, **Anderson ML**, Brandt ML, Dietrich JE. Juvenile granulosa cell tumor: a case report and review of the literature. *J Pediatr Adolesc Gynecol*. 2009 Oct; 22(5): c114-7. PMID: 19576820.
16. Guntupalli S, Ramirez PT, **Anderson ML**, Milam MR, Bodurka DC and Malpica A. Retrospective Outcomes Analysis for Smooth Muscle Tumors of Uncertain Malignant Potential. *Gynecol Oncol*. 2009; (4):1-4. PMID: 19342083.
17. Li Z, Burzawa J, Truong A, Feng S, AgoulNIK I, Tong X, **Anderson ML**, Kovanci E, Rajkovic A, AgoulNIK A. Relaxin Signaling in Uterine Fibroids. *Ann NY Acad Sci*. 2009; 160: 374-8. PMID: 19416222.
18. Rohozinski J*, **Anderson ML***, Edwards CL, Broaddus R, and Bishop C. Expression of Spermatogenesis-Related Retrogenes in Ovarian Cancers. *Plos One*. 2009; 4(3): e5064. PMID: 19333399. *shared first authorship.
19. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM, **Anderson ML**, Matzuk MM. A link between miR-100 and FRAP1/mTOR in clear cell ovarian cancer. *Mol Endocrinol*. 2010 Feb; 24(2): 447-63. PMID: 20081105.
20. Xing D, Scangas G, Nita M, Xu X, He L, Ioffe Y, Aspuria PJ, Hedvat C, **Anderson ML**, Oliva E, Karlan B, Mohapatra, G., Orsulic, S. A Role for BRCA1 in Uterine Leiomyosarcoma. *Cancer Res*. 2009 Nov 1;69(21):8231-5. PMID: 19843854.
21. Creighton CJ, Fountain MD, Yu Z, Nagaraja, AK, Zhu H, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM, **Anderson ML**. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. *Cancer Res*. 2010 Mar 1; 80(5):1906-15. PMID: 20179198.
22. Creighton CJ, Benham AL, Zhu H, Khan MF, Reid JG, Nagaraja AK, Fountain MD, Dziadzek O, Han D, Ma L, Kim J, **Anderson ML**, Matzuk MM, Gunaratne PH. "Discovery of novel miRNAs in reproductive function and dysfunction through Next Generation Sequencing." *PLoS One*. 2010 Mar 10; 5(3): e9637. PMID: 20224791.
23. Kolomeyevskaya N, Miller H, **Anderson ML**, Patsner B. "Cervical Conization in Pregnancy: Case Report and Review of the Literature." *J Gyn Surg*. 2011 Sep; 27(3): 193-197.
24. Li Z, Burzawa J, Truong A, Feng S, AgoulNIK I, Tong X, **Anderson ML**, Kovanci E, Rajkovic A, AgoulNIK A. "Relaxin Signaling in Uterine Fibroids." *Ann NY Acad Sci*. 2009; 160: 374-8. PMID: 19416222.
25. Li Z, Feng S, Lopez V, El Hammady G, **Anderson ML**, Kaftanovskaya EM, AgoulNIK AI. "Uterine Cysts in Female Mice Deficient for Caveolin-1 and Insulin-like3 Receptor RXFP2." *Endocrinol*. 2011 Jun 1; 152(6): 2474-2482. PMID: 21467199.

26. Mullany LK, Fan H-Y, Liu Z, White L, Marshall M, Gunaratne P, **Anderson ML**, Creighton CJ, Xin L, Richards JS. Molecular and Functional “Characteristics of Ovarian Surface Epithelial Cells Transformed by KrasG12D and loss of Pten in a Mouse Model in vivo.” *Oncogene* 2011 Mar 21; 30: 3522–3536. PMID: 21423204.
27. Hawkins SM, Creighton CJ, Han DY, Zariff A, **Anderson ML**, Gunaratne PH, Matzuk MM. “Functional MicroRNA Involved in Endometriosis.” *Mol Endocrinol*. 2011 May; 25(5): 821-32. PMID: 21436257.
28. Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, **Anderson ML**, Ramondetta LR, Tortolero-Luna G, Urbauer DL, Chang S, Gershenson DM, Brown J, Lu KH. “Prospective evaluation of insulin resistance among endometrial cancer patients.” *Am J Obstet Gynecol*. 2011 Apr; 204(4): 355.e1-7. PMID: 21324431.
29. Tang JY, Spaunhurst KM, Chlebowski RT, Wactawski-Wende J, Keiser E, Thomas F, **Anderson ML**, Zeitouni NC, Larson JC, Stefanick ML. “Menopausal Hormone Therapy and Risks of Melanoma and Non-Melanoma Skin Cancer: Women's Health Initiative Randomized Trials.” *J Natl Cancer Inst*. 2011 Oct 5; 103(19): 1469-75. PMID: 21878677.
30. Rohozinski J, Edwards DL, **Anderson ML**. “Does expression of the retrogene UTP14c in the ovary pre-dispose women to ovarian cancer?” *Med. Hypotheses* 2012 Jan 26; 78(4): 446-9. PMID: 22285623.
31. Zhang P, Bill K, Liu J, Young E, Peng T, Bolshakov S, Hoffman A, Song Y, Demicco EG, Terrada DL, Creighton CJ, **Anderson ML**, Lazar AJ, Calin G, Pollock RE, Lev D. “MiR-155 is a liposarcoma oncogene that targets casein kinase-1 α and enhances β -catenin signaling.” *Cancer Res*. 2012 Apr 1; 72(7): 1751-62. PMID: 22350414.
32. Shan W, Akinfenwa PY, Savannah KB, Kolomeyevskaya N, Laucirica R, Thomas DG, Odunsi K, Creighton CJ, Lev DC, **Anderson ML**. “A small molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.” *Clin Cancer Res*. 2012 Apr 25; 18(12): 3352–65. PMID: 22535157.
33. Savannah KB, Demicco EG, Lusby K, Ghadimi MP, Belousov R, Young ED, Zhang Y, Huang K-L, Lazar AJ, Hunt KK, Pollock RE, Creighton CJ, **Anderson ML**, Lev D. “Dual targeting of mTOR and Aurora-A kinase for the treatment of uterine leiomyosarcoma.” *Clin Cancer Res*. 2012 Jul 20; 18: 4633-4645. PMID: 22821997.
34. Patsner B, **Anderson ML**. “What is the Proper Work-up of the Patient with Clinical Early Stage Uterine Adenocarcinoma?” *Korean J Obstet Gynecol*. 2012 Jul; 55(7):447-453.
35. Ramos CA, Narala N, Vyas GM, Leen AM, Gerdemann U, Sturgis EM, **Anderson ML**, Savoldo B, Heslop HE, Brenner MK, Rooney CM. “Human

Papillomavirus Type 16 E6/E7-Specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-Associated Malignancies.” *J Immunother.* 2013 Jan; 36(1):66-76. PMID: 23211628.

36. Lusby K, Savannah KB, Demicco EG, Zhang Y, Ghadimi MPH, Young ED, Colombo C, Lam R, Dogan TE, Hornick JL, Lazar AJ, Hunt KK, **Anderson ML**, Creighton CJ, Lev D, Pollock RE. “Uterine leiomyosarcoma Management, Outcomes and Associated Biomarkers: A Single Institution's Experience.” *Ann Surg Oncol.* 2013 Jul; 20(7): 2364-72. PMID: 23334251.
 37. Rosen ML, **Anderson ML**, Hawkins SM. “Pyomyoma Following Uterine Artery Embolization: Case Report and Literature Review.” *Obstet Gynecol.* 2013 Feb; 121(2 Pt 2 Suppl 1): 431-3. PMID: 23344399.
 38. Mach CM, Kim J, Soibam B, Creighton CJ, Hawkins SM, Zigelboim I, Goodfellow P, Gunaratne PH, Odunsi K, Salem PA, **Anderson ML**. Novel MicroRNAs Regulating Proliferation and Apoptosis in Uterine Papillary Serous Carcinomas. *Cancer Lett.* 2013 Jul 28; 335(2): 314–322. PMID: 23454583.
 39. Hawkins SM, Loomans H, Wan Y-W, Coffey D, Xiao W, Liu Z, Sangi-Haghpeykar H, **Anderson ML**. “Expression and Functional Analysis of NR2F2 in Ovarian Cancer.” *J Clin Endocrinol Metab.* 2013 Jul; 98(7): E1152-62. PMID: 23690307.
 40. Shahzad MMK, Felder M, Ludwig k, Van Galder HR, **Anderson ML**, Kim J, Cook ME, Kapur AK, Patankar MS. “Trans-10, cis-1,2 conjugated linoleic acid inhibits proliferation and migration of ovarian cancer cells by inducing ER stress, autophagy and modulation of Src” *Plos One.* 2018 Jan 11;13(1): e0189524. PMID: 29324748.
 41. Francis JC, Kolomeyevskaya N, Mach CM, Dietrich JE, **Anderson ML**. MicroRNAs and Recent Insights into Pediatric Ovarian Cancer. *Front. Oncol.* 2013 Apr 30; 3:95. PMID: 23641362.
 42. Kabat G, **Anderson ML**, Heo M, Hosgood DH, Kamensky V, Bea JW, Hou L, Lane DS, Wactawski-Wende J, Manson JE, Rohan TE. Adult stature and risk of cancer at different anatomic sites in a cohort of postmenopausal women. *Cancer Epidem Biomarkers Prev.* 2013 Aug; 22(8):1353-1363. PMID: 23887996.
- This paper was highlighted in >30 national and international press outlets, including feature articles in the New York Times, Los Angeles Times, New Republic Magazine, Time, Times (London).*
43. Zhang W, Wan Y-W, Pang K, Allen G, **Anderson ML**, Liu Z. Molecular Pathway Identification Using Biologic Network Regularized Logistic Models. *BMC Genomics* 2013;14 Suppl 8: S7. PMID: 24564637.
 44. Mach CM, Urh A, **Anderson ML**. "Bowel Perforation Associated with Temsirolimus Use in a Recently Radiated Patient." *Am J Health Syst Pharm.* 2014 Jun 1; 71(11): 919-23. PMID: 24830996.

45. Wan Y-W, Mach CM, **Anderson ML***, Liu ZD*. On the Reproducibility of miRNA Expression. *PLoS One* 2014 Jan 29; 9(1): e87782. PMID: 24489963.
*Joint Corresponding Authors

This paper was highlighted by the editor of Nature Methods as "Research Highlight": MiRNA profiling depends on platform. Nature Methods 11, 369 (2014) doi:10.1038/nmeth.2905 Published online 28 March 2014.
<http://www.nature.com/nmeth/journal/v11/n4/full/nmeth.2905.html>.

46. Mansouri-Attia N, Tripurani SK, **Anderson ML**, Eldin K, Pangas SA. TGF-Beta signaling promotes juvenile granulosa cell tumorigenesis by repressing caspase-dependent apoptosis. *Mol Endocrinol*. 2014 Nov; 28(11): 1887-98. PMID: 25243859.
47. Kelm J, Magliaro T, **Anderson ML**, Mach CM. Vismodegib Provides a Novel Treatment for Advanced Basal Cell Carcinoma. *J Cancer Ther*. 2014; 5: 217-221.
48. Hsieh GL, **Anderson ML**. Postpartum Distal Salpingectomy – Timely Arrival or Premature Delivery? *Obstet Gynecol*. 2014 Nov; 124(5):1033. PMID: 25437734.
49. Montealegre J, Gossey JT, **Anderson ML**, Chenier RS, Chauca G, Rustveld LO, Jibaja-Weiss ML. Implementing targeted cervical cancer screening videos at the point of care. *Patient Educ Couns*. 2014 Dec; 97(3): 426-9. PMID: 25269411.
50. **Anderson ML**, Kolomeyevskaya NV. Evaluation of pulmonary metastasectomy for the treatment of gynecologic sarcomas | [Evaluación de la metastasectomía pulmonar para el tratamiento de los sarcomas ginecológicos]. *Salud(i)Ciencia* 2014; 20(5): 518-520.
51. Hsieh GL, Linesch S, Sajjad A, MacDonald A, Bonnen M, **Anderson ML**, Ludwig M. Treatment compliance and outcomes in medically underserved women with locoregionally advanced cervical cancer. *Int J Gynecol Cancer*. 2015 Nov; 25(9): 1669-76. PMID: 26270123.
52. **Anderson ML**, Ogunwale A, Clark BA, Kilpatrick C, Mach C. Preferences and Outcomes for Chemotherapy Teaching in a Postgraduate Obstetrics & Gynecology Training Program. *J Surg Educ*. 2015 Sep-Oct; 72(5): 936-41. PMID: 26119096.
53. Montealegre J, Landgren RM, **Anderson ML**, Hoxhaj S, Williams S, Robinson DJ, Scheurer ME, Ramondetta L. Acceptability of Self-Sample Human Papillomavirus Testing among Medically Underserved Women Visiting the Emergency Department. *Gynecol Oncol*. 2015 Aug; 138(2): 317-22. PMID: 26026733.
54. Ogunwale AN, Sangi-Haghpeykar H, Montealegre J, Jibaja-Weiss M, **Anderson ML**. Non-utilization of the Pap test among women with frequent

- health system contact. *J Immigr Minor Health*. 2016; 18(6): 1404-1412. PMID: 26424729.
55. Ogunwale A, Coleman MA, Sangi-Haghpeykar H, Valverde I, Montealegre J, Jibaja-Weiss M, **Anderson ML**. Assessment of factors impacting cervical cancer screening among low income women living with HIV-AIDS. *AIDS Care* 2016 Oct 23; 28(4): 491-494. PMID: 26493859.
 56. Ogunwale A, **Anderson, ML**, Sangi-Haghpeykar S. Intimate partner violence during pregnancy and maternal and neonatal health among Hispanic women. *J Reprod Med*. 2017 Feb; 62(1): 65-72. PMID:
 57. Vasquez, YM, **Anderson ML**, Hawkins SM, Creighton CL, Tsai S, Tsai M, Lydon JR, DeMayo F. Endometrial Expression of Steroidogenic Factor 1 Promotes Cystic Glandular Morphogenesis. *Mol Endocrinol*. 2016 May; 30(5):518-32. PMID: 27018534.
 58. Dong Y, Betancourt A, Chauhan M, Balakrishnan M, Lugo F, **Anderson ML**, Espinoza J, Fox K, Belfort M and Yallampalli C. Pregnancy increases relaxation in human omental artery to the CGRP family of peptides. *Biol Reprod*. 2015 Dec; 93(6):134. PMID: 26510864.
 59. Ramondetta L, Mayer L, Schmeler KM, Daheri ME, Gallegao J, Scheurer M, Montealegre JR, Milbourne A, **Anderson ML**, Sun CC. Avoidable Tragedies: Disparities in Healthcare Access Among Underserved Women Diagnosed with Cervical Cancer. *Gynecol Oncol*. 2015 Dec; 139(3): 500-5. PMID: 26498912.
 60. Miller H, **Anderson ML**, Fox K. Chylous Ascites Complicating Modified Radical Hysterectomy for Placenta Percreta. *Obstet Gynecol*. 2016 Nov; 128(5): 973-975. PMID: 27741191.
 61. Miller H, Ike C, Parma C, Masand RP, Mach CM, **Anderson ML**. Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma. *Sarcoma* 2016:7018106. PMID: 27721667.
 62. Babic A, Bao Y, Qian ZR, Yuan C, Giovannucci EL, Aschard H, Kraft P, Amundadottir LT, Stolzenberg-Solomon R, Morales-Oyarvide V, Ng K, Stampfer MJ, Ogino S, Buring JE, Sesso HD, Gaziano JM, Rifai N, Pollak MN, **Anderson ML**, Cochrane BB, Luo J, Manson JE, Fuchs CS, Wolpin BM. Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. *Cancer Res*. 2016 Dec 15; 76(24): 7160-7167. PMID: 27780823.
 63. Wan Y-W, Allen GI, Baker Y, **Anderson ML**, Liu Z. XMRF: An R Package to fit Markov networks to high-throughput genetics data. *BMC Syst Biol*. 2016 Aug 26; 10(Suppl 3): 69. PMID: 27586041.
 64. LeBlanc ES, Kapphahn K, Hedlin H, Desai M, Parikh NI, Liu S, Parker DR, **Anderson ML**, Aroda V, Sullivan S, Woods NF, Waring ME, Lewis CE, Stefanick M. Reproductive history and risk of type 2 diabetes mellitus in

- postmenopausal women: Findings from the Women's Health Initiative. *Menopause* 2017 Jan; 24(1): 64-72. PMID: 27465714.
65. Cui Y, Sangi-Haghighi H, Patsner B, Bump JMM, Williams-Brown MY, Binder GL, Masand RP, **Anderson ML**. Prognostic value of endocervical sampling following loop excision of high grade intraepithelial neoplasia. *Gynecol Oncol*. 2017 Mar; 144(3): 547-552. PMID: 28081880.
 66. Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. *Nature* 2017 Jan 23; 543(7645): 378-384. PMID: 28112728.
 67. Mach CM, Kau C, Nguyen D, Shumway J, Meaders KM, Ludwig M, Williams-Brown MY, **Anderson ML**. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin- induced nephrotoxicity. *J Clin Pharm Ther*. 2017 Jun; 42(3): 286-291. PMID: 28276070.
 68. Miller H, Pipkin LS, Tung CS, Hall TR, Masand RP, **Anderson ML**. The role of routine peritoneal biopsies at risk-reducing salpingo-oophorectomy. *J Minim Invasive Gynecol*. 2017 Jul-Aug; 24(4): 772-776. PMID: 28285055.
 69. Delaney MA, Wan Y-W, Kim GE, Creighton CJ, Taylor MG, Masand R, Park A, Valdes C, Gibbons W, Liu ZD, **Anderson ML**. A Role for Progesterone-Regulated sFRP4 Expression in Uterine Leiomyomas. *J Clin Endo Metab*. 2017 Sep 1; 102(9):3316-3326. PMID: 28637297.
 70. Miller H, **Anderson ML**. Response to Risk-Reducing Surgery in BRCA Mutation Carriers: Investigating the Role of Peritoneal Staging. *J Minim Invasive Gynecol*. 2017 Nov-Dec; 24(7):1244. PMID: 28648839.
 71. Ghosh-Choudhury T, Wan Y-W, Kim GE, Guntupalli S, Brewer MA, Behbahkt K, Allen G, Mach CM, Liu Z, **Anderson ML**. Redundant targeting of myotubularin-related protein 9 by miR-148 microRNAs regulates ovarian cancer growth in vitro and in vivo. (Accepted pending revision – OncoTarget)
 72. Cancer Genome Atlas Research Network. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. *Cell* 2017 Nov 2; 171(4):950-965. PMID: 29100075.
 73. Yoder AK, Dalwadi SM, Orma CM, Hall TR, **Anderson ML**, Ludwig MS. Patterns of Care and Outcomes in Early Stage Neuroendocrine Carcinoma of the Uterine Cervix. *Cancer Research Frontiers*. 2017; 3(1):204-214
 74. Shamshirsaz SA, Fox KA, Erfani H, Clark SL, Shamshirsaz AA, Nasser AA, Sundgren NC, Jones JA, **Anderson ML**, Kassir E, Salmanian B, Buffie AW, Hui SK, Espinoza J, Tyler-Viola LA, Rac M, Karbasian N, Ballas J, Dildy GA, Belfort MA. Outcomes of Planned Compared With Urgent Deliveries Using a Multidisciplinary Team Approach for Morbidly Adherent Placenta. *Obstet Gynecol*. 2018 Feb 28; 131(2): 234-241. PMID: 29324609.

75. Desai P, Wallace R, **Anderson ML**, Howard BV, Ray R, Wu C, Safford M, Martin LW, Rohan T, Manson JE, Simon MS. An Analysis of the Association between Statin Use and Risk of Endometrial and Ovarian Cancers in the Women's Health Initiative. *Gynecol Oncol*. 2018 Mar; 148(3): 540-546. PMID: 29422345.
76. Wang Z, Yang B, Cancer Genome Atlas Research Network (**Anderson ML**). lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. *Cancer Cell* 2018 March 31: Epub ahead of print. PMID: 29622465.
77. Taylor AM, Shih J, Cancer Genome Atlas Research Network (**Anderson ML**). Genomic and Functional Approaches to Understanding Cancer Aneuploidy. *Cancer Cell* 2018 Apr 9;33(4):676-689. PMID: 29622463.
78. Schaub FC, Dhankani ... Cancer Genome Atlas Research Network (**Anderson ML**). Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. *Cell Syst*. 2018 Mar; 6(3):282-300. PMID: 29422345.
79. Liu J, Lichtenberg T ... Cancer Genome Atlas Research Network (**Anderson ML**). An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell* 2018 Apr 5; 173(2):400-416. PMID: 29625055
80. Chen H, Li C ... Cancer Genome Atlas Research Network (**Anderson ML**). A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. *Cell* 2018 Apr 5; 173(2): 386-399. PMID: 29625054.
81. Bailey MH, Tokheim C ... Cancer Genome Atlas Research Network (**Anderson ML**). Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell* 2018 Apr 5; 173(2): 371-385. PMID: 29625053
82. Huang KL, Mashl RJ ... Cancer Genome Atlas Research Network (**Anderson ML**). Pathogenic Germline Variants in 10,389 Adult Cancers. *Cell* 2018 Apr 5; 173(2): 355-370. PMID: 29625052.
83. Malta TM, Sokolov A ... Cancer Genome Atlas Research Network (**Anderson ML**). Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. *Cell* 2018 Apr 5; 173(2): 338-354. PMID: 2962505.
84. Sanchez-Vega F, Mina M ... Cancer Genome Atlas Research Network (**Anderson ML**). Oncogenic Signaling Pathways in the Cancer Genome Atlas. *Cell* 2018 Apr 5; 173(2): 321-337. PMID: 29625050.
85. Ding L, Bailey MH ... Cancer Genome Atlas Research Network (**Anderson ML**). Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. *Cell* 2018 Apr 5; 173(2): 305-320. PMID: 29625049.

86. Berger AC, Korkut A ... Cancer Genome Atlas Research Network (**Anderson ML**). A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. *Cancer Cell*. 2018 Apr 1: Epub ahead of print. PMID: 29622464.
87. Chiu HS, Somvanshi S ... Cancer Genome Atlas Research Network (**Anderson ML**). Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. *Cell Rep*. 2018 Apr 3; 23(1):297-312. PMID: 29617668.
88. Seiler M, Peng S ... Cancer Genome Atlas Research Network (**Anderson ML**). Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. *Cell Rep*. 2018 Apr 3; 23(1):282-296. PMID: 29617667.
89. Jayasinghe RG, Cao S ... Cancer Genome Atlas Research Network (**Anderson ML**). Systematic Analysis of Splice-Site-Creating Mutation in Cancer. *Cell Rep*. 2018 Apr 3; 23(1):270-281. PMID: 29617666.
90. Peng X, Chen Z ... Cancer Genome Atlas Research Network (**Anderson ML**). Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. *Cell Rep*. 2018 Apr 3; 23(1):255-269. PMID: 29617665
91. Knijnenburg TA, Wang L ... Cancer Genome Atlas Research Network (**Anderson ML**). Genomic and Molecular Landscape of DNA Damage Repair Deficiency across the Cancer Genome Atlas. *Cell Rep*. 2018 Apr 3; 23(1):239-254. PMID: 29617664
92. Gao Q, Liang WW ... Cancer Genome Atlas Research Network (**Anderson ML**). Driver Fusion and Their Implications in the Development and Treatment of Human Cancers. *Cell Rep*. 2018 Apr 3; 23(1):227-238. PMID: 29617662
93. Ge Z, Leighton JS ... Cancer Genome Atlas Research Network (**Anderson ML**). Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. *Cell Rep*. 2018 Apr 3; 23(1):213-226. PMID: 29617661
94. Saltz J, Gupta R ... Cancer Genome Atlas Research Network (**Anderson ML**). Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. *Cell Rep*. 2018 Apr 3; 23(1):181-193. PMID: 29617659
95. Campbell JD, Yau C ... Cancer Genome Atlas Research Network (**Anderson ML**). Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. *Cell Rep*. 2018 Apr 3; 23(1):194-212. PMID: 29617660
96. Way GP, Sanchez-Vega F ... Cancer Genome Atlas Research Network (**Anderson ML**). Machine Learning Detects Pan-cancer Ras Pathway Activation in the Cancer Genome Atlas. *Cell Rep*. 2018 Apr 3; 23(1):172-180. PMID: 29617658

97. Desai P, Wallace R, **Anderson ML**, Howard BV, Ray R, Wu C, Safford M, Martin LW, Schlecht N, Liu S, Cirillo D, Jay A, Manson JE, Simon MS. An Analysis of the Effects of Statins on the Risk of Non-Hodgkin's Lymphoma in the Women's Health Initiative Cohort. *Cancer Med*. 2018 May;7(5):2121-2130. PMID: 29608241.
98. Thorsson V, Gibbs DL, Brown SD ... Cancer Genome Atlas Research Network (**Anderson ML**), Lazar AJ, Serody JS, Demicco EG, Dissis ML, Vincent BG, Shmulevich L. The Immune Landscape of Cancer. *Immunity* 2018 Apr 4; Epub ahead of print. PMID: 29628290.
99. Ricketts CJ, De Cubas AA, Fan H, Smith CC ... Cancer Genome Atlas Research Network (**Anderson ML**), Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinomas. *Cell Rep*. 2018 Apr 3; 23(1): 313-326. PMID: 29617669.
100. Hoadley KA, Yau C, Hinoue T ... Cancer Genome Atlas Research Network (Anderson ML). Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. *Cell* 2018 Apr 5; 173(2): 291-304. PMID: 29625048.
101. Liu Y, Sethi NS, Hinoue T, Schneider BG, Chendiack AD ... Cancer Genome Atlas Research Network (**Anderson ML**), Thorsson V, Bass AJ, Laird PW. Comparative Molecular Analyses of Gastrointestinal Adenocarcinomas. *Cancer Cell* 2018 Apr 9; 33(4): 721-735. PMID: 29622466.
102. Ellrott K, Bailey MH, Saksena G ... Cancer Genome Atlas Research Network (**Anderson ML**). Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. *Cell Syst*. 2018 Mar 28; 6(3): 271-281. PMID: 29596782.
103. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M ... Cancer Genome Atlas Research Network (**Anderson ML**), Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Rep*. 2018 Jun 19; 23(12): 3698. PMID: 29925010.
104. Kahles A, Lehmann KV, Toussaint NC, Huser M, Stark SG, Sachsenberg T, Stegle O ... Cancer Genome Atlas Research Network (**Anderson ML**), Ratsch G. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. *Cancer. Cell* 2018 Aug 13; 34(2): 211-224. PMID: 30078747.
105. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A ... Cancer Genome Atlas Research Network (**Anderson, ML**), ... Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell* 2018 Aug 9; 174(7): 1034-1035. PMID: 30096302.
106. Zhang C, Wang X, Anaya Y, Parodi L, Cheng L, **Anderson ML**, Hawkins SM. Distinct molecular pathways in ovarian endometrioid adenocarcinoma with concurrent endometriosis. *Int J Cancer*. 2018 Nov 15; 143(10): 2505-2515. PMID: 30152524.

107. Want Y, Xu X, Maglic D, Dill MT, Mojumdar K ... Cancer Genome Atlas Research Network (**Anderson ML**), Camargo F, Liang H. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. *Cell Rep.* 2018 Oct 30; 25(5):1304-1371. PMID: 30380420.
108. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A ... Cancer Genome Atlas Research Network (**Anderson ML**), Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediator of Signaling by the TGF-Beta Superfamily. *Cell Syst.* 2018 Oct 24; 7(7):422-437. PMID: 30268436.
109. Hanania AN, Myers P, Yoder AK, Bulut A, Yu Z, Eraj S, Bowers J, Bonnen MD, Echeverria A, Hall TR, **Anderson ML**, Ludwig M. Inversely and adaptively planned interstitial brachytherapy: A single implant approach. *Gynecol Oncol.* 2019 Feb; 152(2):353-360. PMID: 30449720.
110. Clark DJ, Dhanasekaran, Petralia F, Pan J, Song X, Hu Y, Leprevost FdB, Reva B, Lih T-SM, Chang H-Y, Ma W, Huang C, Ricketts CJ, Chen L, Krek A, li Y, Rykunov D, Li QK, Chen LS, Ozbek U, Vasaikar S, Wu Y, Yoo S, Chowdhury S, Wyczalkowski MA, Li J, Ji J, Schnaubelt M, Kong A, Sethuraman S, Aytonomov DM, Ao M, Colaprico A, Cao S, Cho K-C, Kalayci S, Ma S, Liu W, Ruggles K, Calinawan A, Gumus ZH, Geiszler D, Kawaler E, Teo GC, Wen B, Zhang Y, Keegan S, Li K, Chen F, Edwards N, Pierorazio PM, Chen XS, Pavlovich CP, Hakimi AA, Brominski G, Hsieh JJ, Antczak A, Omelchenko T, Lubinski J, Wiznerowicz M, Linehan WM, Kinsinger CR, Thiagarajan M, Boja ES, Mesri M, Hiltke T, Robles AI, Rodriguez H, Qian J, Fenyo D, Zhang B, Ding L, Schadt E, Chinnaiyan AM, Zhang Z, Omenn GS, Cieslik M, Chan DW, Nesvizhskii AI, Wang P, Zhang H, Clinical Proteomics Tumor analysis Consortium [Hashimi AS, Pico AR, Karpova A, Charamut A, Paulovich AG, Perou AM, Malovannaya A, Marrero-Oliveras A, Agarwal A, Hindenach B, Pruetz B, Kim B-J, Druker BJ, Newton CJ, Birger C, Jones CD, Tognon C, Mani DR, Valley DR, Rohrer DC, Zhou DC, Tansil D, Chesla D, Heiman D, Wheeler D, Tan D, Chan D, Demir E, Malc E, Modugno F, Getz G, Hostetter G, Wilson GD, Hart GW, Zhu H, Liu H, Culpepper H, Sun H, Zhou H, Day J, Suh J, Huang J, McDermott J, Whiteaker JR, Tyner JW, Eschbacher J, Chen J, McGee J, Zhu J, Ketchum KA, Rodland KA, Clauser K, Robinson K, Krug K, Hoadley KA, Um KS, Elburn K, Holloway K, Wang L-B, Blumenberg L, Hannick L, Liqun Qi, Sokoll LJ, Cornwell M, Loriaux M, Domagalski MJ, Gritsenko MA, **Anderson ML**, Monroe ME, Ellis MJ]. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. *Cell* 2019 Oct 31; 179(4):964-983. PMID: 31675502.
111. Wu S-P, **Anderson ML**, Want T, Zhou L, Emery OM, Li X and Demayo FJ. Dynamic Transcriptome, Accessible Genome and PGR Cistrome Profiles in the Human Myometrium. *FASEB J.* 2020 Feb; 34(2): 2252-2268. PMID: 31908010.
112. Dou Y, Kawaler EA, Cui Zhou D, Gritsenko MA, Huang C, Blumenberg L, Karpova A, Petyuk VA, Savage SR, Satpathy S, Liu W, Wu Y, Tsai CF, Wen B, Li Z, Cao S, Moon J, Shi Z, Cornwell M, Wyczalkowski MA, Chu RK, Vasaikar S, Zhou H, Gao Q, Moore RJ, Li K, Sethuraman S, Monroe ME, Zhao

- R, Heiman D, Krug K, Clauser K, Kothadia R, Maruvka Y, Pico AR, Oliphant AE, Hoskins EL, Pugh SL, Beecroft SJI, Adams DW, Jarman JC, Kong A, Chang HY, Reva B, Liao Y, Rykunov D, Colaprico A, Chen XS, Czeakański A, Jędryka M, Matkowski R, Wiznerowicz M, Hiltke T, Boja E, Kinsinger CR, Mesri M, Robles AI, Rodriguez H, Mutch D, Fuh K, Ellis MJ, DeLair D, Thiagarajan M, Mani DR, Getz G, Noble M, Nesvizhskii AI, Wang P, **Anderson ML**, Levine DA, Smith RD, Payne SH, Ruggles KV, Rodland KD, Ding L, Zhang B, Liu T, Fenyö D; Clinical Proteomic Tumor Analysis Consortium. Proteogenomic Characterization of Endometrial Cancer. *Cell* 2020 Feb 20; 180(4):729-748. PMID: 32059776.
113. Jin J, Dalwadi SM, Masand RP, Hall TR, **Anderson ML**, Ludwig MS. Association between metabolic syndrome and endometrial cancer survival in a SEER-Medicare Linked Database. *Am J. Clin Oncol.* 2020 Jun; 43(6):411-417. PMID: 32205571.
114. Read SH, Valverde I, Montealegre JR, Rutherford TJ, **Anderson ML**. Qualitative Assessment of Knowledge and Attitudes Towards Cervical Cancer Screening Among Male Latino Immigrants in Houston, Texas. *BMC Womens Health.* 2020 Jul 6; 20(1):141. PMID: 32631299.
115. Au-Yeung C-L, Yeung T-L, Achreja A, Zhao H, Yip K-P, Kwan SY, Onstad M, Sheng J, Zhu Y, Co N-N, Rynne-Vidal A, Schmandt R, **Anderson ML**, Lu KH, Wong S, Nagrath D, Mok SC. ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. *Nat Commun.* 2020 Jul 15; 11(1):3546. PMID: 32669559.
116. Montealegre JR, **Anderson ML**, Hilsenbeck SG, Chiao EY, Cantor SB, Parker SL, Daheri M, Bulsara S, Escobar B, Deshmukh AA, Jibaja-Weiss ML, Zare M, Scheurer ME. Mailed self-sample HPV testing kits to improve cervical cancer screening in a safety net health system: protocol for a hybrid effectiveness-implementation randomized controlled trial. *Trials.* 2020 Oct 21; 21(1): 872. PMID: 33087164.
117. Clinical Proteomic Tumor Analysis Consortium (CPTAC). Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. *Cancer Cell* 2021 Jan 7: S1535-6108. PMID: 33417831.
118. Clinical Proteomic Tumor Analysis Consortium (CPTAC). Proteogenomic and metabolomic characterization of human glioblastoma. *Cancer Cell.* 2021 Feb 2 S1535-6108. PMID: 33577785.
119. Dziadzek O, Montealegre A, Papanna R, Moise K, **Anderson ML**, Hardy J, Bhalwal A. Cervical Ectopic Pregnancy. *Int J. Clin Gyn. Obstet.* 2:1. DOI.org /04.2021/1/1021 (in press)
120. Martin A, Wells A, **Anderson ML**, Chern JY, Rutherford TJ, Shahzad MM, Wenham RN, Hoffman MS. Trends in ureteral surgery on an academic gynecologic oncology service. *Gyn. Oncol.* 2021 dec; 163(3): 552-556. PMID: 34674890.

121. Buras AL, Barkhurst M, Rutherford RJ, **Anderson ML**, English DP. The intersection of palliative care and genetic counseling in cancer care: A case discussion. *J. Palliat Med.* 2021 Dec 1. doi: 10.1089/jpm.2021.0169. Online ahead of print. PMID: 34851746.
122. Karnolt LE, Buras AL, Rutherford TJ, Anderson ML. Oxidized Regenerated Cellulose Mimicking a Retained Laparotomy Sponge. *Case Rep Surg.* 2022 Feb 1; 022: 4718457. eCollection 2022. PMID: 35154843.
123. Shi F, Yoder AK, Mach C, Dalwadi S, Anderson ML, Hall TR, Ludwig M. concurrent chemoradiation for cervical cancer. *Obstet Gynecol Sci.* 2022 Mar;65(2):176-181. PMID: 351896
124. New EP, Semerci N, Ozmen A, Guo, X, Jonnalagadda VA, Kim JW, **Anderson ML**, Guzeloglu-Kayisli O, Imudia AN, Lockwood CJ, Kayisli UA. “FKBP51 Contributes to Uterine Leiomyoma Pathogenesis by Inducing Proliferation and Extracellular Matrix Deposition.” *Reprod Sci* 2022 Jun; 29(6): 1939-1949. PMID: 35426036
125. Ozonoff A, Schaenman J, Jayavelu ND, Milliren CE, Calfee CS, Cairns CB, Kraft M, Baden LR, Shaw AC, Krammer F, van Bakel H, Esserman DA, Liu S, Sesma AF, Simon V, Hafler DA, Montgomery RR, Kleinstein SH, Levy O, Bime C, Haddad EK, Erle DJ, Pulendran B, Nadeau KC, Davis MM, Hough CL, Messer WB, Higuera NIA, Metcalf JP, Atkinson MA, Brakenridge SC, Corry D, Kheradmand F, Ehrlich LIR, Melamed E, McComsey GA, Sekaly R, Diray-Arce J, Peters B, Augustine AD, Reed EF, Altman MC, Becker PM, Rouphael N; IMPACC study group members. “Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study.” *EBioMedicine.* 2022 Sep;83:104208. doi: 10.1016/j.ebiom.2022.104208. Online ahead of print. PMID: 35952496.
126. Hsieh GL, Wagar MK, Antony KM, Masand R, Anderson ML. A standardized protocol for post-partum salpingectomy with Suture Ligation: A prospective feasibility study. *Reprod. Med.* 2022 May 3, 3(2):150-159.
127. Amboree TL, Parker SL, Bulsara S, **Anderson ML**, Schmeler, KM, Chaio EY, Montealegre JR. Cervical cancer screening among English- and Spanish-speaking Hispanic women in an urban safety net health system, 2015-2020. *BMC Womens Health* 2023 Jun 15;23(1):309. PMID: 37316815.
128. Adzibololu N, Alvero AB, Ali-Fehmi R, Gogoi R, Corey L, Tedja R, Chehade H, Gogoi V, Morris R, **Anderson M**, Vitko J, Lam C, Craig DB, Draghici S, Rutherford T, Mor G. “Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer.” *Front Immunol.* 2023; 14:1204148. PMID: 37435088.
129. Diray-Arce J, Fourati S, Doni Jayavelu N, Patel R, Maguire C, Chang AC, Dandekar R, Qi J, Lee BH, van Zalm P, Schroeder A, Chen E, Konstorum A, Brito A, Gygi JP, Kho A, Chen J, Pawar S, Gonzalez-Reiche AS, Hoch A, Milliren CE, Overton JA, Westendorf K, **IMPACC Network** Multi-omic

- longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients. *Cell Rep Med*. 2023 Jun 20; 4(6): 101079. PMID 37327781.
130. Dou Y, Katsnelson L, Gritsenko MA, Hu Y, Reva B, Jong R, Wang YT, Kolodziejczak I, **Anderson ML***, Rodland KD*, Zhang B*, Liu T*, Fenyo D*, CPTAC. "Proteogenomic insights suggest druggable pathways in endometrial carcinoma." *Cancer Cell* 2023 Sep 11; 41(9): 1586-1605. PMID 37567170. * denotes co-corresponding authors
131. Parker SL, Amboree TL, Bulsara S, Daheri M, **Anderson ML**, Hilsenbeck SG, Jibaja-Weiss ML, Zare M, Schmeler KM, Deshmukh AA, Chaio EY, Scheurer ME, Montealegre JR. "Self-sampling for human papillomavirus testing: acceptability in a U.S. safety net health system." *Am J Prev Med*. 2024 Mar;66(3):540-547. PMID: 37935320.
132. Haslund-Gourley BS, Woloszczuk K, Hou J, Connors J, Cusimano G, Bell M, Taramangalam B ... Comunale MA. (**IMPACC Network**). "IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition. *Nat Commun*. 2024 Jan 9; 15(1): 404. PMID: 38195739.
133. Lui J, Cao S, Imbach KJ, Gritsenko MA, Lih tm, Clinical Proteomic Tumor Analysis Consortium (**CPTAC**). "Multi-scale signaling and tumor evolution in high-grade gliomas." *Cancer Cell*. 2024 Jul 8; 42(7): 1217-1238. PMID: 38981438.
134. Zhang Y, Tedja R, Millman M, Wong T, Fox A, Chehade H, Gershater M, Adzibololu N, Gogoi R, **Anderson M**, Rutherford T, Zhang Z, Chopp M, Mor G, Alvero AB. "Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells." *J Ovarian Res*. 2023 Nov 30; 16(1): 233. PMID: 38037081.
135. Ozonoff A, Jayavelu ND, Liu S, Melamed E, Milliren CE, Qi J, Geng LN, McComsey GA, Cairns CB, Baden LR, Schaenman J, Shaw AC, Samaha H, Seyfert-Margolis V, Krammer F, Rosen LB, Steen H, Syphurs C, Dandekar R, Shannon CP, Sekaly RP, Ehrlich LIR, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Higuera NIA, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeua KC, Davis MM, Sesma AF, Simon V, van Bakel H, Kim-Schulze S, Hafler DA, Levey O, Kraft M, Bime C, Erle DJ, Langelier CR, Eckalbar W, Bosinger SE, (**IMPACC Network**). "Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study. *Nat Commun*. 2024 Jan 3; 15(1): 216. PMID: 38172101.
136. Haslund-Gourley BS, Woloszczuk K, Hou J, Connors J, Cusimano G, Bell M, Taramangalam B, Fourati S, Mege N, Bernui M, Altaman MD, Krammer F, van Bakel H, (**IMPACC Network**). "IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition." *Nat Commun*. 2024 Jan 9; 15(1): 404. PMID 38195739.

137. Kuznicki ML, Yasukawa M, Mallen AR, Lam C, Eggers E, Regis J, Wells A, Todd SL, Roberson SE, Tanner JP, **Anderson ML**, Rutherford TJ. "Feasibility and safety of planned early discharge following laparotomy in gynecologic oncology with enhanced recovery protocol including opioid-sparing anesthesia." *Front Surg*. 2023 Nov 3; 10:1279907. PMID 380264485.
138. Phan HV, Tsitsiklis A, Maguire CP, Haddad EK, Becker PM, Kim-Schulze S, Lee B, Chen J, Hoch A, Pickering ND, ... Langelier CR (**IMPACC Network**). "Host-microbe multi-omic profiling reveals age-dependent immune dysregulation associated with COVID-19 immunopathology." *Sci Transl Med*. 2024 Apr 17; 16(743). PMID 38630846.
139. Ho SJ, Chaput D, Sinkey RG, Garces AH, New PE, Okuka M, Sang P, Arlier S, Semerci N, Steffensen TS, Rutherford TJ, Alsina AE, Cai J, Anderson ML, Magness RR, Uversky VN, Cummings DAT, Tsibris JCM. Proteomic studies of VEGFR2 in human placentas reveal protein associations with pre-eclampsia, diabetes, gravidity and labor. *Cell Commun Signal*. 2024 Apr 9:22(1): 221. PMID: 38594674.
140. Phan HV, Tsitsiklis A, Maguire CP, Haddad EK, Becker PM, Kim-Schulze S, Lee B, Chen J, Hoch A, Pickering H, van Zalm P, Altman MC, Augustine AD, Calfee CS, Bosinger S, IMPACC Network. "Host-microbe multi-omic profiling reveals age-dependent immune dysregulation associated with COVID-19 immunopathology." *Sci Transl Med* 2024. Apr 17;16(743):eadj5154. PMID: 38630846.
141. Guo X, Okuka M, Short B, Ozmen A, Gunay NS, Rymer J, Un B, Guzeloglu-Kayisli O, Rutherford TJ, Kayisli U, **Anderson ML**. "Spatially restricted ecto-5'-nucleotidase expression promotes the growth of uterine leiomyomas by modulating AKT1 activity." *FASEB J*. 2024 Oct 15; 38(19) e70084. PMID: 39354726.
142. Soundararajan R, Maurin MM, Rodriguez-Silva J, Upadhyay G, Alden A, Gowda SGB, Schell MJ, Yang M, Levine NJ, Gowda D, Sundaraswamy PM, Hui SP, Pflieger L, Wang H, Marcet J, Martinez C, Bennett RD, Chudzinski A, Karachristos A, Nywening T, Cavallero PM, **Anderson ML**, Coffey RJ, Nebozhyn MV, Loboda A, Coppola D, Pledger WJ, Halade G, Yeatman TJ. "Integration of lipidomics with targeted, single cell and spatial transcriptomics define an unresolved pro-inflammatory state in colon cancer." *Gut*. 2024 Dec 10:hutjnl-2024-332535. PMID: 39658263.
143. Pickering H, Schaenman J, Phan HV, Maguire C, Tsitsiklis, A, Roupheal N, Higuera NIA, Atkinson MA, Brakenridge S, ... Langelier CR (**IMPACC Network**). "Host-microbe multiomic profiling identifies distinct COVID-19 immune dysregulation in solid organ transplant recipients." *Nat Commun*. 2025 Jan 10 16(1P 586. PMID: 39794319
144. Alvero AB, Wu S, Farrell A, Kim S, Wallbillich JJ, Winer I, Morris R, Spetzler D, **Anderson ML**, Puccini A, Jones NL, Herzog TJ, Thaker PH, Mor G, Gogi RP. "Exploring the differences between BRCA-mutated and HRwild-

type high grade serous ovarian cancer: A multi-omic analysis.” *Gynecol Oncol*. 2025 Mar; 194:71-790. PMID: 39970633.

145. Kohut A, **Anderson ML**, Andikyan V, Yasukawa M, Nguy L, Karachristos A, Nywening T, Mor G, Gogi R, Cohen JG, Lin FJ, Rutherford TJ. “Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy in Cytoreductive Surgery for Advanced-Stage Ovarian Cancer. *Ann Surg Oncol*. 2025 Jun; 32(6): 4326-4334. PMID: 40189674,
146. Apelian S, Martincuks A, Whittum M, Yasukawa M, Nguy L, Mathyk B, Andikyan V, **Anderson ML**, Rutherford T, Cristea M, Stewart D, Kohut A. “PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence and Evolving Strategies. *Biomedicines*. 2025 May 6; 13(5): 1126. PMID: 40426953.
147. Montealegre JR, Hilsenbeck SG, Bulsara S, Parker SL, Amboree TL, **Anderson ML**, Daheri M, Jibaja-Weiss ML, Schmeler KM, Deshmukh AA, Chaio EY, Scheurer ME. “Self-Collection for Cervical Cancer Screening in a Safety-Net Setting: The PRESTIS Randomized Clinical Trial.” *JAMA Intern Med*. 2025 Jun 6: PMID: 40478588.
148. Rosado R, Guo X, Rymer J, Un B, Mathyk BA, Cai J, Short B, Kayisli U, Rutherford TJ, **Anderson ML**. “Overexpression of high affinity Type I adenosine receptors promotes the growth of uterine leiomyomas.” *Mol Hum Reprod*. 2025. Jun 9: PMID: 40489662.
149. Wu SPS, Quiroz E, Want T, Montague Redcke SG, Xu X, Lin L, **Anderson ML**, DeMayo FJ. “Assessment of the histone mark-based epigenomic landscape in human myometrium at term pregnancy.” *Elife*. 2025 Jun 10:13:RP95897. PMID: 40493036.

Submitted

1. Martin N, Holbrook EA, Rutherford TJ, Wilson JA, **Anderson ML**. “Provider perspectives on the use of endometrial biopsy in an urban safety-net emergency department Western JEM. (Submitted).
- 2.–Wellcome J, Vitko J, English D, Kohut A, Rutherford TJ, **Anderson ML**. Molecular Features of Vulvar Breast Cancer: Report of Two Cases and Literature Review. *Gyn Onc Rep*. (Submitted)
3. Sun G, Hadfield MJ, Wu S, Wellcome J, Thanker P, Anderson ML, Dizon D. Differential molecular profiling in endometrial carcinoma by site of metastatic disease. *Clinical Cancer Res* (Submitted).

Abstracts given during the last 13 years

1. Guntupalli S, **Anderson ML**, Milam MR, Bodurka D, Ramirez PE, “Retrospective Outcomes Analysis of Patients with Uterine Smooth Muscle Tumors of Uncertain Malignant Potential” 38th Annual Meeting, Society of Gynecologic Oncologists, Tampa, FL, March 9-11, 2008.

2. Hawkins SM, Mangal R, Franklin R, Heard M, **Anderson ML**, Matzuk M. "Chromosomal Variants and Gene Expression Dysregulation in Endometriosis." Annual Meeting, Society for the Study of Reproduction, Kona, Hawaii, June, 2008.
3. Nagaraja A, Creighton C, Reid J, Gunaratne P, Hawkins SM, Lang M, **Anderson ML**, Matzuk M. "MicroRNAs in Human Ovarian Cancer." 2008 Annual Meeting, Society for the Study of Reproduction, Kona, Hawaii, June, 2008. (*Selected as Plenary Presentation*).
4. Creighton C, Nagaraja A, **Anderson ML**, Matzuk M. "Integration of Gene Expression Profiles of Human Ovarian Cancers with Expression Profiles of Pathways, Drugs and Mouse Models." 4th Canadian Conference on Ovarian Cancer, May, 2008. (*Selected as Plenary Presentation*)
5. Nagaraja A, M. F. Khan, E. Olokpa, O. Dziadzek, C. Creighton, D. Han, S. Hawkins, H. Zhu, P. Gunaratne, **Anderson ML**, M. Matzuk. "Comprehensive Profiling of the MicroRNA Transcriptome in Uterine Smooth Muscle Tumors." Keystone Symposium on Reproductive Biology, Santa Fe, New Mexico, February 3, 2009.
6. Kan MF, Olokpa E, Dziadzek O, Creighton CK, Nagaraja A, Roden R, Thomas D, Gunaratne P, Matzuk M, **Anderson ML**. "MicroRNA Profiling using Next Generation Sequencing: A Powerful Tool for Understanding Uterine Leiomyosarcomas." 2009 Annual Meeting, Keystone Symposium on Reproductive Biology, Santa Fe, New Mexico, February 4, 2009. (*Selected for Lalor Scholarship Award*)
7. Fountain MD, Olokpa E, Khan M, Nagaraja A, Creighton C, Zhu H, Hawkins SM, Gunaratne P, **Anderson ML**, Matzuk M. "MicroRNA Signatures for Serous Epithelial Ovarian Cancer." 2009 Annual Meeting, Keystone Symposium on Reproductive Biology, February 4, 2009.
8. Burzawa JK, Schmeler PT, Soliman RA, Lacour LA, Meyer MW, Bevers M, Frumovitz M, Pustilnik TB, Brown J, **Anderson ML**, Ramondetta LM, Tortolero-Luna G, Gershenson DM, Lu KH. "Prospective, Population-based Evaluation of Insulin Resistance, Polycystic Ovary Syndrome and Metabolic Syndrome in a Cohort of Patients with Endometrial Cancer." 40th Annual Meeting. Society of Gynecologic Oncologists, San Antonio, Texas, March 6, 2009.
9. Olokpa, E., Khan MF, Dziadzek O, Li C, Creighton CJ, Chegini N, AgoulNIK A, **Anderson ML**. "A Novel Xenograft Model Identifies Centrosome Pathways as Therapeutic Targets for Uterine Leiomyosarcoma." 2009 Annual Scientific Meeting, Society for Gynecologic Investigation, Glasgow, Scotland, March 17, 2009. (*Selected as Plenary Presentation and Pardi Best New Investigator Award*).
10. Khan MF, Olokpa E, Dziadzek O, Creighton C, Nagaraja CK, Kantilal A, Hawkins S, Zui H, Gunaratne P, **Anderson ML**. "Differentially Expressed

MicroRNAs and Their Targets in Uterine Leiomyomas. 2009 Annual Meeting, Society for the Study of Reproduction, Pittsburgh, PA, July 18, 2009.

11. **Anderson ML**, M.F. Khan MF, Olokpa E, Zhu H, Ewelike N, Orsulic S, Roden R, Thomas D, Creighton CR, P. Gunaratne. "Role of MicroRNAs in Uterine Leiomyosarcoma." 2009 Annual Meeting, Connective Tissue Oncology Society, Miami Beach, FL, November 5, 2009. (Abstract #5, Selected for Lead Plenary Session; 2009 Best Basic Science Prize, SGO).
12. Creighton CJ, Gunaratne P, Matzuk MM, **Anderson ML**. "Massively Parallel Sequencing Identifies miR-31 as a Key Tumor Suppressor in Papillary Serous Ovarian Cancers" 41st Annual Meeting, Society of Gynecologic Oncologists, San Francisco, CA. March 8, 2010. (Selected for Plenary Presentation)
13. Gunaratne P, Ghosh R, Mach C, Creighton CJ, Levine DA, Hayes DN, Wheeler D, Matzuk MM, **Anderson ML**, Gibbs RA. "Identification of novel tumor suppressor microRNAs implicated in epithelial ovarian cancer from the 19q13.41 non-coding RNA cluster." 101st Annual Meeting, American Association for Cancer Research, Washington, D.C., April 19, 2010.
14. Khan MF, Li Z, Olokpa A, Dziadzek O, Creighton CJ, Roden R, Thomas R, **Anderson ML**. "Overexpression of Centrosome-Regulating Pathways in Uterine Leiomyosarcoma" Annual Meeting, Society for Gynecologic Investigation, Orlando, FL, March, 2010. (Selected as Plenary Presentation)
15. Akinfenwa J, Kolomeyevskaya N, Mach CM, Li Z, **Anderson ML**. "A Novel Small Molecule Inhibitor for Aurora-A Kinase Inhibits the Growth of Cervical Cancer in Vitro and In Vivo." Society for Study of Reproduction, 2010 Annual Meeting, Milwaukee, WI, July 31, 2010.
16. Arias P, Creighton CJ, Yu Z, Gunaratne P, **Anderson ML**, Matzuk MM, Hawkins, SM. "MicroRNAs in Endometrioid Ovarian Cancer Target the Ephrin Receptor Signaling Pathway" Society for the Study of Reproduction, Milwaukee, WI (2010) Abstract #692
17. Yu Z, Creighton CJ, Fountain MF, Nagaraja A, Zhu H, Khan MF, Han D, Olokpa E, Hawkins SM, Gunaratne P, **Anderson ML**, Matzuk MM. "MiR-31 Is a Tumor Suppressor microRNA That Functions in Ovarian Cancer." Society for the Study of Reproduction, Milwaukee, WI (2010) Abstract #35. (Selected as Plenary Presentation)
18. Mach C*, **Anderson ML***, Benham A, Gunaratne P for TCGA Investigators. "A Novel Family of MicroRNAs that Determine Chemosensitivity and Survival for Women with Ovarian Cancer." 1st Annual Symposium, Cancer Prevention and Research Institute of Texas, Austin, TX. November 17-19, 2010. *Co-First Authors.
19. Benham A, **Anderson ML**, Gunaratne G. "MiR-130b Functions as a Tumor Suppressor in Ovarian Cancer by Promoting p53-Mediated Apoptotic Pathways." 1st Annual Symposium, Cancer Prevention and Research Institute of Texas, Austin, TX. November 17-19, 2010.

20. Mach CM, Kim J, Creighton CJ, Gunaratne PH, **Anderson ML**. "A Unique MicroRNA Locus at 19q13.41 Sensitizes Ovarian Cancers to Chemotherapy. Annual Meeting, Society of Gynecologic Oncologists, Orlando, FL. March 5, 2011. Abstract #4. (*Selected for Lead Plenary Session and Best Basic Science Award*)
21. Mach CM, Kim J, Zigelboim I, Goodfellow P, Odunsi K, Gunaratne P, Hawkins SM, **Anderson ML**. "Next Generation Sequencing Identifies miR-143 as a Putative Tumor Suppressor in Uterine Papillary Serous Carcinoma" Society for Gynecologic Investigation, Miami Beach, FL, March, 2011. Abstract #37 (*Selected as Plenary Presentation*).
22. Shan W, Akinfenwa, PY, Brewer KJ, Lev D, **Anderson ML**. "Dysregulation of the Mitotic Spindle Checkpoint Contributes to the Development of Human Genital Tract Leiomyosarcoma." Annual Meeting, American Association for Cancer Research, Orlando, FL April 5, 2011.
23. Kim, J, Mach, CM, Soibam B, Creighton CJ, Xiao W, Gunaratne P, **Anderson ML**. "Genome-wide Analysis of Small RNA Transcripts Reveals Novel Roles of MicroRNAs and MicroRNA Processing in Uterine Papillary Serous Carcinoma." Cell Symposium: Non-coding RNAs, Chicago, IL, October 12, 2011.
24. Kim, J, Mach, CM, Soibam B, Creighton CJ, Xiao W, Gunaratne P, **Anderson ML**. "Novel MicroRNAs Regulating Growth and Metastasis of Uterine Papillary Serous Carcinoma." Annual Symposium, Dan L. Duncan Cancer Center, Houston, TX, November 11, 2011.
25. Loomans HA, Tsai MJ, Sangi-Haghpeykar H, Hawkins SM, **Anderson ML**. "Altered COUP-TFII Expression Contributes to Epithelial Ovarian Cancer by Impacting Expression of FOXM1-Regulated Genes NEK2 and RAI14." Annual Symposium, Dan L. Duncan Cancer Center, Houston, TX November 11, 2011.
26. Ghosh-Choudhury T, Xiao W, Gunaratne PH, **Anderson ML**. "Role of miR-148a/b in High Grade Serous Ovarian Carcinomas." Annual Symposium, Dan L. Duncan Cancer Center, Houston, TX November 11, 2011.
27. Kim, J, Mach, CM, Soibam B, Creighton CJ, Xiao W, Gunaratne P, **Anderson ML**. "miR-143 Targets Exportin 5 to Promote the Growth of Uterine Papillary Serous Carcinomas. 2nd Annual Symposium, Cancer Prevention and Research Institute of Texas, Austin, TX. November 15-17, 2011.
28. Ramos CA, Narala N, Leen AM, Gerdemann U, **Anderson ML**, Sturgis EM, Savoldo B, Heslop HE, Brenner MK, Rooney CM. Human Papillomavirus Type 16 (HPV16) E6/E7-Specific Cytotoxic T Lymphocytes (CTLs) for Immuno-therapy of HPV-Associated Malignancies. 53rd Annual Meeting, American Society of Hematology. San Diego, CA. December 10, 2011.
29. Anaya Y, Khatri S, Xiao W, **Anderson ML**, Hawkins SM. "Distinct Molecular Pathways in Endometriosis Associated Ovarian Cancer." Annual Meeting,

Society for Gynecologic Investigation, March 22, 2012. (*Selected as Plenary Presentation*)

30. Shan W, Creighton CJ, **Anderson ML**. "Mir-140-3p Targets IQGAP3 and Promotes Growth and Metastasis of Uterine Leiomyosarcoma" Annual Meeting, Society for Gynecologic Investigation, March 22, 2012. (*Selected as Plenary Presentation*).
31. Mach C, Kim J, Creighton CJ, Gunaratne PH, **Anderson ML**. "Loss of miR-143 Promotes the Proliferation of UPSC by Enhancing Exportin-5 Expression" Annual Meeting on Women's Cancer, Society for Gynecologic Oncology, Austin, TX. March 26, 2012.
32. Ghosh-Choudhury T, Xiao W, Gunaratne PH, **Anderson ML**. "Loss of miR-148a/b Expression Promotes Ovarian Cancer by Targeting Erbb3 and MYB". Annual Meeting on Women's Cancer, Society for Gynecologic Oncology, Austin, TX. March 26, 2012.
33. Shahzad MMK, Van Galder HR, **Anderson ML**, Kapur A, Jallow F, Rose SL, Patankar MS. "MicroRNA Modulation and Potent Anticancer Activity by Conjugated Linoleic Acid in Epithelial Ovarian Carcinoma." Annual Meeting on Women's Cancer, Society for Gynecologic Oncology. Austin, TX. March 26, 2012.
34. Stover J, Lee N, McCoy R, Patel P, Hanke J, Mach CM, **Anderson ML**. "Targeting Cervical Cancer Prevention in an Uninsured/Underinsured Patient Population" Annual Seminar & Arcade, Texas Association of Health-System Pharmacists, Dallas, TX, April 12-15, 2012.
35. **Anderson ML**, Shan W, Kim G, Creighton CJ, Gunaratne PH, Lev D. "Genome-wide Transcriptional Profiling Identifies miR-10b as a Key Tumor Suppressor in Uterine Leiomyosarcoma." 2012 Annual Meeting, Cancer Prevention and Research Institute of Texas, Austin, TX. October 25, 2012.
36. **Anderson ML**, Hanser L, Daheri M, Bailey-Delesbore CL, Ramondetta L, Sangi-Haghpeykar. "Developing a Comprehensive Cervical Cancer screening Program for High Risk Uninsured and Underinsured Women in Harris County." 2012 Annual Meeting, Cancer Prevention and Research Institute of Texas. Austin, TX October 25, 2012.
37. Shan W, Kim G, Lev D, **Anderson ML**. "Small Molecule Inhibitors for Polo-like Kinase 1 (Plk-1) Sensitize Uterine Leiomyosarcoma to Rapamycin." Connective Tissue Oncology Society, Prague, Czech Republic. November 16, 2012. (*Selected as Primary Plenary presentation*).
38. Mach C, Wan Y-W, Liu Z, **Anderson ML**. "Lasso Analysis Identifies Novel Pathways by which Lin28 Paralogs Determine Ovarian Cancer Susceptibility and Metastasis." 2nd Annual Meeting, Cancer Genome Atlas Consortium, Arlington, VA, November 26, 2012.

39. Ghosh-Choudhury T, Loomans HA, Wan Y-W, Liu Z, Hawkins SM, Anderson **ML**. "Hyperactivation of FOXM1 Drives Ovarian Cancer Growth and Metastasis Independent of the G2-M Cell Cycle Checkpoint" American Association for Cancer Research, Washington, D.C, April 9, 2013.
40. Mach C, Wan Y-W, Liu Z, **Anderson ML**. "Lasso Analysis Identifies Novel Pathways by which Lin28 Paralogs Determine Ovarian Cancer Susceptibility and Metastasis, American Association for Cancer Research, Washington, D.C, April 8, 2013.
41. Sun G, **Anderson ML**, Meng F, Shan W, Yu Y, Brewer MA. "The omental microenvironment promotes in vivo metastasis via CD-133 mediated ovarian cancer self-assembly." American Association for Cancer Research, Washington, D.C, April 8, 2013.
42. Mach CL, **Anderson ML**. "Novel Function for Lin28a/b in Ovarian Cancer Predisposition and Tumorigenicity." 2014 Annual Meeting, Society for Gynecologic Oncology, Tampa, FL.
43. Hsieh, G, Antony K, Masand R, **Anderson ML**. "Interim Analysis of Prospective Feasibility Study of Postpartum Salpingo-Oophorectomy." 2014 Annual Meeting, Society for Gynecologic Oncology, Tampa, FL. (*Selected as Featured Poster*).
44. Desai P, Wallace R, **Anderson ML**, Alqwasmī A, Howard BV, Wu CH, Safford M, Martin LW, Schlect N, Liu S, Cetnar J, Cirillo D, Jay A, Manson JE, Simon MS. "Prospective Analysis Of Statin Use and Risk Of Non-Hodgkin's Lymphoma In The Women's Health Initiative Cohort" American Society for Hematology.
45. Hsieh GL, Antony K, Masand R, **Anderson ML**. "Histologic Characterization of the Post-Partum Fallopian Tube" 2014 Annual Meeting, Society for Gynecologic Investigation, Florence, Italy, March 27, 2014.
46. Ghosh-Choudhury T, Wan Y-W, Mach CM, Liu Z, **Anderson ML**. "Loss of MiR-148 Enhances Ovarian Cancer Growth and Metastasis by Promoting MTMR9 Expression." 2014 Annual Meeting, Society for Gynecologic Investigation, Florence, Italy, March 27, 2014. (*Selected for a Pardi Award and presentation as part of the Presidential New Investigator Plenary Session*).
47. Mach C, Magliaro T, **Anderson ML**. "ECT2: A Molecular Target for the Treatment of Uterine Papillary Serous Carcinoma (UPSC)" 2014 Annual Meeting, Society for Gynecologic Investigation, Florence, Italy, March 27, 2014.
48. Mach CM, Magliaro T, **Anderson ML**. "Overexpression of ECT2 promotes proliferation and metastasis of UPSC" Annual Meeting, American Association for Cancer Research, San Diego, CA, April 8, 2014.
49. **Anderson ML**, Kim GE, Mach CM, Creighton CJ, Lev D. "miR-10b functions as a novel tumor suppressor in uterine leiomyosarcoma by promoting

overexpression of SDC1” Annual Meeting, American Association for Cancer Research, San Diego, CA, April 9, 2014.

50. Hsieh G, Antony K, Masand R, **Anderson ML**. “A Prospective Feasibility Study of Post-Partum Distal Salpingectomy” 2014 Annual Meeting, American College of Obstetrics & Gynecology, Chicago, IL. April 20, 2014.
51. Hsieh G, Antony K, Masand R, **Anderson ML**. “A Prospective Feasibility Study of Risk-Reducing Distal Salpingectomy.” Edmond T. Gonzales, Jr., Research Day, Department of Surgery, Baylor College of Medicine, May 9, 2014.
52. Ogunwale A, Sangi-Haghpeykar H, Montealegre J, Nosek MA, Bailey-Delesbore CL, Lucinda-Thomas C, Jibaja-Weiss M, **Anderson ML**. “Predictors of Cervical Cancer Screening among Women Receiving Care through a Safety-Net Health System” 7th Annual Conference on the Science of Health Disparities,” American Association for Cancer Research, San Antonio, TX, November 11, 2014.
53. Delaney M, Wan Y-W, Taylor MG, Kim G, Valdes C, Liu ZD, **Anderson ML**. “Progesterone Promotes Smooth Muscle Tumorigenesis by Down-Regulating SFRP4 Overexpression” Annual Retreat, Center for Reproductive Medicine Baylor College of Medicine, Houston, TX, February 25, 2015.
54. Biernacka A, **Anderson, ML**, Masand RL. “Papillary Squamous Cell “Carcinoma of the Uterine Cervix – Removing an Aggressive Label.” 104th Annual Meeting, United States & Canadian Academy of Pathology, Boston, MA. March 21-27, 2015.
55. Hsieh, GL, **Anderson, ML**, Ludwig M. “Treatment Compliance Among Medically Underserved Women Undergoing Chemoradiation for Locoregionally Advanced Cervical Cancer.” 45th Annual Meeting, Society for Gynecologic Oncology, Chicago, IL. March 28-31, 2015.
56. Betancourt A, Chauhan M, Dong Y, Balakrishnan M, **Anderson ML**, Belfort M, Yallampalli C. “Vasodilatory Responses to CGRP Family Peptides and Their Receptor Levels in Human Omental Arteries are Increased During Pregnancy” Annual Meeting, Society for Reproductive Investigation, San Francisco, CA, March 25-28, 2015.
57. Delaney M, Wan Y-W, Taylor MG, Kim G, Valdes C, Liu ZD, **Anderson ML**. “Progesterone Promotes Smooth Muscle Tumorigenesis by Down-Regulating SFRP4 Overexpression” Annual Meeting, Society for Reproductive Investigation, San Francisco, CA, March 25-28, 2015. (*Selected for Plenary Presentation and Best New Investigator Award*)
58. Ezra Cohen E, Moore KN, Slomovitz BM, Chung CW, **Anderson ML**, Morris S, Mauro D, Burtneiss B. “Phase 1-2 study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV) positive head and neck cancer.”

Annual Meeting, Society for Immunotherapy of Cancer, Baltimore, MD.
November 4-8, 2015.

59. Ludwig M, Hsieh G, Bonnen M, Linesch S, MacDonald A, **Anderson ML**.
“Abstract#652: Treatment compliance and outcomes for women with
locoregionally advanced cervical cancer treated in a safety-net health system.”
Innovations in Cancer Prevention and Research Conference. Cancer Prevention
and Research Institute of Texas, Austin, TX, November 9-10, 2015.
60. **Anderson ML**, Cui Y, Daheri M, Bailey-Delesbore CL, Montealegre JM,
Ogunwale A, Ramondetta LR, Sangi-Haghpeykar H, Hanser L, Jibaja-Weiss M.
“Abstract#649: Impact of a Comprehensive Program Focused on Cervical
Cancer Screening and Follow up Within a Texas Safety Net Health System.”
Innovations in Cancer Prevention and Research Conference. Cancer Prevention
and Research Institute of Texas, Austin, TX, November 9-10, 2015.
61. Mach CM, Mhawech-Fauceglia P, Sangi-Haghpeykar H, **Anderson ML**.
“Abstract#717: Overexpression of Exportin-5 (XPO5) Defines a Novel Subset
of MicroRNA-Addicted Uterine Cancers with Poor Outcome.” Innovations in
Cancer Prevention and Research Conference. Cancer Prevention and Research
Institute of Texas, November 9-10, 2015.
62. Montealegre JM, Hanser L, Chenier R, Valverde I, Chauca G, Daheri M,
Rustveld L, Reed B, **Anderson ML**, Ramondetta LR, Gould-Suarez M, Musher
B, Scott L, Nangia J, Hoagland-Sorensen J, Rieber A, Jibaja-Weiss M.
“Abstract#116: The Community Network for Cancer Prevention: Using the RE-
AIM Framework to Develop and Implement a Cancer Screening Educational
Tool.” Innovations in Cancer Prevention and Research Conference. Cancer
Prevention and Research Institute of Texas, November 9-10, 2015.
63. Jibaja-Weiss M, Montealegre JM, Hanser L, Daheri M, Chenier R, Valverde I,
Chauca G, Rustveld L, **Anderson ML**, Ramondetta LR, Gould-Suarez M,
Musher B, Scott L, Nangia J, Reed B, Hoagland-Sorensen J, Rieber A. “The
Community Network for Cancer Prevention: Developing a Multi-Level
Intervention to Improve Cancer Screening and Follow-Up among the Medically
Underserved.” Innovations in Cancer Prevention and Research Conference.
Cancer Prevention and Research Institute of Texas, November 9-10, 2015.
64. Montealegre JR, Hanser L, Daheri M, Chenier R, Valverde I, Chauca GS,
Rustveld LO, **Anderson ML**, Ramondetta L, Gould-Suarez M, Musher BL,
Scott LD, Nangia JR, Reed BC, Hoagland-Sorensen J, Rieber A, Jibaja-Weiss
ML. “Using community theater to promote cancer screening among the
medically underserved.” Innovations in Cancer Prevention and Research
Conference, Cancer Prevention and Research Institute of Texas, Austin, Texas
November 9-10, 2015.
65. Montealegre JR, Hanser L, Daheri M, Chenier R, Valverde I, Chauca GS,
Rustveld LO, **Anderson ML**, Ramondetta L, Gould-Suarez M, Musher BL,
Scott LD, Nangia JR, Reed BC, Hoagland-Sorensen J, Rieber A, Jibaja-Weiss
ML. Patient navigation to ensure diagnostic follow-up among patients with
abnormal cancer screening results.” Innovations in Cancer Prevention and

Research Conference. Cancer Prevention and Research Institute of Texas 2015, Austin, Texas November 9-10, 2015.

66. Montealegre JR, Hanser L, Daheri M, Chenier R, Valverde I, Chauca GS, Rustveld LO, **Anderson ML**, Ramondetta L, Gould-Suarez M, Musher BL, Scott LD, Nangia JR, Reed BC, Hoagland-Sorensen J, Rieber A, Jibaja-Weiss ML. "Using the Quality in the Continuum of Cancer Care framework to develop a multilevel intervention to improve cancer screening and follow-up among the medically underserved." The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, American Association for Cancer Research Conference on, Atlanta, Georgia November, 2015.
67. Lawson B, Soundar E, **Anderson ML**, Masand P. "Intraoperative Consultation in Low Grade Endometrial Endometrioid Adenocarcinoma: Is Frozen Section Superior to Gross Examination?" United States & Canadian Academy of Pathology March 18-22, 2016.
68. Montealegre JR, McGee L, Boom J, Scheurer M, **Anderson ML**, Jibaja-Weiss M. A Baseline Assessment to Inform a Multi-Level Intervention to Increase HPV Vaccine Initiation and Completion in a Safety net Healthcare System in Houston, Texas. HPV Vaccination Summit, Columbus, Ohio, June, 2016.
69. Montealegre JR, Cui Y, Hanser L, Daheri M, Mallory M, **Anderson ML**, Jibaja-Weiss ML. "Patient navigation ensures diagnostic follow-up among patients with an abnormal pap test." American Public Health Association Meeting, Denver, Colorado, November, 2016.
70. Guner JZ, Kim GE, Delaney MA, Ghosh-Choudhury T, Valdes C, Gibbons W, **Anderson ML**. "Expression of Tumor Suppressor PCDH10 in Uterine Leiomyomas and Leiomyosarcomas" Annual Meeting, Society for Reproductive Investigation, San Francisco, CA, March 17, 2017. (*Selected for presentation and Pardi Award as part of the Presidential New Investigator Plenary Session.*)
71. Wu S-P, **Anderson ML**, Wang T, Li X, DeMayo FJ. "Investigation of Human Myometrial Transcriptome and Progesterone Receptor Cistrome." Annual Meeting, Society for Reproductive Investigation, San Francisco, CA, March 18, 2017.
72. Chang G, Li J, Wang B, Yamamoto Y, Rajasekaran M, Duleba M, Rao W, Xie J, Wang S, Jazaeri A, Davis P, Torti S, Draetta G, **Anderson ML**, Brewer MB, Crum c, McKeon F, Xian W. "Cloning and vulnerability of intrinsically resistant subset of ovarian cancer stem cells" AACR Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment. October 1-4, 2017, Pittsburgh, PA.
73. Montealegre JR, McGee L, Boom JA, **Anderson ML**, Mallory M, Scheurer ME, Jibaja-Weiss ML. "A baseline assessment of HPV vaccine initiation and completion rates in a safety net healthcare system in Houston, Texas." International Papillomavirus Conference, Cape Town, South Africa, March, 2017.

74. Hall TH, Daheri M, Montealegre J, Hanser L, Turnbull C, Jibaja-Weiss M, **Anderson ML**. “Factors associated with navigation failure among medically underserved women screened for cervical cancer.” Innovations in Cancer Prevention and Research Conference. Cancer Prevention and Research Institute of Texas, November 13-14, 2017.
75. Xie J, Yamamoto Y, Wang, B, Mahalingam R, Duleba M, Rao W, Wang S, Jazaeri A, Davies P, Torti S, Draetta G, **Anderson ML**, Brewer M, Crum C, McKeon F, Xian W. “Cloning and Vulnerability of Intrinsically Resistant Subset of Ovarian Cancer Stem cells.” Innovations in Cancer Prevention and Research Conference. Cancer Prevention and Research Institute of Texas, November 13-14, 2017
76. Hall TR, Montealegre J, Daheri M, Turnbull C, Jibaja-Weiss M, Sangi-Haghpeykar H, **Anderson ML**. “Factors associated with navigation failure among medically underserved women screened for cervical cancer.” Innovations in Cancer Prevention and Research Conference, Cancer Prevention and Research Institute of Texas, November 13-14, 2017.
77. Elshaikh B, Chang R, **Anderson ML**, Masand R. “Coexistent Endometrial and Ovarian Endometrioid Carcinoma: A Clinicopathologic Analysis of 18 Cases with Immunohistochemistry Testing for Mismatch Repair Proteins.” Annual Meeting, United States and Canadian Academy of Pathology, 2018.
78. Chang R, Elshaikh B, **Anderson ML**, Masand R. “Uterine Carcinosarcomas: A Clinicopathologic Study of 22 cases.” Annual Meeting, United States and Canadian Academy of Pathology, 2018.
79. Montealegre JR, McGee L, Daheri M, Sangi-Haghpeykar H, Mallory-McRae M, Hanser L, Klein K, **Anderson ML**, Boom J, Scheurer M, Jibaja-Weiss ML. “Interim Results of a Tiered Patient Recall/Reminder Program for Human Papillomavirus Vaccination in a Safety Net Healthcare System in Houston, Texas.” American Society for Preventive Oncology, New York, New York, March, 2018.
80. **Anderson ML**, Lazar AN “Integrated genomic analyses distinguish leiomyosarcomas arising at distinct anatomic origins.” Annual Meeting, Society for Gynecologic Oncology, March 26, 2018. (*Selected for Lead Basic Science Plenary Presentation - top 5 abstracts for 2018 meeting*)
81. Hall TR, Montealegre J, Daheri M, Turnbull C, Jibaja-Weiss M, Sangi-Haghpeykar H, **Anderson ML**. “Factors associated with navigation failure among medically underserved women screened for cervical cancer.” Annual Meeting, Society for Gynecologic Oncology, March 25-27, 2018. (*Selected for Plenary Presentation*)
82. Xian W, McKeon F, Crum C, Xie J, Wang B, Yamamoto Y, Torti S, Brewer M, **Anderson ML**, Jazaeri A, Draetta G, Wang S, Mahalingam R, Chen H, Duleba M, Rao W. “Pre-existence of poly-resistant cancer stem cells in high grade-

- ovarian cancer.” Annual Meeting, American Association for Cancer Research, April 14, 2018.
83. Yoder AK, Dalwadi S, Dorman CM, Hall TR, **Anderson ML**, Ludwig MS. “Patterns of Care and Outcomes in Early Stage Neuroendocrine Carcinoma of the Uterine Cervix.” American Radium Society, May 8, 2018.
84. **Anderson ML**, Hall TR, Mach CM, Turnbull C, Spoo L, Kilpatrick C. “Online Learning Module for Improving Oncologic Fund of Knowledge among OB-GYN Postgraduate Trainees. Texas Educators Academies Collaborative for the Health Professions - Southeast (TEACH-S) Educational Symposium May 11, 2018. (*Selected for Plenary Presentation*)
85. Wu S-P, Wang T, Peavey M, **Anderson ML**, Li X, DeMayo F. “Regulation of the Smooth Muscle Program by Progesterone Receptor during Pregnancy.” Keystone Symposia - Gene Control in Development and Disease, June, 2018.
86. Ressler K, Payne KS, Daheri M, **Anderson ML**, Jibaja-Weiss ML, Montealegre JR. Using the RE-AIM framework to evaluate a cervical cancer screening recall and patient navigation intervention in a safety net health system. Implementation and Dissemination Science, Crystal City, VA, December, 2018.
87. Payne KS, Ressler K, Daheri M, **Anderson ML**, Scheurer ME, Hanser L, Hernández R, Escobar B, Rosen A, Jibaja-Weiss ML, Montealegre JR. Interim Results: Recall and Patient Navigation to Increase Cervical Cancer Screening Among Un-/Under-screened Women in a U.S. Safety Net Healthcare System. Eurogin, Lisbon, Portugal, December, 2018.
88. **Anderson ML**, Ding L, Grisenko MA, Kawaler E, Thiagarajan M, Dou Y, Liu W, Zhou DC, Mesri M, Q Gao, SH Payne, B Wen, L-B Wan, CR Kinsinger, Y Wu, Levine DA, Smith DA, Ellis MJ, Ruggles RV, Rodriguez H, Rodland KD, Zhang B, Fenyo D, Liu T. “Approach to a Comprehensive Proteogenomic Analysis of Uterine Cancer.” 50th Annual Meeting, Society for Gynecologic Oncology, March, 2019.
89. Yoder AK, Mach C, Dalwadi S, Hall TR, **Anderson ML**, Ludwig MS. “Association of hematologic toxicities and outcomes in the treatment of cervical cancer with definitive chemoradiation.” 50th Annual Meeting, Society for Gynecologic Oncology, March, 2019.
90. Jin J, Dalwadi S, Masand RM, Hall TR, **Anderson ML**, Ludwig MS. “Association between metabolic syndrome and endometrial cancer survival in a SEER-Medicare linked database.” 50th Annual Meeting, Society for Gynecologic Oncology, March, 2019.
91. Kuznicki ML, Mallen A, Eggers E, Regis J, Todd S, Tanner JP, **Anderson ML**, Rutherford TJ. “Preliminary Quality of Life and Clinical Outcomes with an Opiate Restrictive Enhanced Recovery Protocol in a Gynecologic Oncology Population.” Annual Meeting, Florida Society for Gynecologic Oncology, June 6, 2019. (*Selected for Plenary Presentation*)

92. Xie J, Yamamoto Y, Liew A-A, Want B, Mahalingam R, Duleba M, Rao W, Niroula S, Goller K, Zhang Y, Wang S, Jazaeri A, Davies P, Torti S, Draetta G, **Anderson ML**, Brewer MB, Crum C, McKeon F and Xian W. “Pre-existing, poly-resistant cancer stem cells in high-grade serous ovarian cancer.” AACR Special Conference on Advances in Ovarian Cancer Research; September 13-16, 2019.
93. Montealegre JR, **Anderson ML**, Hilsenbeck SG, Zare M, Parker SL, Cantor SB, Daheri M, Jibaja-Weiss ML, Chiao EY, Scheurer ME. Planning for Implementation: Protocol for a randomized controlled hybrid type I trial of mailed self-sample human papillomavirus (HPV) testing among under-screened women in a safety net healthcare system. Implementation and Dissemination Science, Crystal City, VA, 12/2019.
94. Fadiel A, Sharma N, **Anderson ML**. “Standardized Exosome Isolation and Profiling for Biomarker Discovery.” AACR Special Conference on Advances in Liquid Biopsies, January 13-16, 2020.
95. Read S, Dou Y, Jonnalagadda VA, Rutherford TJ, **Anderson ML**. “PAX8 represents a Potential Novel Therapeutic Target in Copy Number Nigh Uterine Carcinomas.” USF Health Research Day Symposium, Tampa, FL February 21, 2020.
96. Jonnalagadda VA, Guner JZ, Read SM, Patil NM, Masand RP, Valdes CT, Gibbons WE, **Anderson ML**. “Heterogenous Expression of HES6 Promotes the Growth of Uterine Leiomyomas.” USF Health Research Day Symposium, Tampa, FL February 21, 2020.
97. Mallen AR, Cline K, Cao B, Williams HR, Better MH, Buras AL, Read S, Rutherford TJ, Shahzad MM, Vadapampil S, **Anderson ML**. “Patterns of genetic profiling for ovarian cancer among gynecologic oncology providers.” Moffitt Research Symposium, Tampa, FL, March, 2020.
98. Montealegre JR, Parker SL, Zare M, Hilsenbeck SG, Bulsara S, Daheri M, Escobar B, Jibaja-Weiss ML, **Anderson ML**, Cantor SB, Chiao EY, Scheurer ME. “Cervical Cancer Screening among Primary Care Patients in an Urban Public Safety Net Health System.” American Society for Preventive Oncology. Tucson, Arizona (converted to online conference due to COVID-19), March, 2020.
99. Kuznicki ML, Mallen A, Eggers E, Regis J, Todd S, Tanner JP, **Anderson ML**, Rutherford TJ. “Clinical Outcomes for an Opiate Restrictive Enhanced Recovery Protocol in a Gynecologic Oncology Population.” 51st Annual Meeting, Society for Gynecologic Oncology, March, 2020. (*Selected for Plenary Presentation*).
100. Mallen AR, Cline K, Cao B, Williams HR, Better MH, Buras AL, Read S, Rutherford TJ, Shahzad MM, Vadapampil S, **Anderson ML**. “Patterns of genetic profiling for ovarian cancer among gynecologic oncology providers.” 51st Annual Meeting, Society for Gynecologic Oncology, March, 2020.

101. Read SH, Dou YC, Jonnalagadda VA, Rutherford TJ, Zhang B, **Anderson ML**. “PAX8 represents a potential novel therapeutic target in copy number high uterine serous carcinoma.” AACR Virtual Special Conference: Endometrial Cancer - New Biology Driving Research and Treatment. November 9-10, 2020.
102. Wells AE, **Anderson ML**, Williams B, Kayisli U, Louis J, English DP, Lockwood CJ, Rutherford TJ. “Impact of a Standardized Surgical Workflow on Outcomes of Hysterectomy Performed for Morbidly Adherent Placenta. Virtual Annual Meeting, Society for Maternal Fetal Medicine, January 25-30, 2021.
103. Rooker J, Rutherford TJ, **Anderson ML**, Martin TE, English DP, Sanchez, V. “A Routine Early screening for Chemotherapy-Induced Hearing loss and other Neuropathies in Patients Undergoing Cancer Treatment: A Pilot Study.” Virtual 52nd Annual Meeting, Society for Gynecologic Oncology, March, 2021. (*Selected for Plenary Presentation*)
104. Read SH, Cline K, Mallen AR, Cao B, Fridley B, Vadapramparil S, Chern J, **Anderson ML**. “Patterns of Genetic Testing for Women Recently Diagnosed with Uterine Cancer” Virtual 52nd Annual Meeting, Society for Gynecologic Oncology, March, 2021.
105. Wells A, **Anderson ML**. “Evaluation of Abnormal Vaginal Bleeding in the Emergency Department: Logical Opportunities to Favorably Impact a Key Cancer Disparity” Virtual 52nd Annual Meeting, Society for Gynecologic Oncology, March, 2021.
106. Wellcome JL, Wells AE, Rutherford RJ, **Anderson, ML**. “Heated Intraperitoneal Chemotherapy in Low-Grade Serous Ovarian Carcinoma: A Case Series.” USF Health Research Day, February 26, 2021.
107. Parker SL, Daheri M, Benavides E, Kasbaum M, Escobar B, Chiao EY, **Anderson ML**, Deshmukh A, Hilsenbeck SG, Jibaja-Weiss ML, Bulsara S, Zare M, Scheurer ME, Montealegre JR. “Barriers to cervical cancer screening and acceptability of at-home HPV self-test kits: preliminary results.” 34th Annual Papilloma Conference, Toronto, CA, November, 2021.
108. Parker SL, Daheri M, Chiao EY, **Anderson ML**, Deshmukh A, Hilsenbeck SG, Jibaja-Weiss ML, Scheurer ME, Montealegre JR. “Health care use and access among Hispanic women in a safety-net healthcare system during the COVID-19 pandemic.” 2021 Annual Meeting, American Public Health Association. Denver, CO October 24-27, 2021.
109. Okuka M, Guner J, Venkatarama A, Patil N, Ruggles K, **Anderson ML**. “Dysregulation of the HES6:HES1 Transcriptional Axis promotes uterine leiomyoma growth by targeting mitochondrial metabolism. 2023 Annual Meeting, Society for Reproductive Investigation, Brisbane, Australia; March 23, 2023.
110. Rymer J, Okuka M, Borresen, B, Guo X, Yi Z, Alvero A, Rutherford TJ, **Anderson ML**. “Comprehensive Characterization of Endometrial and

Endometrial Cancer Exosomes” Society for Reproductive Investigation,
Brisbane, Australia, March 23, 2023.

111. Guo X, Okuka M, Borresen B, Semerci N, Martin N, Guzeloglu-Kayisli O, Kayisli U, **Anderson ML**. “Loss of CD73 promotes the growth of uterine leiomyomas via ADORA2B-regulated AKT signaling pathways.” Society for Reproductive Investigation, Brisbane, Australia, March 24, 2023.
112. Wu S-P, **Anderson ML**, Wang T, Quiroz E, Lin L, DeMayo FJ. “An epigenomic landscape for remodeling of the human myometrium” Society for Reproductive Investigation, Brisbane, Australia; March 23, 2023.
113. Parker SL, Amboree, T, Daheri M, Chiao EY, Schmeler K, **Anderson ML**, Deshmukh AA, Hilsenbeck S, Jibaja-Weiss M, Bulsara S, Zare M, Scheurer ME, Montealegre JR. Perceived barriers to clinic-based cervical cancer screening and motivators for HPV self-sampling during the COVID-19 pandemic. Oral presentation. EUROGIN 2023. February 8-11, 2023; Bilbao, Spain.
114. Parker SL, Amboree, T, Daheri M, Chiao EY, Schmeler K, **Anderson ML**, Deshmukh AA, Hilsenbeck S, Jibaja-Weiss M, Bulsara S, Zare M, Scheurer ME, Montealegre JR. Fear of cancer and HPV as barriers to clinic- and home-based cervical cancer screening among under-screened women in a safety net healthcare system. ASPO Annual Meeting 2023. March 12-15, 2023; San Diego, CA.
115. Parker SL, Amboree, T, Daheri M, Chiao EY, Schmeler K, **Anderson ML**, Deshmukh AA, Hilsenbeck S, Jibaja-Weiss M, Bulsara S, Zare M, Scheurer ME, Montealegre JR. Preferences for HPV self-sampling implementation in a safety net healthcare system. International Papillomavirus Conference 2023. April 17-21, 2023; Washington, D.C.
116. Katsnelson L, Dou Y, Gritsenko MA, **Anderson, ML**, Rodland KD, Zhang B, Liu T, Fenyo D and the Clinical Proteomic Tumor Analysis Consortium. Proteogenomic insights suggest druggable pathways in endometrial cancer. AACR Annual Meeting, April 15-19, 2023; Orlando FL
117. Jhavari V, Tanner JP, Rutherford TJ, David J, **Anderson ML**. “Survival Following Radical Hysterectomy in an expanded NCDB dataset.” ASCO Annual Meeting, June 2-6, 2023, Chicago, IL.
118. Doroshow DB, Tolcher AW, Fleming GF, Segar J, Mamdani H, Mathews C, Chern J-Y, Mendivil AA, **Anderson ML**, Miller D, Sen S, Mahdi HS, Brownstein C, Trivedi T, Petrell J, Ngaara-Woodward C, Reckner M, Meric-Bernstam F. “Safety and Efficacy of Monotherapy Azenosertib (ZN-c3), a Selective WEE1 Inhibitor, in Patients (Pts) With Advanced Solid Tumors.” European Society for Medical Oncology (ESMO), Annual Meeting, October 20-24, 2023, Madrid, Spain.

119. Jane R. Montealegre JR, Chiao EY, **Anderson ML**, Hilsenbeck SG, Bulsara S, Parker SL, Daheri M, Amboree TL, Schmeler KM, Jibaja-Weiss ML, Zare M, Deshmukh AA, Scheurer ME. "Mailed at-home self-sampling for HPV testing increases screening participation among under-screened patients in a U.S. safety net health system: Results of the PRESTIS trial." 2024 Annual Meeting Amer. Assoc. Cancer Research, San Diego, CA, April 8, 2024.
120. Hadfield MJ, Wu S, Farrell A, Oberly M, Sun G, Thaker P, Wellcome J, Anderson M, Dizon D. "Describing the molecular landscape of cervical cancer metastases: Implications for future therapeutic targets 2024 Annual Meeting Amer. Assoc. Cancer Research, San Diego, CA, April 8, 2024.
121. Guo, X, Guest H, Rosado R, Rodriguez K, Rutherford TJ, **Anderson ML**. "C1QL1, a paralog of complement factor C1q is secreted by uterine smooth muscle and promotes leiomyoma growth." 2024 Annual Meeting, Society for Reproductive Investigation, Vancouver, BC, Canada, March 14, 2024
122. Guo X, Okuka M, Short B, Rutherford TJ, **Anderson ML**. "Selective Overexpression of Adenosine Receptor A1 (ADORA1) Promotes the Growth of Uterine Leiomyomas by modulating Akt Signaling Pathways." 2024 Annual Meeting, Society for Reproductive Investigation, Vancouver, BC, Canada, March 14, 2024
123. Gogoi R, Gogoi V, Adzibolosu N, Alvera A, Morris RT, **Anderson ML**, Rutherford TJ, Draghici S, Mor GG. Supervised machine learning with a novel set of 20 genes predicts likelihood of early or late recurrence of high grade serous ovarian cancer." Annual Meeting, Society for Gynecologic Oncology, San Diego, CA; March 17, 2024.
124. Rooker J, **Anderson ML**, Rutherford TJ, Schwarzberg R, Sanchez VA. 2024 Annual Meeting, American Society for Clinical Oncology, June 6, 2024 (J Clin Oncol 42, 2024, Suppl 16, abstr e24102)
125. Hadfield MJ, Wu S, Farrell A, Oberley MJ, Sun G, Wellcome J, Anderson ML, Dizon D. "Heterogeneous Molecular Landscape of Cervical Cancer Metastases." 2024 Annual Meeting, Florida Society for Gynecologic Oncology, Longboat Key, FL; June 6, 2024.
126. Yasukawa Rymer J, Okuka M, Short B, Guo X, Yi Z, Alvero A, Chengqi W, Rutherford TJ, Anderson ML. "Comprehensive analysis of exosomes in uterine lavage from endometrial cancer patients." 2024 Annual Meeting, Florida Society for Gynecologic Oncology, Longboat Key, FL; June 6, 2024
127. Komrokji S, Sangi-Haghpeykar H, **Anderson ML**. "Utilizing ArcGIS to Discover Geographic Disparities in Lung Cancer Screening." 2025 CADeX Annual Meeting, Association of American Cancer Institutes (AACI) San Diego, CA. January 29, 2025. (*Plenary Presentation*)
128. Guo X, Rosado R, Rymer R, Un B, Guzeloglu-Kayisli O, Kayisli U, Short B, Rutherford RJ, Anderson ML "Activated Adenosine Receptor A2B (Adora2b) Suppress the Growth of Uterine Leiomyomas by Modulating Akt Signaling

Pathways” 2025 Annual Meeting. Society for Reproductive Investigation. Charlotte, NC; March 27, 2025.

129. Safa A, Guo X, Rosado R, Upadhyaya K, Tian Y, Siddique R, Gondhi S, Aydogan-Mathyk B, Borreson B, Schoeller R, Rutherford TJ, Anderson ML. “An Autocrine Role for Complement Factor C1s in Uterine Leiomyomas” Anderson ML. 2025 Annual Meeting. Society for Reproductive Investigation. Charlotte, NC; March 28, 2025.
130. Tian Y, Siddique R, Aydogan-Mathyk B, Guo X, Upadhyaya K, Safa A, Rosado R, Short B, Rutherford TJ, Anderson ML. “Dysregulated Collagen Type XII Alpha 1 Chain Expression Promotes the Growth of Uterine Leiomyomas.” 2025 Annual Meeting, Society for Reproductive Investigation. Charlotte, NC; March 29, 2025.
131. Begum Mathyk B, Pandya S, Wright H, Anderson ML, Kohut A. “Handheld Point-of-Care Ultrasound for Gynecologic Imaging in Microgravity” 2025 AIUM Annual Convention, Orlando, FL; March 29–April 1, 2025.
132. Reddy Karu S, Aydogan Mathyk B, Anderson M, Zhang J, Xiao S. “Simulated Microgravity Interferes with Oocyte Meiotic Maturation in a 3D Ex Vivo Mouse Folliculogenesis System.” Annual Meeting, Society for the Study of Reproduction, Washington D.C, USA July, 2025.
133. Mathyk B, Pandya S, Wright BH, Anderson ML, Kohut A. “Surgery in Space: Realities and Challenges of Procedural Medicine and Critical Care For Exploration-Class Space Missions’. Handheld Point-of-Care Ultrasound for Gynecological Imaging Under Microgravity. Space Surgery Association Panel: Aerospace Medical Association (AsMA), Atlanta, GA; June, 2025.

Book Chapters and Reviews

1. Pejovic T, Odunsi K, Anderson ML. Molecular Biology of Endometrial Cancer. In Genomic and Personalized Medicine (2nd Edition). HF Willard, GS Ginsburg, eds. 2021.
2. Naqvi K, **Anderson ML**. Uterine Cancer. In Tumor Boards Review: Guidelines and Case Reviews in Oncology (2nd Edition). Todd RF, Cooney KA, Hayes TG, Mims MP, Worden FP, eds. 2014.
3. Odunsi K, Pejovic T, **Anderson ML**. Molecular Pathogenesis of Gynecologic Cancers. In Principles and Practice of Oncology, Vol 2, 10th Edition. DeVita VT, Rosenberg JS, eds. Lippincott, Williams and Wilkins, 2014.
4. **Anderson ML** and Kolomeyevskaya N. Uterine Sarcomas. In Current Multidisciplinary Oncology: Gynecologic Cancer. Pejovic T and Odunsi K, eds. Demos Publishing, 2013.
5. Anan A, **Anderson ML**. Uterine Cancer. In Tumor Boards Review: Guidelines and Case Reviews in Oncology. Todd RF, Cooney KA, Hayes TG, Mims MP, Worden FP, eds. 2011.

6. Pejovic T, **Anderson ML**, Odunsi K. Molecular Biology of Ovarian Cancer. In Genomic and Personalized Medicine. HF Willard, GS Ginsburg, eds. 2011
7. Odunsi K, Pejovic T, **Anderson ML**. Molecular Pathogenesis of Gynecologic Cancers. In Principles and Practice of Oncology, Vol 2, 9th Edition. Devita VT, Rosenberg JS, eds. Lippincott, Williams and Wilkins. 2011.
8. Patsner B, **Anderson ML**. Genital Cancers in Pregnancy. In Complications of Pregnancy. 6th Edition. Cohen W. and August P, eds. 2012.
9. Ke S, Chun Q, Zhang FJ, Mach CM, **Anderson ML**, Konopleva M, Yustein JT, Zao C, Lin J. Retinoic acid: An old compound with the potential for future personalized molecular medicine. In Retinoic Acid: Structure, Metabolism and Roles in Disease. 2009.
10. Odunsi K, Pejovic T, **Anderson ML**. Molecular Pathogenesis of Gynecologic Cancers. In Principles and Practice of Oncology, Vol 2, 8th Edition. Devita VT, Rosenberg LS, eds. Lippincott, Williams and Wilkins. 2008. p1487-1495.
11. Pejovic T, **Anderson ML**, Odunsi K. Molecular Biology of Ovarian Cancer. In Genomic and Personalized Medicine Vol 2. Willard HF, Ginsburg GS, eds. 2008. p 913-921.
12. **Anderson ML**. Obstetrical Hemorrhage. In Critical Care: Clinical Companion. Seth Spector, ed., Lippincott, Williams and Wilkins. 2000.
13. **Anderson ML**, Schwartz, PE. Evaluation and Management of Cervical Cancer in Pregnancy. In Cancer and Pregnancy. Barnea AR, Jauniaux E, and Schwartz PE, eds. Springer-Verlag. 2001.
14. **Anderson ML**, Schwartz PE. Case Studies in the Management of Gynecologic Malignancies. In Cancer and Pregnancy. Barnea, A.R., Jauniaux, E., Schwartz, P.E., eds. Springer-Verlag 2001.
15. **Anderson ML**. Cell Communication as Human Disease. Yale J. Biol. Med., 1992.

Patents

1. MiR-520 microRNAs sensitize cancer to chemotherapy. Inventors: **Anderson, ML**, Mach C, Gunaratne PH. Patent No. 9,758,785; granted USPTO: September 12, 2017. 9/2017
2. MicroRNA-130a, b as a tumor suppressor and sensitizing agent for chemotherapy. Inventors: Gunaratne PH, Benham AL, **Anderson ML**. Patent No. 9,192,622; granted USPTO, Nov 24, 2015. 11/2015
3. MicroRNA-140-5p as a tumor suppressor and sensitizing agent for chemotherapy. Inventors: Gunaratne PH, Benham AL, **Anderson ML**. Patent No. 8,765,707; granted USPTO, July 1, 2014. 7/2014

4. Compositions and methods for treating uterine leiomyomas. **Anderson, ML**, Guo X, Kayisli U. Submitted to USPTO May, 2024. 5/2024

National Scientific Service

OneFlorida+ Research Consortium

Executive Committee	2020 -
COVID-19 Ancillary Review Committee	2020 - 2022

NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC)

Phase IV Scientific Advisory Panel	2018-2019
Endometrial Cancer Working Group	2017 - 2023
Biospecimen Working Group	2016 –
Sarcoma Working Group	2023 -

NCI Cancer Genome Atlas Consortium (TCGA)

Data Analysis and Publication Committee, Pan Gynecologic Cancer Working Group	2016 - 2018
Data Analysis and Publication Committee, Sarcoma Working Group,	2014 - 2017
Data Analysis and Publication Committee, Cervical Cancer Working Group	2013 - 2016
Cervical Cancer Working Group	2011 - 2016
Uterine Cancer Working Group	2012 - 2015

Society for Gynecologic Investigation/Society for Reproductive Investigation

Scientific Session Moderator, Annual Meeting	2016, 2008, 2011-2014
Scientific Abstract Reviewer	2009 - 2019
Mini-Symposium Organizer	2004, 2006, 2010
Annual Meeting Awards Committee	2011 -2018

National Influenza Vaccine Collaborative (NIAID)

Data Safety Monitoring Board	2009-2012
------------------------------	-----------

Southwest Oncology Group (SWOG)

Gynecology Working Group	2007-2010
--------------------------	-----------

Society for Gynecologic Oncology

Annual Meeting Scientific Review Panel	2009-2012
Member, Communications Committee	2011

NIH Women's Health Initiative (WHI)

Annual Meeting Scientific Review Panel	2013
--	------

Texas State Department of Health

Steering Committee, Cervical Cancer Strategic Plan

2005-2006

Editorial Boards

Scientific Reports	2024 -
Journal of Reproductive Medicine, Gynaecology & Obstetrics	2018 -
Plos One	2012-2018
American Journal of Physiology - Endocrinology and Metabolism	2010-2018
American Journal of Cancer Research	2010 -

Review Panels

Ad hoc Journal Review

American Journal of Obstetrics and Gynecology
BMC Women's Health
Cancer Discovery
Cancer Epidemiology, Biomarkers and Prevention
Cancer Letters
Cancer Research
Case Reports in Obstetrics and Gynecology
Clinical Cancer Research
Gene
Expert Review of Molecular Diagnostics
Gynecologic Oncology
Gynecologic and Obstetric Investigation
International Journal of Gynecologic Cancer
International Journal of Medical Sciences
Journal of Proteomics & Bioinformatics
Journal of Clinical Endocrinology and Metabolism
Medical Oncology
Molecular Endocrinology
Obstetrics and Gynecology
Oncotarget
Plos One
Reproductive Sciences
Scientific Reports
Translational Medicine
Translational Research

Grant Review

U.S. Department of Defense Congressionally Mandated Ovarian Cancer Research Program

Ad Hoc Scientist Reviewer	2016, 2018-2020
Regular Member, Cell and Molecular Biology Peer Review Panel	2012

U.S. Department of Defense Congressionally Mandated Endometriosis Research Program

Ad Hoc Scientist Reviewer	2020
<u>Medical Research Council (United Kingdom)</u>	
Ad Hoc Scientist Reviewer	2020
<u>Agence National de la Recherche (France)</u>	
Ad Hoc Scientist Reviewer, Young Researchers Programme,	2013
<u>Scientific Review Panel, Austrian Science Fund (FWF)</u>	
Ad Hoc Scientist Reviewer	2013
<u>Liddy Shriver Sarcoma Initiative</u>	
Ad Hoc Scientist Reviewer	2012-2014
<u>Baylor College of Medicine</u>	
Department of Surgery (Young Investigators Program)	2013
Department of Head and Neck Surgery (Mini Grant Program)	2015
<u>Professional Societies</u>	
American College of Obstetrics and Gynecology	
American Association for the Advancement of Science	
Gynecologic Oncology Group	
Full Member, Society for Gynecologic Oncology	
American Association for Cancer Research	
Society for Gynecologic Investigation	
Southwest Oncology Group	
The Felix Rutledge Society	
Society for the Study of Reproduction	
Connective Tissue Oncology Society	
<u>Patient Care Responsibilities</u>	
<i>University of South Florida Morsani College of Medicine</i>	
<u>Affiliated Institutions:</u> Tampa General Hospital	2018-current
<u>Section or Specialty:</u> Gynecologic Oncology	
<u>Clinical Productivity:</u> ~5500 wRVU for FY2024 (>115% of Expected)	
<i>Baylor College of Medicine</i>	
<u>Affiliated Institutions:</u> Texas Children's Hospital Pavilion for Women, Ben Taub General Hospital, Smith Clinic (Harris Health System), CHI Baylor St. Luke's Medical Center, Houston Methodist Hospital, Woman's Hospital of Texas.	2002-2018

Section or Specialty: Gynecology and Gynecologic Oncology
Clinical Productivity: 89-350% of Quarterly Expected

Clinical Laboratory Responsibilities

N/A

National Education or Voluntary Health Organization Participation

Medical Mission, Chincha Medical and Educational Center, Peruvian American Medical Association	Feb-2013
Medical Mission, Chincha Medical and Educational Center, Peruvian American Medical Association	Feb-2014

Administrative Assignments

Departmental Administration, Committees

University of South Florida Morsani College of Medicine

Awards, Promotion & Tenure Committee, Department of Obstetrics & Gynecology, USF Morsani College of Medicine	2021 - current
Director, Gynecologic Oncology Research, USF Morsani College of Medicine	2020 - current
Member, Core Curriculum Committee, Gynecologic Oncology Fellowship, USF Morsani College of Medicine	2018 - current

Baylor College of Medicine

Director of Research (Gynecology), Department of Obstetrics & Gynecology, Baylor College of Medicine	2014-2018
Resident Research Committee, Department of Obstetrics & Gynecology, Baylor College of Medicine	2014-2018
Research Leadership Committee, Department of Obstetrics & Gynecology, Baylor College of Medicine	2014-2018
Director, Gynecologic Oncology Research, Baylor College of Medicine	2009-2014
Founding Director, BCM Gynecologic Tissue Repository	2007-2018
Executive Leadership Committee, Department of Obstetrics & Gynecology, Baylor College of Medicine	2005-2009
Director, Division of Gynecologic Oncology, Baylor College of Medicine,	2005-2009
Co-Director, Division of Gynecologic Oncology, Baylor College of Medicine	2004-2005
Member, Resident Research Committee, Department of Obstetrics & Gynecology, Baylor College of Medicine	2003-2006
Member, Resident Education Committee, Department of Obstetrics & Gynecology, Baylor College of Medicine	2002-2005

College-Wide and Institutional Administration, Committees

University of South Florida/Tampa General Hospital

Steering Committee, USF Virology Institute	2025 – current
--	----------------

TGH Cancer Institute Clinical Research Leadership Council	2025 – current
Executive Committee, Tampa General Hospital Cancer Institute	2022 - current
Grand Rounds/Journal Club Committee, TGH Cancer Institute	2021 - current
Chair, Executive Advisory Committee, USF/TGH Caris Precision Oncology Initiative	2022 - current
Chair, USF/TGH Research Advisory Committee	2021 - current
Founding Director, TGH/USF Health Precision Medicine Biorepository	2020 - current
Member, MD-PhD Program Committee, University of South Florida	2020 - current
Medical Director, Office of Clinical Research, Tampa General Hospital	2019 - current
Physician Champion, EPIC COSMOS installation, Tampa General Hospital	2020 - 2022
Member, Dean's Committee on Assessing the New Normal, USF Morsani College of Medicine	2020 - 2022
Co-Chair, Clinical & Translational Research Core, USF Pandemic Response Network	2020
Member, USF Federal Corona Virus Relief Package Task Force	2020
Member, Search Committee, Division Chief, Maternal Fetal Medicine, USF Morsani College of Medicine	2020
Member, USF/TGH Joint Research Bioinformatics Committee	2019-2020
Member, Executive Steering Committee, TGH/USF Clinical Research Assessment Committee, Tampa, FL	2019-2020
Member, Robotic Steering Committee, Tampa General Hospital	2019 - 2022
Member, Cancer Committee, Tampa General Hospital (TGH)	2018-
Member, Surgical Block Time Committee, Tampa General Hospital, Tampa, FL	2018-2019
Selection Committee, Associate Chief of Staff for Research, James A. Haley Veteran's Hospital, Tampa, FL	2018

Baylor College of Medicine

Academic Lead, Gynecologic Disease-Oriented Working Group, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine	2015-2018
Vice Chair, Institutional Review Board, Baylor College of Medicine	2005-2017
Scientist Member, Institutional Review Board, Baylor College of Medicine,	2004-2005
Member, Dan L. Duncan Cancer Center Planning Committee, BCM	2004-2009
Member, Harris Health Cancer Committee, Harris Health System, Houston, TX	2004-2013
Chair, Partnership for Gynecologic Oncology Quality Improvement, Ben Taub General Hospital, Houston, TX	2004-2009
Chair, Gynecologic Oncology Tumor Board, St. Luke's Episcopal Hospital, Houston, TX	2005-2015
Chair, Baylor College of Medicine/Ben Taub General Hospital Gynecologic Oncology Tumor Board	2005-2011
Member, End of Life Care Planning Committee, Harris County Hospital District, Houston, TX	2007-2008
Member, Outpatient Facilities Planning Committee, Harris County Hospital District, Houston, TX	2007-2009
Member, Clinical Practice Leadership Group, Baylor Clinic	2008-2009
Member, Adult Working Group, Protocol Review Committee, Dan L. Duncan Cancer Center, Baylor College of Medicine	2009-2010
Examination Committee, Program in Translational Biology & Molecular Medicine, Baylor College of Medicine	2010-2013
Member, Ethics Committee, Ben Taub General Hospital	2010-2018
Member, Scientific Advisory Committee, General Clinical Research Center,	2010-2012

Texas Children's Hospital, Houston, TX	
Cancer Committee, St. Luke's Episcopal Hospital, Houston, TX	2009-2010
Cancer Committee, St. Luke's Episcopal Hospital, Houston, TX	2012-2013

Other Pertinent Information not given above

Junior Faculty Research Mentorship

<u>Claire Mach, Pharm.D</u> , Assistant Professor, College of Pharmacy, University of Houston. I have served as primary advisor for mentored junior faculty position since 2010 with goal of establishing an independent research program. Now supported through multiple external grants, including grant support from Gynecologic Cancer Foundation (2012) and Department of Defense Ovarian Cancer Research Program (2015). (Carol's Cause Uterine Cancer Research Award, 2011; Presidential Plenary Presentation, Society of Gynecologic Oncologists, 2012). PI, DOD Ovarian Cancer Research Program Pilot Project Grant (OC140169) <i>Four manuscripts published, 7 manuscripts in substantial preparation, >14 abstracts published, five manuscripts in preparation.</i>	2009-2015
<u>Yvette Williams-Brown, MD</u> , Division of Gynecologic Oncology; Mentoring Dr. Brown on health disparities research projects and grant applications, including Woman to Woman Survivorship Grant awarded by Ovarian Cancer Research Fund, 2013). PI, Quality Improvement Grant, American College of Obstetrics & gynecology, 2015; Co-Investigator, PP120091 since 2014. Two abstracts and one manuscript submitted.	2012-2015
<u>Celestine Tung, MD</u> , Assistant Professor, Division of Gynecologic Oncology; (Co-PI, Woman to Woman Survivorship Grant, Ovarian Cancer Research Fund, 2013). One abstract submitted; one manuscript submitted.	2012-2014
<u>Aba Coleman, MD, MEd</u> , Assistant Professor, Department of Obstetrics & Gynecology Since 2014, mentored and advised in successful NCI P30 Supplement on HPV Vaccination (\$100,000 awarded 9/2014). Two abstracts published; one manuscript in press; one manuscript in preparation. Co-Investigator; PP120091,	2014-2016
<u>Jennifer Bump, MD</u> , Assistant Professor, Department of Obstetrics & Gynecology. Two abstracts published; one manuscript under revision; one manuscript in preparation. Co-Investigator, PP120091, PP160049. 2014 – 2018.	2014-2016
<u>Michelle Ludwig, MD, PhD</u> , Assistant Professor, Department of Radiation Oncology. Since 2014, I have been mentoring Dr. Ludwig with initiation of investigator initiated clinical trial now approved by BCM DLDC; One manuscript published; one manuscript submitted/in revision; one grant application in preparation. Two grants submitted (AACR and private foundation). Investigator-Initiated Phase II Clinical Research Trial – Funded.	2014-2017
<u>Anuja Vyas, MD</u> , Assistant Professor, Department of Obstetrics & Gynecology, BCM. Developed multiple translational research projects with goal of supporting development of BCM Pelvic Health Center, starting 2016.	2015-2017

Matthew L. Anderson, MD, PhD, FACOG
July 1, 2025

Adrian Kohut, MD, Assistant Professor, Division of Gynecologic Oncology, 2023 -
University of South Florida Morsani College of Medicine. Mentored development as
a lab-based translational cancer researcher. 2 abstract submitted; 2 manuscripts
submitted